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ABSTRACT 
This thesis describes technologies for the rapid and scalable production of high-
affinity, high-specificity protein capture agents which possess the affinities and 
specificities of antibodies, but also exhibit improved chemical, biochemical, and 
physical stability.  I will discuss how the chemical flexibility of comprehensive, one-
bead-one-compound (OBOC) libraries of oligopeptides may be combined with iterative 
in situ click chemistry to select multi-ligand capture agents.  Large OBOC libraries form 
the basis of individual peptide ligands, and also permit chemically designed stability 
through the incorporation of artificial (azide or acetylene) and non-natural amino acid 
building blocks.  The in situ click chemistry method then utilizes the target protein as the 
catalyst, or template, for assembling its own biligand via formation of a 1,2,3-triazole 
linkage between two individual ligands (azide and acetylene).  This process can be 
repeated to produce triligands, tetraligands, and other higher-order multi-ligands with an 
accompanying increase in affinity and specificity through cooperative interactions.  
Once found, multi-ligand capture agents can be produced in gram amounts via 
conventional synthetic methods such as the Cu(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC).  This is a general and robust strategy for the inexpensive, high-throughput 
construction of protein capture agents that can be exploited to detect protein biomarkers 
in multi-parameter clinical diagnostic assays. 
While high-affinity protein capture agents represent a significant technology 
advance, they are just one component of what is necessary for highly multiplexed 
measurements of protein biomarkers.  It is also important to develop or optimize the 
actual assay platforms that can enable sensitive multi-parameter protein measurements 
using these capture agents.  Silicon nanowire (SiNW) nanoelectronic sensors can 
vii 
provide quantitative, label-free multi-parameter measurements of protein biomarkers in 
real time.  However, SiNW sensors can be challenging to deploy because unprotected Si 
forms a native oxide layer that can significantly reduce the detection sensitivity of the 
nanowire sensors via dielectric shielding.  Another technical challenge is the 
development of chemistries which allow for the selective encoding of nanowire surfaces 
with the capture agents.  To overcome these challenges, the final part of this thesis 
presents a general method to functionalize organic and biological molecules on highly 
passivated Si(111) surfaces with minimal surface oxidation. 
 
viii 
TABLE OF CONTENTS 
LIST OF FIGURES, SCHEMES, AND TABLES……………..……….…….…xiii
 
CHAPTER 1: Introduction………………………………………………………
 
1 
1.1  High-Affinity Protein Capture Agents in Medical Diagnostics…......... 2 
1.2  Assay Platforms for Multi-Parameter Protein Measurements...…......... 8 
1.3  References……………………………………………………...…........12 
 
CHAPTER 2: Selection of a Multi-ligand Capture Agent for Carbonic 
 
Anhydrase II by Iterative In Situ Click Chemistry…………………...………….. 15 
2.1  Introduction…………………………………….……….………….......16 
2.2  Materials and Experimental Methods…….……….…………………...18 
            2.2.1  Materials…………………..…….……….………………….. 18 
            2.2.2  Artificial Amino Acids…………………..…….……….….... 20 
            2.2.3  OBOC Oligopeptide Library Construction...………………...24 
            2.2.4  Screening Procedures for Anchor Ligand....…………………25 
            2.2.5  In Situ Click Screening Procedures for Biligand.……….…...28 
            2.2.6  In Situ Click Screening Procedures for Higher-Order  
                      Multi-ligands……………………………………………...... 32 
            2.2.7  Validation of In Situ Click/OBOC Multi-ligand  
                      Screening Procedures………………………………………...32 
            2.2.8  Bulk Peptide Synthesis……..…….……….………...………. 33 
            2.2.9  On-Bead Biligand and Triligand Synthesis………..………... 39 
ix 
2.3  Results and Discussion…………………………………………........... 41 
            2.3.1  Screening for Anchor (1°) Ligand against bCAII…………....41 
            2.3.2  Identification of Secondary (2°) Ligands:  Biligand Screens.. 43 
            2.3.3  Identification of Tertiary (3°) Ligands:  Triligand Screens….50 
2.4  Conclusions………………………………………………………….…52 
2.5  Acknowledgements.……………………………………………………53 
2.6  References……...……………………………………….……………...54 
 
CHAPTER 3: Affinities, Specificities, and Implementation of Multi-ligand  
 
Capture Agents in Standard Assays of Protein Detection……………….…....... 59 
3.1  Introduction…………………………………….…………………........60 
3.2  Materials and Experimental Methods…….……….………...…….…...62 
            3.2.1  Chemicals……………………………………………...…..... 62 
            3.2.2  Characterization of Affinity by Fluorescence Polarization..... 62 
            3.2.3  Characterization of Affinity by Surface Plasmon Resonance. 63 
            3.2.4  Enzymatic Activity Assay of Carbonic Anhydrase II………. 65 
            3.2.5  Circular Dichroism of Triligand.............................................. 65 
            3.2.6  Dot Blot Specificity/Sensitivity Assays of Biligand and  
                      Triligand in Serum...................................................................65 
            3.2.7  Western Blot Analysis Using Triligand...................................66 
            3.2.8  Sandwich (ELISA-like) Assays Using Triligand.................... 67 
3.3  Results and Discussion…………………………………………........... 67 
            3.3.1  Characterization of Anchor (1°) Ligand Affinities..................68 
x 
            3.3.2  Characterization of Biligand Affinities................................... 70 
            3.3.3  Characterization of Triligand Affinities.................................. 74 
            3.3.4  Enzymatic Activity Assay of Carbonic Anhydrase II............. 74 
            3.3.5  Circular Dichroism of Triligand.............................................. 77 
            3.3.6  Dot Blot Specificity/Sensitivity Assays of Biligand and   
                      Triligand in Serum...................................................................77 
            3.3.7  Western Blot Analysis Using Triligand……………...............83 
            3.3.8  Sandwich (ELISA-like) Assays Using Triligand.................... 86 
3.4  Conclusions…………………………………………………………….89 
3.5  Acknowledgements.……….…………………………………………...90 
3.6  References……...….…………………………………….……………..91 
 
CHAPTER 4: Assays for Quantifying Protein-Catalyzed Multi-ligands and  
 
Extensions to Other Proteins…………………………………………….......……...92 
4.1  Introduction…………………………………….…………………........93 
4.2  Materials and Experimental Methods.………….……………………...94 
            4.2.1  Materials…………….............................................................. 94 
            4.2.2  On-Bead Detection of In Situ Triazole Formation.………..... 95 
            4.2.3  QPCR Assay for the Detection and Quantitation of the  
                      Formation of On-Bead, Protein-Catalyzed Triligand  
                      Capture Agent…...……………………………..….................96 
            4.2.4  Selection of Biligand Capture Agent for Prostate-  
                      Specific Antigen.……………................................................. 98 
xi 
4.3  Results and Discussion……………………..……………………......... 101
            4.3.1  Initial Validation of Protein-Catalyzed Multi-ligand Product. 101
            4.3.2  Direct Detection of Protein-Catalyzed In Situ Multi-ligand....102
            4.3.3  Strategies for Improving Signal-to-Noise Ratio during In   
                      Situ Click/OBOC Screens........................................................107
            4.3.4  Selection of Biligand Capture Agent for Prostate-  
                      Specific Antigen…………………………………………….. 112
4.4  Conclusions…………………………………………………………….119
4.5  Acknowledgements.………….………………………………………...120
4.6  References……...………….………………….………….…………….121
 
CHAPTER 5: A Non-Oxidative Approach toward Chemically and  
 
Electrochemically Functionalizing Si(111)…………………………………………..124
5.1  Introduction…………………………………….…………………........125
5.2  Materials and Experimental Methods…….……………………….…...128
            5.2.1  Chemicals………………………………………………...…. 128
            5.2.2  Acetylenylation of Si(111)……………………………..….... 129
            5.2.3  Synthesis of Electroactive Benzoquinone 1………..……….. 131
            5.2.4  Click Reaction to Attach 1 onto Acetylene-Terminated   
                      Si(111)………………………………………………………. 134
            5.2.5  Electrochemical Activation to Attach Ferrocene Carboxylic  
                      Acid and Biotin.……………………………………………...135
5.3  Surface Characterization...………………………………………..........137
xii 
            5.3.1  X-ray Photoelectron Spectroscopy……...………………...… 137
            5.3.2  Contact Angle Goniometry…………………………………..137
            5.3.3  Electrochemical Characterization of Surface Coverages….... 138
            5.3.4  Fourier-Transform Infrared Spectroscopy…………….……..138
5.4  Results…………...………………………………………………..........139
            5.4.1  XPS Survey Scans and Contact Angle Measurements…….... 139
            5.4.2  High-Resolution XPS Measurements……………………….. 139
            5.4.3  Electrochemical Measurements….…………...……...…….... 145
5.5  Discussion..…………………………...……………………….….........147
5.6  Conclusions…………………………………………………………….154
5.7  Acknowledgements.……………………………………………………154
5.8  References……...……………………………………….……………...155
 
APPENDIX A: Iterative In Situ Click Chemistry Creates Antibody-Like  
 
Protein Capture Agents (Angewandte Chemie International Edition 2009, 48, 
4944–4948)……..……..............................................................................................
 
161
APPENDIX B: Complete Hit Sequencing Results………………………………167
APPENDIX C: Custom Edman Degradation………...………………………… 176
APPENDIX D: A Non-Oxidative Approach toward Chemically and  
Electrochemically Functionalizing Si(111) (Journal of the American Chemical 
Society 2006, 128, 9518–9525……………………………………………………..
 
179
xiii 
LIST OF FIGURES, SCHEMES, AND TABLES 
FIGURES, Chapter 2: 
Figure 2.1.  Schematic of preparing a multi-ligand capture agent……………... 19 
Figure 2.2.  Structures of representative 1° ligands, 2° ligands, and biligands....35 
Figure 2.3.  Structures of biligand anchors…………………………………….. 37 
Figure 2.4.  Structures of 3° ligands and triligands ………………………….....38 
Figure 2.5.  Results of selecting a primary or anchor ligand of bCAII….….......42 
Figure 2.6.  Schematic of two types of biligand screen….…………………….. 44 
Figure 2.7.  Identification of a 2° ligand against bCAII………………………...46 
Figure 2.8.  Distribution of D-amino acids found in biligand hits……………...48 
Figure 2.9.  Binary component in situ click chemistry screen…………………. 49 
Figure 2.10.  Method to validate protein-templated formation of multi-ligand   
      capture agent…………...…………………………………………………... 51 
 
FIGURES, Chapter 3: 
Figure 3.1.  Fluorescence polarization for a fluoresceinated anchor ligand.…... 69 
Figure 3.2.  SPR interactions of anchor ligands with bCAII………............……71 
Figure 3.3.  SPR interactions of biligands with bCAII….................................... 73 
Figure 3.4.  SPR interactions of triligand with bCAII and hCAII………...….... 75 
Figure 3.5.  Enzymatic activity of bCAII in the presence of triligand……….....76 
Figure 3.6.  CD spectrum for triligand capture agent…………..……………….78 
Figure 3.7.  Structures of biotinylated triligand and biligand anchor………….. 80 
      Figure 3.8.  Dot blot of triligand and biligand for b(h)CAII detection………….81 
xiv 
      Figure 3.9.  Dot blot of triligand vs. antibody for b(h)CAII detection………….82 
      Figure 3.10.  Denaturing and non-denaturing Western blots detected with a  
            triligand capture agent………………………………………………………85 
      Figure 3.11.  Sandwich (ELISA-like) assay utilizing a triligand as primary         
            capture agent for bCAII detection…..............................................................87 
 
FIGURES, Chapter 4: 
      Figure 4.1.  In situ click assay for on-bead triazole formation………………….103
      Figure 4.2.  On-bead multi-ligand detection by QPCR…………………………106
      Figure 4.3.  General screening strategies to improve signal-to-noise ratio   
            and reduce number of false positives in OBOC selections.…………………109
      Figure 4.4.  Screening and anti-screening strategies to target a particular   
            protein epitope or modification ……………………………………………..110
      Figure 4.5.  Two-stage in situ/click OBOC screening strategy to identify a   
            biligand capture agent for PSA ……………………………………………..111
      Figure 4.6.  Representative image of an in situ click/OBOC screen with   
            enzymatic amplification…….……………………………………………….117
      Figure 4.7.  Structures of active site targeted cyclic anchor and cyclic   
            biligand, and SPR interactions with PSA.  ………………………………....118
 
FIGURES, Chapter 5: 
Figure 5.1.  XPS data of H-C≡C-[Si(111)]………………………..…...………. 142
Figure 5.2.  High-resolution XPS spectra of H-C≡C-[Si(111)]………...….…... 143
xv 
Figure 5.3.  Cyclic voltammograms (CVs) for 1s and 3s…………………….....146
Figure 5.4.  ATR-FTIR characterization of H-[Si(111)] and H-C≡C-[Si(111)].. 150
Figure 5.5.  Demonstration of bioattachment to acetylenylated Si(111)………. 153
 
FIGURES, Appendix C: 
 
Figure C.1.  Pulsed-Liquid cLC Extended method and gradient………………. 177
Figure C.2.  Final steps of Flask Normal Extended flask cycle………………...178
Figure C.3.  Edman traces for artificial azide-containing amino acids……........ 178
 
SCHEMES, Chapter 2: 
Scheme 2.1.  Artificial amino acid synthesis…………….………………..…… 22 
Scheme 2.2.  Selection of anchor ligand by OBOC screen……...……….……..27 
Scheme 2.3.  Selection of biligand by in situ click/OBOC screen……..…….....31 
Scheme 2.4.  Acetylation and click reactions for a 6-mer peptide……………...40 
 
SCHEMES, Chapter 3: 
Scheme 3.1.  Esterase activity of bCAII……………………………………….. 76 
 
SCHEMES, Chapter 5: 
Scheme 5.1.  Strategy for the functionalization of Si(111)...…………………... 130
Scheme 5.2.  Synthesis of electroactive benzoquinone 1.………………….…...132
Scheme 5.3.  Steps required to non-oxidatively activate Si(111) surfaces…….. 136
  
xvi 
TABLES, Chapter 2: 
Table 2.1.  Libraries used in selecting a triligand capture agent for bCAII…….26 
      Table 2.2.  Screening summary………………………………………………….29 
 
TABLES, Chapter 5: 
 
Table 5.1.  Measured contact angles for various Si(111) surfaces……………...140
      Table 5.2.  Measured molecular surface coverages for Si(111) surfaces.............148
 
TABLES, Appendix B: 
 
      Table B.1.  First-generation anchor ligand screen An1………....………………168
      Table B.2.  Second-generation anchor ligand screens An2a and An2b.……......169
      Table B.3.  In situ biligand screen Bi1……….…………………………………170
      Table B.4.  On-bead biligand screens Bi2a and Bi2b………..………………….171
      Table B.5.  First-generation in situ triligand screen Tri1……………….............172
      Table B.6.  First-generation on-bead triligand screen Tri2……………………..173
      Table B.7.  Second-generation triligand screens Tri3 and Tri4….......................174
      Table B.8.  Azide-free in situ triligand screen TriX (control)………….............175
  
 
1 
 
 
 
 
 
 
Chapter 1 
Introduction 
 
 
2 
1.1  High-Affinity Protein Capture Agents in Medical Diagnostics 
A fundamental goal of medical diagnostics is to detect and monitor changes in 
biomarkers, which are substances used as an indicator of a biological state.  Exemplary 
biomarkers are proteins, genes, mRNA, or small molecules.  With the information 
provided by measurement of biomarkers, the current state of a patient’s health can 
potentially be determined and predictive features can be claimed.  Medical diagnostics, 
and in particular cancer diagnostics, is increasingly requiring measurements of large 
panels of biomarkers based on the complex and heterogeneous molecular composition of 
diseased tissues and organs.  Such a multi-parameter approach, namely simultaneously 
measuring as many different biomarkers as possible in a single experiment, should 
improve the accuracy and efficiency of diagnostic assays.  Through the measurement of 
a collection of biomarkers, multi-parameter diagnostics have the potential to offer 
unique molecular signatures, or fingerprints, of a patient’s health status and a high level 
of sensitivity and specificity for diagnosing, staging, monitoring treatments over time, 
and predicting future disease.1 
 Genetic (DNA) and transcriptomic (mRNA) biomarker panels are already 
employed in the clinic on a routine basis, but technologies enabling the routine 
implementation of protein biomarker panels have lagged behind.  This is quite 
unfortunate, as protein biomarker measurements are perhaps the most informative 
clinically.  However, they are also by far the most expensive, in terms of cost per 
biomarker.  In addition, the majority of the approximately 20,000 proteins in the human 
proteome are post-translationally modified at some stage in their existence, and such 
modifications can often change the basic function of the protein.2  These modifications 
(e.g., glycosylation, phosphorylation) can only be detected by directly detecting the 
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modified protein.  Furthermore, temporal changes in post-translational modifications, 
such as evolving glycosylation patterns on a given protein, have been implicated as 
indicators of disease stage.3 
The dominant clinical technologies for detecting protein biomarkers are antibody 
based and, in fact, the gold standard protein assays, and the only ones that are highly 
reproducible from clinic to clinic and across geographical locations, require two 
antibodies per protein detected.  These are sandwich assays, or enzyme-linked 
immunosorbent assays (ELISAs).4  The cost and instability of antibodies generally 
prohibit the measurement of more than a handful of proteins in a single assay, and the 
cost per protein is about $50.  Nevertheless, ultimately one would like to routinely assess 
the levels of hundreds or more proteins for disease diagnosis, or monitor a few proteins 
at high frequency.  This will require inexpensive protein capture agents that possess the 
affinities and specificities of antibodies, but also exhibit chemical, biochemical, and 
physical stability.  A technology for the rapid and scalable production of such capture 
agents would revolutionize disease diagnostics.  It would also significantly impact 
benchtop research, providing the realization of quantitative and highly multiplexed 
assays that can replace the pauci-parameter protein measurement approaches (e.g., 
Western blots) that are standard today. 
Non-antibody protein capture agents have been pursued for several years.  The 
chemical nature of such capture agents is typically limited to nucleic acids, peptides, and 
small molecules, but a capture agent can also incorporate lipids, carbohydrates, and even 
other proteins.  Nucleic acid aptamers5 hold promise, but possess the intrinsic limitation 
of chemical diversity, as there are only 4 standard nucleobases, as compared to the 20 
natural amino acids from which proteins are constructed.  Other issues, such as nuclease 
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resistance and synthetic scale-up, comprise additional hurdles in the widespread 
applicability of nucleic acid aptamers.  On the other hand, peptides selected from phage 
display libraries6 can offer reasonable to excellent performance.  However, the L-amino 
acids comprising such peptides are sensitive to proteolytic cleavage.  Chemical stability 
and water solubility can be an additional limitation as they are highly sequence 
dependent. 
A third alternative is peptide affinity agents that are identified using one-bead-
one-compound (OBOC) libraries.7  This chemical library-based approach allows for the 
inclusion of broad classes of amino acids, including artificial and non-natural amino 
acids, along with peptide mimetics.8  This diverse chemical flexibility can be harnessed 
to infer attributes including biochemical, chemical, and physical stability, and water 
solubility.  However, compromises have to be reconciled between peptide length and 
library diversity, since OBOC libraries of oligopeptides are practically only 105–106 
elements in size.7  In addition, even a small OBOC library of polypeptides (or 
polypeptide mimetics) can be challenging to build, since the synthetic purity of an on-
bead peptide correlates with peptide length, and very-high purity libraries are required 
for affinity screening.  As a result, OBOC libraries have rarely been employed for the 
identification of high-affinity, high-specificity protein capture agents. 
Small molecule ligands can exhibit a high affinity for their protein targets, but 
selectivity is limited since they only sample a small part of the protein.9  One small-
molecule method that is relevant to the work of this thesis is that of in situ click 
chemistry,10 which was originally developed by K. B. Sharpless and M. G. Finn.  Their 
goal was to identify small molecule enzymatic inhibitors that could be catalytically 
assembled using the scaffold of the protein target itself.  Some of these studies started 
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with a known small molecule inhibitor that was then divided into two components, each 
of which was expanded into a small library of building blocks.  One library contained 
molecules functionalized with an azide group, and the other library contained molecules 
functionalized with an acetylene group.  During the screening of the target protein 
against the molecular libraries, the protein plays an active role in the selection and 
covalent assembly of a new inhibitor.  In these systems, the protein accelerates the 
Huisgen 1,3-dipolar “click” cycloaddition by holding elements from each library in close 
proximity.  The protein exhibits exquisite selectivity; it only promotes the formation of a 
1,2,3-triazole between those library elements that can be brought into precise molecular 
proximity on the protein surface.  The result is a biligand inhibitor with an affinity that 
approaches the product of the affinities of the individual molecular components.  
Furthermore, the triazole itself can contribute to the binding affinity observed for this 
inhibitor. 
In Chapters 2 and 3 of this thesis, I will discuss how the chemical flexibility of 
comprehensive, OBOC libraries of oligopeptides may be combined with iterative in situ 
click chemistry to select a high-affinity, high-specificity triligand capture agent against 
the protein biomarker carbonic anhydrase II (CA II), for both the human and bovine 
varieties (KD ≈ 45 and 64 nM, respectively).  Furthermore, this triligand capture agent 
can be used in a dot blot assay to detect those proteins at the ≥20 ng level from 10% 
porcine serum.  Results from Western blots, sandwich (ELISA-like) assays, and protein 
activity assays, with the triligand implemented as the primary capture agent, are 
presented in Chapter 3. 
The triligand is built from peptides comprised of non-natural and artificial amino 
acids, including amino acids containing azido and acetylene functionalities.  For this 
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selection scheme, the OBOC method was utilized first to identify an anchor (1°) ligand 
for CA II which contained a terminal acetylene-containing amino acid.  This screen 
resulted in a 7-mer peptide that binds CA II with KD ≈ 500 µM, which is a suitable 
affinity value for further maturation.  Then, the protein target was utilized to template 
the covalent coupling between two peptide ligands, the pre-identified 1° ligand and a 
secondary (2°) ligand, which was selected by the protein target and the 1° ligand from a 
comprehensive OBOC library of 2° ligands displaying a terminal azide-containing 
amino acid.  This in situ click chemistry screen resulted in a biligand that binds CA II 
with KD ≈ 3 µM.  After modifying the biligand with a terminal acetylene-containing 
amino acid, this capture agent became the new anchor for selection of a 3° ligand.  A 
final protein-templated in situ click chemistry screen between the biligand anchor and a 
comprehensive OBOC library of 3° ligands (azides) resulted in the triligand capture 
agent.  Interestingly, the triligand does not bind to the enzymatically active binding site 
of CA II—a result that argues for the generality of this approach. 
This iterative in situ click chemistry approach has several significant advantages 
over both traditional in situ click chemistry10 and traditional OBOC peptide libraries7 for 
affinity agent screening.  These include:  (1) Production of the capture agent requires no 
prior knowledge of affinity agents against the protein of interest, but can potentially take 
advantage of such ligands if they exist.  (2) The approach permits the sampling of a very 
large chemical space.  (3) The process can be repeated to produce tetraligands, 
pentaligands, and other higher-order multi-ligands with an accompanying increase in 
affinity and specificity from cooperative interactions.  (4) The approach may be 
harnessed to produce branched capture agents, thus providing low molecular weight 
capture agents that mimic the 3-D folded structures of antibodies or polypeptides.   
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(5) The capture agents can be designed, ab initio, to contain desirable features such as 
chemical, biochemical, and thermal stability, water solubility, fluorophore conjugation, 
and ability for highly oriented attachment to a substrate or surface in a monoparameter 
or multiparameter assay.  (6) The final capture agents may be prepared in gram 
quantities and stored as a powder under ambient conditions.  Chapters 2 and 3 have been 
taken in part from Angewandte Chemie International Edition 2009, 48, 4944–4948 (see 
also Appendix A). 
Protein-templated in situ click chemistry is a low-yielding reaction requiring 
precise alignment of the azide and alkyne with respect to each other and the protein.  
Therefore, only a small fraction (<<1%) of the peptides on a particular bead will be 
converted to multi-ligands.  In Chapter 4, both colorimetric and quantitative polymerase 
chain reaction (QPCR)-based methods for detection and quantitation of the formation of 
on-bead, protein-catalyzed multi-ligand capture agent will be discussed.  The low but 
detectable yield per protein-catalyzed in situ click reaction—approximately 0.000005% 
for bCAII—confirms the exquisite demands of the process.  This result encouraged us to 
develop more sophisticated screening strategies that incorporated anti-selections 
(following the selections) and also direct detection of the bead-bound products of the 
protein-catalyzed click reaction.  In other words, we developed screens that identified 
the protein target, secondary screens that identified the in situ click product, and even 
tertiary screens that identified potential side-reactions.  These new screening strategies 
were applied toward the selection of a biligand capture agent (KD ≈ 140 nM) against the 
blood-based cancer biomarker prostate-specific antigen (PSA).  The rapid assembly of 
the biligand capture agent by the protein-catalyzed process was expedited to two weeks 
by utilization of a previously reported anchor ligand11 and the new selection/anti-
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selection strategies, and demonstrates the potential feasibility of a high throughput route 
toward production of high-affinity, high-specificity protein capture agents. 
 
1.2  Assay Platforms for Multi-Parameter Protein Measurements 
While the high-affinity protein capture agents of Chapters 2 to 4 represent a 
significant technology advance, they are just one component of what is necessary for 
highly multiplexed measurements of protein biomarkers.  In addition, it is also important 
to develop or optimize the actual assay platforms that can enable sensitive multi-
parameter protein measurements using these capture agents.  There are a number of 
drawbacks associated with the existing gold-standard approaches.  As mentioned above, 
the gold standard for protein diagnostic assays are ELISA assays, and the standard 
clinical procedures are to extract a few milliliters of blood from a patient, centrifuge that 
blood to separate plasma (or serum) from whole blood, and then carry out ELISA assays 
for one or two proteins in 96-well plate format under diffusion-limited conditions.   
One drawback of this approach involves the stability of the antibodies utilized 
within the ELISA assays.  ELISA assays require at least two antibody capture agents for 
detection of the protein biomarker—a monoclonal surface-immobilized antibody for 
protein capture, and a secondary enzyme-linked polyclonal antibody which binds to a 
second epitope on the protein.  Binding of the secondary antibody is visualized by 
applying a colorimetric substrate which, for example, changes color or yields a 
fluorescence signal in the presence of enzyme.  In Chapter 3, I will describe how peptide 
multi-ligands, identified by in situ click chemistry, show feasibility as capture agents in 
ELISA and other standard biological assays such as Western blots.  Using multi-ligand 
capture agents instead of antibodies in these platforms avoids problems often associated 
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with antibody use—namely high cost, poor stability, and subtle variations in 
performance (e.g., sensitivity). 
A second drawback of the current gold-standard clinical approach is that it is 
slow.  During the time between blood draw and assay completion (typically a few hours 
to a few days), the biospecimen may degrade, so that the measured protein levels no 
longer reflect the patient status at the time of the blood draw.  In addition, the few 
milliliters of blood that are drawn make it easier to handle the blood, but, in principle, 
the same protein assays could be accomplished with only a few microliters of plasma or 
serum (and thus, with a significantly reduced amount of patient discomfort).   
While multi-ligand capture agents avoid the inherent problems of antibody 
instabilities (and potentially antibody costs), they do not change the inherently large 
sample volume, lengthy assay time, or number of measurement parameters per assay.  
The use of microfluidics to miniaturize and expedite protein assays can solve many of 
these problems.1a  Other technologies, such as label-free nanoelectronic sensors, can 
provide further advantages.  Silicon nanowire (SiNW) nanoelectronic sensors12 can 
provide quantitative multi-parameter measurements from nanoliter to microliter volumes 
of protein biomarkers in real time.  The “label-free” characteristic of these sensors 
means that no secondary antibodies are required to detect the binding between the 
protein of interest and capture agent.  SiNWs fabricated by the SNAP technique13 
represent ultra-dense arrays of electronically addressable nanowires, where each wire 
may be functionalized with a different protein capture agent.  When the protein of 
interest specifically binds to the capture agent, both the electrical conductance of the 
nanowire and the electrical capacitance between the nanowire and the surrounding 
solution is altered.  These electrical changes may be directly correlated to the absolute 
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amount of protein in the solution.  However, SiNW sensors can be challenging to deploy.  
For example, working with Si surfaces can be challenging because unprotected Si forms 
a native oxide (SiO2), and this insulating layer can significantly reduce the detection 
sensitivity of the nanowire sensors via dielectric shielding.  In addition, the native oxide 
on silicon also has a low isoelectric point, meaning that under physiological conditions 
(= pH 7.4), SiO2 surfaces are negatively charged.14  These surface charges can 
potentially limit the sensitivity of silicon nanowire field effect biosensors through Debye 
screening at the sensor surface.15  Finally, the native oxide layer contains electrical 
defect sites at the Si-SiO2 interface.16  For high surface area devices, such as SiNWs, this 
phenomenon can reduce charge carrier mobilities significantly.16,17   
In Chapter 5, a general method for the non-oxidative functionalization of single-
crystal silicon (111) is described.  To prevent the formation of this oxide, the silicon 
(111) surface was modified with an acetylene (-C≡C-H) monolayer of ~100% surface 
coverage.  An electroactive monolayer of a benzoquinone-masked primary amine was 
subsequently formed on the acetylene-passivated surface via Cu(I)-catalyzed Huisgen 
1,3-dipolar cycloaddition (“click” chemistry).  Molecules presenting a carboxylic acid 
group were finally immobilized onto regions where the benzoquinone had been reduced 
and cleaved to reveal the underlying amine on the surface.  This strategy provides a 
general platform to incorporate most organic and biological molecules, such as proteins, 
antibodies, or multi-ligand capture agents, on highly passivated silicon (111) surfaces 
with minimal surface oxidation.  This work can be further extended toward the non-
oxidative biopassivation of silicon-on-insulator (SOI) wafers, whose topmost 30–50 nm 
single-crystal silicon layer is the substrate in the fabrication of SiNW sensors.  Chapter 5 
11 
has been taken in part from the Journal of the American Chemical Society 2006, 128, 
9518–9525 (see also Appendix D). 
12 
1.3  REFERENCES 
1. (a) Fan, R.; Vermesh, O.; Srivastava, A.; Yen, B. K. H.; Qin, L.; Ahmad, H.; 
Kwong, G. A.; Liu, C.-C.; Gould, J.; Hood, L.; Heath, J. R. Nat. Biotechnol. 
2008, 26, 1373–1378. (b) Hood, L.; Heath, J. R.; Phelps, M. E.; Lin, B. Science 
2004, 306, 640–643. (c) Phelan, M. L.; Nock, S. Proteomics 2003, 3, 2123–2134. 
2. Larsen, M. R. Methods Mol. Biol. 2003, 251, 245–262. 
3. Dudkin, V. Y.; Miller, J. S.; Dudkina, A. S.; Antczak, C.; Scheinberg, D. A.; 
Danishefsky, S. J. J. Am. Chem. Soc. 2008, 130, 13598–13607. 
4. Engvall, E.; Perlmann, P. J. Immunol. 1972, 109, 129–135. 
5. (a) Cox, J. C.; Hayhurst, A.; Hesselberth, J.; Bayer, T. S.; Georgiou, G.; 
Ellington, A. D. Nucleic Acids Res. 2002, 30, e108–e108. (b) Lee, J. F.; 
Hesselberth, J. R.; Meyers, L. A.; Ellington, A. D. Nucleic Acids Res. 2004, 32, 
D95–D100. (c) Famulok, M.; Mayer, G.; Blind, M. Acc. Chem. Res. 2000, 33, 
591–599. (d) Gold, L.; Polisky, B.; Uhlenbeck, O.; Yarus, M. Annu. Rev. 
Biochem. 1995, 64, 1094–1110. (e) Burmeister, P. E.; Lewis, S. D.; Silva, R. F.; 
Preiss, J. R.; Horwitz, L. R.; Pendergrast, P. S.; McCauley, T. G.; Kurz, J. C.; 
Epstein, D. M.; Wilson, C.; Keefe, A. D. Chem. Biol. 2005, 12, 25–33. (f) Proske, 
D.; Blank, M.; Buhmann, R.; Resch, A. Appl. Microbiol. Biotechnol. 2005, 69, 
367–374. (g) Thiel, K. Nat. Biotechnol. 2004, 22, 649–651. 
6. Smith, G. P.; Petrenko, V. A. Chem. Rev. 1997, 97, 391–410. 
7. Lam, K. S.; Lebl, M.; Krchňák, V. Chem. Rev. 1997, 97, 411–448. 
8. (a) Lam, K. S.; Lebl, M.; Krchňák, V.; Wade, S.; Abdul-Latif, F.; Ferguson, R.; 
Cuzzocrea, C.; Wertman, K. Gene 1993, 137, 13–16. (b) Liu, R.; Marik, J.; Lam, 
K. S. J. Am. Chem. Soc. 2002, 124, 7678–7680. (c) Alluri, P. G.; Reddy, M. M.; 
13 
Bachhawat-Sikder, K.; Olivos, H. J.; Kodadek, T. J. Am. Chem. Soc. 2003, 125, 
13995–14004. (d) Torn øe, C. W.; Sanderson, S. J.; Mottram, J. C.; Coombs, G. 
H.; Meldal, M. J. Comb. Chem. 2004, 6, 312–324.  
9. Fabian, M. A.; Biggs III, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. 
D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. 
M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, 
M. A.; Lai, A. G.; Lélias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; 
Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. Nat. Biotechnol. 
2005, 23, 329–336. 
10. (a) Lewis, W. G.; Green, L. G.; Grynszpan, F.; Radić, Z.; Carlier, P. R.; Taylor, 
P.; Finn, M. G.; Sharpless, K. B. Angew. Chem. Int. Ed. 2002, 41, 1053–1057.  
(b) Manetsch, R.; Krasiński, A.; Radić, Z.; Raushel, J.; Taylor, P.; Sharpless, K. 
B.; Kolb, H. C. J. Am. Chem. Soc. 2004, 126, 12809–12818. (c) Bourne, Y.; Kolb, 
H. C.; Radić, Z.; Sharpless, K. B.; Taylor, P.; Marchot, P. Proc. Natl. Acad. Sci. 
USA 2004, 101, 1449–1454. (d) Kolb, H. C.; Finn, M. G.; Sharpless, K. B. 
Angew. Chem. Int. Ed. 2001, 40, 2004–2021. (e) Whiting, M.; Muldoon, J.; Lin, 
Y.-C.; Silverman, S. M.; Lindstrom, W.; Olson, A. J.; Kolb, H. C.; Finn, M. G.; 
Sharpless, K. B.; Elder, J. H.; Fokin, V. V. Angew. Chem. Int. Ed. 2006, 45, 
1435–1439. 
11. (a) Wu, P.; Leinonen, J.; Koivunen, E.; Lankinen, H.; Stenman, U.-H. Eur. J. 
Biochem. 2000, 267, 6212–6220. (b) Pakkala, M.; Jylhäranta, A.; Wu, P.; 
Leinonen, J.; Stenman, U. H.; Santa, H.; Vepsäläinen, J.; Peräkylä, M.; Närvänen, 
A. J. Pept. Sci. 2004, 10, 439–447. (c) Koistinen, H.; Närvänen, A.; Pakkala, P.; 
14 
Hekim, C.; Aaltonen, J.; Zhu, L.; Laakkonen, P.; Stenman, U.-H. Biol. Chem. 
2008, 389, 633–642. 
12. (a) Bunimovich, Y. L.; Shin, Y.-S.; Yeo, W.-S.; Amori, M.; Kwong, G. A.; 
Heath, J. R. J. Am. Chem. Soc. 2006, 128, 16323–16331. (b) Zheng, G.; Patolsky, 
F.; Cui, Y.; Wang, W. U.; Lieber, C. M. Nat. Biotechnol. 2005, 23, 1294–1301. 
13. Melosh, N.; Boukai, A.; Diana, F.; Gerardot, B.; Badolato, A.; Petroff, P.; Heath, 
J. R. Science 2003, 300, 112–115. 
14. Hu, K.; Fan, F.-R. F.; Bard, A. J.; Hillier, A. C. J. Phys. Chem. B 1997, 101, 
8298–8303.  
15. (a) Lud, S. Q.; Nikolaides, M. G.; Haase, I.; Fischer, M.; Bausch, A. R. 
ChemPhysChem 2006, 7, 379–384. (b) Neff, P. A.; Wunderlich, B. K.; Lud, S. 
Q.; Bausch, A. R. Phys. Status Solidi A 2006, 203, 3417–3423. 
16. Buriak, J. M. Chem. Rev. 2002, 102, 1271–1308. 
17. Israelachvili, J. Intermolecular and Surface Forces (London: Academic Press, 
1985). 
 
 
15 
 
 
 
 
 
 
Chapter 2 
Selection of a Multi-ligand Capture Agent for Carbonic Anhydrase II by Iterative In Situ 
Click Chemistry 
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2.1  INTRODUCTION 
Protein biomarkers comprise an important aspect of in vitro diagnostics.  Most 
protein detection methods rely upon antibody-based capture agents.1  A high-quality 
antibody exhibits a high affinity and specificity for its cognate protein.  However, 
antibodies are expensive, and can be unstable toward dehydration, pH variation, thermal 
shock, and many other chemical and biochemical processes.2,3  In addition, antibodies 
are not available for many potential protein biomarkers.  Thus, a major challenge is to 
discover an efficient and general approach for producing protein capture agents that 
display the positive attributes of antibodies, and exhibit a high level of chemical and 
biochemical stability.  This is becoming an increasingly important problem as single 
protein-based diagnostics are being replaced by measurements of large panels of protein 
biomarkers.4 
Several alternative protein capture agents, including oligonucleotide aptamers 
and phage display peptides, have been reported.  Each of them have attributes as well as 
significant limitations.5–11  A third alternative is to utilize one-bead one-compound 
(OBOC) peptide or peptide mimetic libraries.12–16  An advantage of OBOC libraries is 
that chemical stability, water solubility, and other desired properties may be achieved by 
design.  However, OBOC libraries are typically only 104–106 elements, and so 
significant trade-offs are made between peptide length and library chemical diversity.  
Phage display methods, by contrast, produce ~1012 element peptide libraries.  As a result, 
high-quality protein capture agents can be challenging to identify directly from standard 
OBOC peptide libraries. 
Herein, we combine the chemical flexibility of comprehensive, OBOC libraries 
of oligopeptides with in situ click chemistry17–21 to yield a target-guided,22–24 potentially 
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general screening approach for building high-affinity protein capture agents.  For this 
selection scheme, the protein target replaces the role of a Cu(I) catalyst for promoting 
the 1,3-dipolar “click” cycloaddition reaction between azide-functionalized and 
acetylene-functionalized peptide affinity agents.  First, an anchor (1°) ligand, containing 
acetylene (or azido) functionality, is selected for specific binding to a protein target via 
standard OBOC methods.  Second, the same protein target is utilized to template the 
covalent coupling between two peptide ligands, the pre-identified 1° ligand and a 
secondary (2°) ligand, which is selected by the protein target and the 1° ligand from a 
comprehensive OBOC library of 2° ligands displaying azido (or acetylene) functionality.  
Synthetic scale-up yields a biligand composed of the 1° and 2° ligands, joined together 
via the 1,2,3-triazole linker.  This biligand can then be used as a new anchor ligand, and 
the in situ click chemistry selection may be repeated to form a triligand, and so forth.  As 
the number of peptide ligands that comprise the multi-ligand capture agent increases, the 
binding affinity and specificity rapidly increase.25,26  Thus, multivalent binding agents 
can provide a potential shortcut to high affinity.27 
By instituting iterative in situ click chemistry selections with OBOC, we exploit 
both technologies to produce a triligand capture agent against human and bovine 
carbonic anhydrase II (hCAII and bCAII, respectively).  These two proteins are >80% 
identical in sequence (PDB ID: 1CA2, 1V9E).  Carbonic anhydrase II belongs to a 
family of metalloenzymes that catalyze the reversible hydration of carbon dioxide.  CA 
II expression is induced in the endothelium of neovessels in melanoma, renal carcinoma, 
and other cancers.28  Furthermore, CA II represents a major target antigen for stimulating 
an autoantibody response in melanoma patients,29 and is potentially a therapeutic target 
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for glial tumors.30  It has served as a model protein to understanding protein-ligand 
interactions, and is a demonstrated receptor for bivalent ligands.31–34 
In this chapter, the discovery process for high-affinity protein capture agents is 
discussed, using the triligand capture agent for b(h)CAII as the prototype.  First, the 
construction of OBOC libraries containing artificial amino acids is detailed.  Through 
iterative OBOC and in situ click chemistry selections, specific binders of b(h)CAII are 
identified sequentially—1° ligands, then biligands, and finally a triligand capture agent 
which displays ≥20 ng sensitivity for the protein target in dilute serum.  The entire 
screening approach is summarized in Figure 2.1. 
 
2.2  MATERIALS AND EXPERIMENTAL METHODS 
2.2.1  Materials 
Fmoc-D-X-OH (Fmoc, fluoren-9-ylmethoxycarbonyl) (X = Ala, Arg(Pbf) (Pbf, 
pentamethyldihydrobenzofuran-5-sulfonyl), Asn(Trt) (Trt, trityl), Asp(OtBu) (tBu, tert-
butyl), Glu(OtBu), Gln(Trt), Gly, His(Trt), Ile, Leu, Lys(Boc) (Boc, tert-
butyloxycarbonyl), Met, Phe, Pro, Ser(tBu), Thr(tBu), Trp(Boc), Tyr(tBu), and Val) 
were purchased (Anaspec; San Jose, CA) and used as received. TentaGel S-NH2 resins 
(90 μm, 0.31 mmol/g) (Rapp-Polymere; Tübingen, Germany) were utilized for OBOC 
library construction.  Amino acid coupling reactions were performed in 1-methyl-2-
pyrrolidinone (NMP, 99%) with HATU (2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylammonium hexafluorophosphate, ChemPep; Miami, FL) and N,N′-
diisopropylethylamine (DIEA).  For removal of Nα-Fmoc protecting groups, a solution 
of 20% piperidine in NMP was used.  For final deprotection of the peptide libraries, 
trifluoroacetic acid (TFA, 98% min. titration) and triethylsilane (TES) were used.  All 
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Figure 2.1.  A schematic representation of a method for preparing a multi-ligand capture 
agent.  (A) In the first step, a plurality of candidate oligopeptides in an OBOC library is 
contacted with a labeled target to identify an anchor (1°) ligand.  (B) In the second step, 
a modified 1° ligand from the first step is contacted with the same OBOC library now 
appended with an azide linker to identify a secondary (2°) ligand.  A biligand, formed by 
the 1° ligand of the first step and the 2° ligand, can be obtained.  (C) In the third step, the 
screen is repeated by employing the biligand formed from the second step as the new 
primary ligand to allow identification of higher-order multi-ligands. 
 
 
 
 
(A) 
(B) 
(C) 
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solvents and reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used as 
received, unless otherwise noted. 
 OBOC libraries were synthesized using a 180-degree variable-speed shaker, 
fitted with small sample adapter (St. John Associates; Beltsville, MD).  Fritted 
polypropylene solid-phase synthesis tubes were used for repeated split-mix cycles.  A 
24-port SPE vacuum manifold system (Grace; Deerfield, IL) was used for exchanging 
coupling solutions and washing the resins. 
Bovine carbonic anhydrase II (bCAII, C2522), from bovine erythrocytes, 
lyophilized powder, was obtained (Sigma-Aldrich; St. Louis, MO) and used as received.  
To prepare the protein for screening, dye-labeling was accomplished with the Alexa 
Fluor 647 Microscale Protein Labeling Kit (Invitrogen; Carlsbad, CA) following the 
manufacturer’s protocol for a low degree of labeling (DOL).  Protein (100 μg) was 
incubated with 6 mol equiv Alexa Fluor 647 succinimidyl ester for 15 min at 25 °C.  
Excess dye was removed by BioGel P-6 size exclusion resin (Bio-Rad; Hercules, CA).  
The labeled protein (bCAII-Alexa Fluor 647) was characterized by UV-Vis and mass 
spectrometry. 
Human carbonic anhydrase II (hCAII, C6165), from human erythrocytes, 
lyophilized powder, was obtained (Sigma-Aldrich; St. Louis, MO) and used in affinity 
and specificity studies.  Both bCAII and hCAII were tested by SDS gel electrophoresis, 
and confirmed to display a single band corresponding to 29,000 Da. 
 
2.2.2  Artificial Amino Acids 
Fmoc-D-propargylglycine (Fmoc-D-Pra-OH) was acquired (Chem-Impex 
International; Wood Dale, IL) and used as the acetylene handle for construction of 
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ligands.  Azide-containing amino acids Fmoc-Az4-OH (and intermediates 1a-3a) and 
Fmoc-Az8-OH (and intermediates 1b-3b) were synthesized using a modification of 
literature protocols (Scheme 2.1).35–37 
Azidobutylbromide (1a).  To a solution of 1,4-dibromobutane (123 mmol), 
sodium azide (61.5 mmol) was added and stirred overnight in N,N′-dimethylformamide 
(DMF) at 50 °C.  The reaction was diluted with ethyl acetate, and the organic layer was 
washed with water, then brine, and then dried over MgSO4.  The crude residue was 
purified by silica gel chromatography (100% hexanes) to give a product (80%) as a clear 
oil.  1H NMR (300 MHz, CDCl3): δ 3.44 (2H, t, J = 6.3 Hz), 3.34 (2H, t, J = 6.6 Hz), 
1.93-1.98 (2H, m), 1.74-1.79 (2H, m). 
Azidooctylbromide (1b).  Synthesis was carried out as described above, except 
1,8-dibromooctane was used as the starting material.  1H NMR (300 MHz, CDCl3):  
δ 3.41 (2H, t, J = 6.9 Hz), 3.26 (2H, t, J = 6.6 Hz), 1.86 (2H, p, J = 6.9 Hz), 1.60 (2H, p, 
J = 8.7 Hz), 1.34-1.55 (4H, m). 
Diethyl 2-acetamido-2-(4-azidobutyl)malonate (2a).  To a solution of 0.598 g 
(0.026 mol) sodium metal in 25 mL absolute EtOH, 5.65 g diethyl acetamidomalonate 
(0.026 mol) was added, following previously published procedures.35  The mixture was 
stirred for 30 min at room temperature.  By dropwise addition, azidobutylbromide 1a 
(4.82 g, 0.027 mol) was added with stirring.  The reaction mixture was stirred for 2 h at 
room temperature and refluxed for 6 h at 80 °C. After cooling overnight, the reaction 
mixture was concentrated to dryness, and the residue was extracted with diethyl ether.  
The combined ether extracts were washed with water, sat. NaHCO3, water, and brine, 
and were dried over MgSO4 and then concentrated.  Silica gel chromatography 
(Hex:EtOAc = 1:1) gave a product (63%) as a clear, viscous oil.  1H NMR (300 MHz,  
22 
 
 
 
 
 
 
 
Scheme 2.1.  Artificial amino acid synthesis.  
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CDCl3): δ 6.77 (1H, s), 4.24 (4H, q, J = 6.9 Hz), 3.26 (2H, t, J = 6.9 Hz), 2.31-2.37 (2H, 
m), 2.04 (3H, s), 1.59 (2H, p, J = 7.5 Hz), 1.26 (6H, t, J = 6 Hz), 1.16-1.27 (2H, m).  
ESI-MS m/e 315. 
Diethyl 2-acetamido-2-(8-azidooctyl)malonate (2b).  Similar synthetic protocol 
as 2a was adopted, only with azidooctylbromide 1b serving as the starting material.  1H 
NMR (300 MHz, CDCl3): δ 6.76 (1H, s), 4.24 (4H, q, J = 7.2 Hz), 3.24 (2H, t, J =  
6.9 Hz), 2.27-2.33 (2H, m), 2.04 (3H, s), 1.56 (2H, p, J = 7.5 Hz), 1.25 (6H, t, J =  
7.2 Hz), 1.06-1.16, 1.2-1.4 (10H, m).  ESI-MS m/e 371. 
2-Azidobutyl amino acid (3a).  Following standard methods,36 the diester 2a 
(2.8 mmol) in 25 mL of 10% NaOH solution was heated to reflux for 4 h.  The solution 
was then neutralized with concentrated HCl and evaporated.  The residue was dissolved 
in 25 mL of 1 M HCl and heated to reflux for 3 h.  The solvent was reduced and 
extraction with MeOH afforded amino acid 3a as the hydrochloride salt (85%).  1H 
NMR (300 MHz, CD3OD): δ 3.98 (1H, t, J = 6.3 Hz), 3.35 (2H, t, J = 7.8 Hz), 1.45-1.7, 
1.85-2.05 (6H, m).  MALDI-MS m/e 173. 
2-Azidooctyl amino acid (3b).  Synthesis was carried out as described above, 
using diester 2b as the starting material.  1H NMR (300 MHz, CD3OD): δ 3.94 (1H, t,  
J = 6.3 Hz), 3.27 (2H, t, J = 6.9 Hz), 1.3-1.52, 1.52-1.62, 1.8-1.98 (14H, m).  ESI-MS 
m/e 229. 
Fmoc-2-Azidobutyl amino acid (Fmoc-Az4-OH).  The amino acid 3a  
(26.3 mmol) was dissolved in 0.45:0.55 H2O:THF (150 mL), and NaHCO3 (22.1 g,  
263 mmol) was added, following published methods.37  After the mixture was cooled to 
0 °C, Fmoc-OSu (9.7 g, 28.9 mmol) was added dropwise over 5 min.  The reaction 
mixture was allowed to come to room temperature and stirred overnight.  Evaporation of 
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THF was completed in vacuo and the aqueous residue was washed with diethyl ether  
(2 × 200 mL).  The aqueous layer was then collected and acidified with conc. HCl to  
pH 2 before extraction with ethyl acetate (4 × 100 mL).  The combined organic layers 
were washed with brine, dried over MgSO4, filtered, and concentrated.  The organic 
residue was purified by column chromatography (2% MeOH in DCM) to yield a white 
powder (48% yield).  1H NMR (300 MHz, CDCl3): δ 7.76 (2H, d, J = 7.5 Hz), 7.59 (2H, 
d, J = 6.9 Hz), 7.40 (2H, t, J = 7.5 Hz), 7.31 (2H, t, J = 7.5 Hz), 5.34 (1H, d, J = 7.8 Hz), 
4.49-4.59 (1H, m), 4.43 (2H, d, J = 6.6 Hz), 4.22 (1H, t, J = 6.6 Hz), 3.27 (2H, t, J =  
6.6 Hz), 1.3-2.0 (6H, m).  ESI-MS m/e 395. 
Fmoc-2-Azidooctyl amino acid (Fmoc-Az8-OH).  The amino acid 3b was 
treated to Fmoc protection as described above.  1H NMR (300 MHz, CDCl3): δ 7.75 (2H, 
d, J = 7.5 Hz), 7.57-7.61 (2H, m), 7.39 (2H, t, J = 7.5 Hz), 7.30 (2H, t, J = 7.2 Hz), 5.40 
(1H, d, J = 8.1 Hz), 4.42-4.52 (1H, m), 4.40 (2H, d, J = 7.2 Hz), 4.21 (1H, t, J = 7.2 Hz), 
3.23 (2H, t, J = 6.9 Hz), 1.18-1.98 (14H, m).  ESI-MS m/e 450. 
 
2.2.3  OBOC Oligopeptide Library Construction 
Randomized OBOC libraries of penta- to heptapeptides were synthesized 
manually via standard split-and-mix solid-phase peptide synthesis methods on 90 µm 
polyethylene glycol-grafted polystyrene beads (TentaGel S-NH2, 0.31 mmol/g, 2.86 × 
106 beads/g).12–14  Non-natural D-stereoisomers (denoted by lowercase one-letter amino 
acid code) were used at every possible position in the peptide sequence to infer intrinsic 
biochemical stability.  At least a 5-fold excess of beads was utilized in each library 
synthesis to ensure adequate representation of each library element.  A standard solid-
phase peptide synthesis method with Fmoc chemistry was used.38  All wash, 
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deprotection, and coupling steps were facilitated by 180-degree shaking of the resin.  
The resin was pre-swelled in NMP in a plastic fritted reaction vessel, and was separated 
into multiple aliquots.  Each aliquot was reacted with 2-fold molar excess (relative to 
resin) of a single Nα-Fmoc-amino acid.  Amide coupling was initiated by addition of a 2-
fold molar excess of HATU and a 6-fold molar excess of DIEA.39  The coupling reaction 
was run for 15 min.  Another 2 equiv Nα-Fmoc-amino acid, 2 equiv HATU, and 6 equiv 
DIEA were added, and allowed to react for 15 min (“double coupling”).  In some cases, 
“triple coupling” was performed with a third set of coupling reagents and Nα-Fmoc-
amino acids (Table 2.1, Libraries D, E, F, and G).  Following coupling, the aliquots were 
thoroughly washed (5 × NMP), mixed together into a single vessel, and deprotected with 
20% piperidine in NMP (30 min).  The resin was thoroughly washed (5 × NMP), dried 
(5 × DCM), and re-divided into multiple equal-mass aliquots for the next cycle of 
coupling.  The procedures were repeated until the desired length of peptide was attained. 
The amino acid side chain protecting groups were then removed by incubation in 
trifluoroacetic acid (95%), water (5%), and triethylsilane (2-fold molar excess per 
protected side chain) for 2 h at 25 °C.  The library resin was then neutralized with DMF, 
and washed thoroughly with DMF (5 ×), water (5 ×), methanol (MeOH, 5 ×), and 
methylene chloride (DCM, 5 ×),40 and then dried under vacuum and stored in phosphate-
buffered saline [PBS (pH 7.4)] + 0.05% NaN3 at 25 °C. 
 
2.2.4  Screening Procedures for Anchor Ligand 
A method for identifying an anchor (1°) ligand is schematically illustrated in 
Scheme 2.2.  In particular, in the illustration of Scheme 2.2, a fluorescently labeled 
protein of interest (11) is screened against an OBOC library of peptides (12).  Each bead  
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Table 2.1.  Libraries used in selecting a triligand capture agent for bCAII.a 
a Randomized positions are denoted by xi (for D-amino acids) and Azn (for azide-
containing artificial amino acids). 
 
 
 Formula Components # of unique 
sequences 
A x1x2x3x4x5 xi = 19 D-amino acids 
(no D-Cys) 
2,476,099 
B x1x2x3x4x5x6 xi = r, k, l, w, f, h, y 117,649 
C Azn-x2x3x4x5x6-Azn xi = 19 D-amino acids 
(no D-Cys) 
Azn = 1/3 Az4, 1/3 Az8, 
1/3 nothing 
22,284,891 
D x1x2x3x4x5x6-Tz1-kfwlkl xi = k, l, w, f, i, G, v 117,649 
Tz1 = triazole formed between Az4 (on terminal k) and D-Pra (on x6) 
E x7x6x5x4x3x2-Tz2-kwlwGl-
Tz1-kfwlkl 
xi = d, r, s, w, G, f, l 117,649 
Tz1 = triazole formed between Az4 (on terminal k) and D-Pra (on l) 
Tz2 = triazole formed between Az4 (on terminal x2) and D-Pra (on k) 
F Az4-x2x3x4x5x6x7 3200 
G x7x6x5x4x3x2-Tz2-kwlwGl-
Tz1-kfwlkl 
x2 = r, n, l, i; 
x3 = w, f, l, i; 
x4 = r, w, f, l, i; 
x5 = w, f, v, l; 
x6 = r, w, f, l, k; 
x7 = f, r 
3200 
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Scheme 2.2.  Selection of anchor ligands by OBOC screen. 
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contains a unique peptide (13) comprised of non-natural amino acids (D-stereoisomers) 
or artificial amino acids (displaying azide or acetylene functionalities).  The protein (11) 
and the library (12) are incubated for a period of time at a particular protein 
concentration (Table 2.2, Screen An1), and the “hit” beads (14) are identified by their 
fluorescence using a GenePix 4200 array scanner (λex = 635 nm).  Typically 0.1% or less 
of the beads are identified as hit beads, and are separated manually from the non-hit 
beads by micropipette (15).  The protein is removed from the beads by incubation with 
7.5 M guanidine hydrochloride (GuHCl, pH 2.0) for 1 h, and the peptides on single hit 
beads are sequenced using Edman degradation41 (Procise cLC Sequencing System, 
Applied BioSystems, Foster City, CA; see Appendix C) or MALDI-TOF/TOF mass 
spectrometry.42 
Once the hit peptide sequences (16) are identified, a histogram (17) that 
correlates the amino acid frequency vs. amino acid identity is prepared.  A second, more 
focused library (18) that uses those most commonly identified amino acids can then be 
prepared and re-screened against the protein (11) (Table 2.2, Screens An2a and An2b).  
This focused library can contain slightly longer peptides, and the screening process can 
involve a lower concentration of the protein (11).  This process can then be repeated 
until the desired affinity of peptide anchor ligand (19) is achieved.  The affinity of the 
peptide anchor ligand will depend upon the number of amino acids in the peptide, and 
the three-dimensional structure of the peptide, among other factors.  Affinities in the 
order of 10–4–10–6 M are typically achievable. 
 
2.2.5  In Situ Click Screening Procedures for Biligand 
Identification of the secondary (2°) ligand and formation of a biligand then can  
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   a All screens were conducted at pH = 7.4 and T = 25 °C, unless otherwise noted. 
 
 
Table 2.2.  Screening summary.a 
 
Screen Library [bCAII-
AF647] 
Time(h) % hit    
beads 
Buffer Other 
components 
An1 A 100 nM 1 h 0.02% PBS  N/A 
An2a B 50 nM 1 h 0.09% PBS  N/A 
An2b B 8 nM 24 h 2 hits PBS  N/A 
Bi1 C 50 nM 2 h; 37o C 
(no beads) + 
48 h; 37o C 
0.007% PBS + 1% 
DMSO (v/v) 
100 µM of 
lklwfk-(D-
Pra) 
Bi2a D 50 nM 17 h 0.07% PBSTBNaN3  N/A 
Bi2b D 10 nM 17 h 0.008% PBSTBNaN3  N/A 
Tri1 C 10 nM 2 h (no 
beads) +15 h 
0.007% PBSTBNaN3 
+ 1% DMSO 
(v/v)   
100 µM of 
(D-Pra)-
kwlwGl-Tz1-
kfwlkl 
Tri2 E 10 nM 17 h 0.008% PBSTBNaN3  N/A 
TriX A 10 nM 17 h 0.007% PBSTBNaN3 
+ 1% DMSO 
(v/v)   
100 µM of 
(D-Pra)-
kwlwGl-Tz1-
kfwlkl 
Tri3 F 0.5 nM 2 h (no 
beads) +18 h 
0.005%
-0.01% 
PBSTBNaN3 
+ 1% DMSO 
(v/v)   
100 µM of 
(D-Pra)-
kwlwGl-Tz1-
kfwlkl 
Tri4 G 0.25 nM 18 h 0.005%
-0.01% 
PBSTBNaN3  N/A 
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be performed according to the method schematically illustrated in Scheme 2.3.  A typical 
screen begins with incubation of a library (12) in PBS (pH 7.4) + 0.1% Tween 20 + 
0.1% bovine serum albumin (BSA) + 0.05% NaN3 (PBSTBNaN3) for 1 h, with shaking, 
to block non-specific protein binding.34  One of the anchor ligands (19) from the 
screening procedures in Section 2.2.4 is added to the protein of interest (11) at a 
concentration that is dependent upon its binding affinity.  It is desirable that this 
concentration of anchor ligand (19) is at least two orders of magnitude higher than the 
KD.  All in situ click chemistry screens (Scheme 2.3) started with an initial 2 h pre-
incubation of bCAII-Alexa Fluor 647 with the anchor ligand (20), which was followed 
by addition of the OBOC library of 2° ligands (21) and continuation of the screen (Table 
2.2, Screen Bi1).  This OBOC oligopeptide library is constructed similarly to the 
candidate library for anchor ligands (12), except that the azide components (22) are 
replaced by acetylene functionalities.  Following in situ screening, beads are washed 
with 3 × 5 mL PBSTBNaN3, 3 × 5 mL PBS (pH 7.4) + 0.1% Tween 20, and then 6 × 5 
mL PBS (pH 7.4). 
As with the screening procedures in Section 2.2.4, the hit beads (23) are 
identified by their fluorescence and separated from the non-hit beads (15).  While the hit 
beads can contain a certain amount of biligand formed by the protein-catalyzed coupling 
of bead-bound 2° ligand with anchor ligand, the majority of the peptide on the hit beads 
(23) is actually 2° ligand that did not participate in the “click” reaction.  The protein 
target and excess anchor ligand are removed from the bead by incubation with 7.5 M 
GuHCl (pH 2.0) for 1 h, the peptide (24) on the bead is sequenced using standard 
methods, and a histogram (25) that correlates amino acid frequency vs. amino acid 
identity is constructed.  A second, more focused library (26) that utilizes those most  
31 
 
Scheme 2.3.  Selection of biligand by in situ click/OBOC screen.  Similarly, triligands 
(27) may be selected by iteration of this screening method, utilizing a biligand as the 
anchor unit (19). 
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commonly identified amino acids may then be prepared and re-screened against the 
protein (11).  Once again, the hit beads are identified via peptide sequencing (24).  This 
second library of 2° ligands can contain slightly longer peptides, and the screening 
process can involve a lower concentration of the protein (11). 
 
2.2.6  In Situ Click Screening Procedures for Higher-Order Multi-ligands 
In situ click screening procedures operate similarly to Scheme 2.3 for 
identification of higher-order multi-ligands such as the triligand in Figure 2.1.  The in 
situ click/OBOC screen for this triligand (Table 2.2, Screens Tri1 and Tri3) contained 
an initial 2 h pre-incubation of bCAII-Alexa Fluor 647 with biligand anchor, which was 
followed by addition of the OBOC library of 3° ligands and continuation of the screen.  
As a negative control, screen TriX was performed with an azide-free OBOC library of 
3° ligands. 
 
2.2.7  Validation of In Situ Click/OBOC Multi-ligand Screening Procedures 
Binary component screen for in situ biligand.  Stock solutions of 2° ligand 
(azide, Az4-kiwiG, 13.1 mM) and anchor ligand (acetylene, lklwfk-(D-Pra), 2.1 mM) 
were prepared in DMSO.  Stock solutions of bCAII and bovine serum albumin (BSA) 
were prepared in PBS (pH 7.4).  Each reaction contained 394 μM azide, 65 μM alkyne, 
and 36 μM protein in 100 μL PBS (pH 7.4) + 6% DMSO (v/v).  Reactions proceeded for 
48 h at 37 °C, followed by 5 days at 25 °C.  Reactions were quenched with 100 μL of  
7.5 M GuHCl (pH 2.0), and proteins were subsequently removed by centrifugal filtration 
(Microcon YM-3, Millipore, Billerica, MA). 
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The formation of in situ biligands was identified by MALDI-MS.  Control 
experiments were conducted (1) in the absence of bCAII, and (2) replacing bCAII with 
BSA, to verify that the click reaction between the azide and alkyne is specific to the 
bCAII protein target.  A third control, performed in the absence of protein, represents the 
slow thermally driven reaction between solutions of azide and alkyne. 
On-bead biligand screen.  Synthesis of Library D was achieved on bead via the 
Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC),43–45 as described in Section 2.2.9.  
Screens Bi2a and Bi2b (Table 2.2) were conducted using Library D following the 
general OBOC screening protocol described in Section 2.2.4.  After initial blocking with 
PBSTBNaN3 for 1 h, 10 nM to 50 nM bCAII-Alexa647 in PBSTBNaN3 was incubated 
with the library for 17 h at 25 °C, with shaking.  The screened beads were washed with 3 
× 5 mL PBSTBNaN3, then 3 × 5 mL PBS (pH 7.4) + 0.1% Tween 20, and finally 6 × 5 
mL PBS (pH 7.4).  The beads were imaged for fluorescence, and the hits were selected 
by micropipette.  After washing the hits to remove bound protein [7.5 M GuHCl (pH 
2.0)], their sequences were determined by Edman degradation. 
On-bead triligand screen.  Synthesis of Libraries E and G was achieved on 
bead via the CuAAC, as described in Section 2.2.9.  Screens Tri2 and Tri4 (Table 2.2) 
were conducted following the general OBOC screening protocol described in Section 
2.2.4, using <10 nM bCAII-Alexa647 and fluorescent detection of hits. 
 
2.2.8  Bulk Peptide Synthesis 
Bulk synthesis of hit peptide sequences was performed on either Fmoc-Rink 
amide MBHA (50 μm, 0.67 mmol/g, AnaSpec) or Biotin-PEG-NovaTag resin (0.48 
mmol/g; Novabiochem), on a typical resin scale of 0.2 g per sequence.  Crude peptides 
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were precipitated with ether, and then purified to >95% by HPLC (Beckman Coulter 
System Gold 126 Solvent Module and 168 Detector, Fullerton, CA) on a C18 reversed-
phase semi-preparative column (Phenomenex Luna 10 µm, 250 × 10 mm).  The pure 
peptides were used for affinity measurements, in situ click/OBOC screens, and binding 
assays.  Hit peptide sequences were also re-synthesized on TentaGel S-NH2 on a similar 
resin scale, and used for on-bead binding assays. 
Installation of polyethylene glycol linkers (EG)n was achieved by Fmoc-NH-
(PEG)5-COOH (22 atoms) (Novabiochem) via SPPS with standard HATU/DIEA 
coupling.  N-terminal biotin labeling of certain sequences was achieved via SPPS with 
standard HATU/DIEA coupling and overnight reaction. 
It should be noted that the protein-templated in situ click reaction may yield 
product regioisomers that are either anti (1,4), syn (1,5), or a mixture of the two 
geometries.  Although we have not yet determined which regioisomers of the in situ 
click products were formed, the authentic multi-ligands synthesized by CuAAC to test 
affinity and specificity were definitely the 1,4-triazole (see Chapter 3). 
All anchor ligands, biligands, and triligands were prepared in bulk by solid-phase 
synthesis, purified by HPLC, and analyzed by mass spectrometry prior to further study.  
Their characterization is as follows: 
lklwfk-(D-Pra) (Figure 2.2A).  MALDI-MS of the purified 1° ligand gave peaks 
at m/z 928.7 for [M + H]+ and 950.7 for [M + Na]+. 
Az4-kiwiG (Figure 2.2B).  ESI-MS of the purified 2° ligand gave peaks at m/z 
385.2 for [M + 2H]2+ and 769.5 for [M + H]+. 
lklwfk-Tz1-kiwiG (Figure 2.2C).  MALDI-MS of the purified biligand gave a 
peak at m/z 1808.4 for [M + H]+. 
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Figure 2.2.  Structures of representative 1° ligands (A, E), 2° ligands (B, D, F), and 
biligands (C, G, H) which were isolated as moderate affinity binders of bCAII. 
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Az4-kfwlkl (Figure 2.2E).  ESI-MS of the purified 1° ligand gave peaks at m/z 
329.9 for [M + 3H]3+, 494.3 for [M + 2H]2+, and 987.6 for [M + H]+. 
kwlwGl-(D-Pra) (Figure 2.2D).  MALDI-MS of the purified 2° ligand gave 
peaks at m/z 897.0 for [M + H]+, 919.0 for [M + Na]+, and 935.0 for [M + K]+. 
kwiwGw-(D-Pra) (Figure 2.2F).  MALDI-MS of the purified 2° ligand gave 
peaks at m/z 970.1 for [M + H]+ and 992.1 for [M + Na]+. 
kwlwGl-Tz1-kfwlkl (Figure 2.2G).  MALDI-MS of the purified biligand gave a 
peak at m/z 1993.6 for [M + H]+. 
kwiwGw-Tz1-kfwlkl (Figure 2.2H).  MALDI-MS of the purified biligand gave 
peaks at m/z 2066.9 for [M + H]+ and 2088.7 for [M + Na]+. 
(D-Pra)-kwlwGl-Tz1-kfwlkl (Figure 2.3A).  ESI-MS of the purified biligand 
anchor gave peaks at m/z 711.1 for [M + 3H]3+ and 1066.1 for [M + 2H]2+. 
(D-Pra)-k(Boc)w(Boc)lw(Boc)Gl-Tz1-k(Boc)fw(Boc)lk(Boc)l (Figure 2.3B).  
ESI-MS of the biligand anchor as the fully protected peptide gave peaks at m/z 1365.3 
for [M + 2H]2+ and 2731.6 for [M + H]+. 
Biotin-(EG)5-(D-Pra)-kwlwGl-Tz1-kfwlkl (Figure 2.3C).  MALDI-MS of the 
purified biotinylated biligand anchor gave peaks at m/z 1325.9 for [M + 2H]2+ (minor) 
and 2649.9 for [M + H]+ (major). 
Az4-nlivfr (Figure 2.4A).  MALDI-MS of the purified 3° ligand gave a peak at 
m/z 914.5 for [M + H]+. 
Az4-nlivfr-(EG)3-Biotin (Figure 2.4B).  MALDI-MS of the purified biotinylated 
3° ligand gave a peak at m/z 1343.8 for [M + H]+. 
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Figure 2.3.  (A) Biligand anchor, employed for in situ click/OBOC screens.  (B) Fully 
protected biligand anchor, used in bulk triligand synthesis.  (C) Biotinylated biligand 
anchor, used in specificity experiments and assays for detecting on-bead, protein-
templated multi-ligand. 
 
  
 
Figure 2.4.  (A, B) Tertiary (3°) ligands.  (C, D) Triligand capture agent, where the 1° ligand is colored in blue, the 2° ligand in red, 
and the 3° ligand in light green.  The connections between the ligands are formed by 1,2,3-triazoles (Tz1 and Tz2).
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rfviln-Tz2-kwlwGl-Tz1-kfwlkl (Figure 2.4C).  MALDI-MS of the purified 
triligand gave peaks at m/z 1522.9 for [M + 2H]2+ (minor) and 3045.7 for [M + H]+ 
(major). 
rfviln-Tz2-kwlwGl-Tz1-kfwlkl-(EG)3-Biotin (Figure 2.4D).  MALDI-MS of the 
purified biotinylated triligand gave peaks at m/z 1737.5 for [M + 2H]2+ (minor) and 
3472.0 for [M + H]+ (major). 
 
2.2.9  On-Bead Biligand and Triligand Synthesis 
For preparing Libraries D, E, and G (Table 2.1), as well as for bulk synthesis of 
biligand and triligand candidates, the Cu(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC)43–45 was carried out on bead, with 4 general steps: (1) anchor ligand synthesis, 
(2) acetylation, (3) click reaction, and (4) addition of 2° ligand sequence.  Scheme 2.4 
illustrates the acetylation and click reactions for a 6-mer peptide (Z = any amino acid).  
The fully protected TentaGel S-NH2 bead-bound anchor ligand (0.420 g, 0.13 mmol) 
was capped by a solution of acetic anhydride (1 mmol) in 2,6-lutidine and DMF.46  The 
acetylated peptide was reacted with Fmoc-D-Pra-OH (0.218 g,  
0.65 mmol) in the presence of CuI (0.124 g, 0.65 mmol), L-ascorbic acid (0.114 g,  
0.65 mmol), and DMF/piperidine (8/2) at 25 °C for 6 h.47  The resin was washed with  
5 × 5 mL Et2NCSSNa•3H2O (sodium diethyldithiocarbamate trihydrate, 1% w/v), 
containing 1% DIEA (v/v) in DMF to remove the coordinated copper from click 
reaction.48 
The biligand anchor (D-Pra)-kwlwGl-Tz1-kfwlkl was synthesized on 2-
chlorotrityl chloride (1.6 mmol/g) resin (Anaspec, San Jose, CA) using Scheme 2.4.  The 
biligand anchor was released either as the fully deprotected peptide by cleavage with  
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Scheme 2.4.  Acetylation and click reactions for a 6-mer peptide (Z = any amino acid) 
by solid-phase synthesis.  Peptide synthesis may continue via the Fmoc-protected 
primary amine of Zi to generate a linear multi-ligand capture agent. 
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95:5 TFA:water (+ 2 mol equiv TES per side chain protecting group), or as the fully 
protected peptide by cleavage with 99:1 DCM:TFA.49  To facilitate the on-bead click 
reaction, it is noted that the 1° ligand was synthesized here as Az4-kfwlkl (displaying N-
terminal Azn modification), and to this sequence was coupled D-Pra and the 2° ligand to 
produce the linear biligand. 
Triligands were synthesized by click reaction between the fully protected 
biligand anchor (D-Pra)-kwlwGl-Tz1-kfwlkl (0.274 g, 0.1 mmol, >95% HPLC) and 
bead-bound 3° ligand Az4-nlivfr (0.1 g, 0.03 mmol) using CuI (0.021 g, 0.1 mmol) and 
L-ascorbic acid (0.020 g, 0.1 mmol) in DMF/piperidine (8/2). 
 
2.3  RESULTS AND DISCUSSION 
2.3.1  Screening for Anchor (1°) Ligand against bCAII 
The anchor (1°) ligand was selected from a two-generation screen (An1, An2a, 
An2b) as summarized in Table 2.2.  For the first screen (An1), following Edman 
sequencing of hits, a histogram correlating the (position-independent) frequency of 
amino acid occurrence vs. amino acid identity (Figure 2.5A) suggested the importance of 
basic/charged (k, r) and aromatic residues (y, f, w) for an 1° ligand for bCAII.  A second, 
more focused library (Library B) of ~105 D-peptide compounds was constructed from 
the most commonly occurring amino acids, as identified from screen An1, but expanded 
into a 6-mer peptide, and screened under 50 nM bCAII (An2a) and 8 nM bCAII (An2b) 
conditions.  Figure 2.5B illustrates the results of these second-generation 1° ligand 
screens.  The more stringent screen (An2b) yielded two hits, hlyflr and lklwfk.  From 
these two candidates, one peptide (lklwfk) was arbitrarily chosen as the starting point for  
42 
        
R K W Y F H L S G T M I V A D P N E Q
0
20
40
60
80
100
D-amino acid
~500 (0.01%-0.02%)100 nM
# Hits, Library AbCAII-Alexa647
Fr
eq
ue
nc
y 
(re
ga
rd
le
ss
 o
f p
os
iti
on
)
2 (0.005%) → lklwfk, hlyflr8 nM
40 (0.09%)50 nM
# Hits, Library BbCAII-Alexa647
 
Figure 2.5.  Results of selecting a primary or anchor ligand of bCAII.  (A) Diagram 
plotting frequency vs. D-amino acid for 51 hit sequences isolated from screening Library 
A (first-generation anchor ligand screen).  (B) Hit rates for Library A and B (second-
generation anchor ligand) screens, leading to the selection of two anchor ligands (lklwfk 
and hlyflr). 
(A) 
(B) 
43 
a 1° ligand for use in multi-ligand screens.  A complete list of 1° ligand hit sequences 
from OBOC selections can be found in Appendix B. 
The peptide lklwfk was then functionalized with either an azide (-N3) or 
acetylene (-C≡C-H) terminus, fluoresceinated, and produced in bulk quantities for 
affinity measurements by fluorescence polarization.  Chapter 3 will describe that one 
such 1° ligand lklwfk-(D-Pra) displays an equilibrium dissociation constant of KD ≈  
500 µM for its interaction with bCAII.  This value is an estimate, since weak affinities 
are hard to quantify.  Surface plasmon resonance (SPR) was also employed to measure 
the affinity of bCAII for Az4-kfwlkl and lklwfk-(D-Pra) as 1° ligands, and a similarly 
low affinity was recorded (at least >10 µM, see Chapter 3). 
 
2.3.2  Identification of Secondary (2°) Ligands:  Biligand Screens 
A biligand is constructed of a 2° ligand that is covalently attached, via a 1,2,3-
triazole linkage, to the 1° ligand.  As illustrated by Figure 2.6, secondary (2°) ligands 
were identified by two complementary approaches: (1) in situ click/OBOC biligand 
screens; (2) on-bead biligand screens.  In the first approach (Figure 2.6A), the protein 
acts as a catalyst for the in situ click assembly of the biligand on bead.  During this 
screen, the 1° ligand and protein coexist in solution, while the cognate library of 2° 
ligands is on bead.  In the second approach (Figure 2.6B), the 1° ligand is covalently 
coupled to the on-bead library of 2° ligands via the copper(I)-catalyzed azide-alkyne 
cycloaddition (CuAAC).  Such a library of pre-assembled biligands is screened against 
the protein target to discover 2° ligand candidates.  The protein target is not a catalyst in 
this approach; this screen was used as a validation tool for comparison against the in situ 
click/OBOC screens. 
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Figure 2.6.  A schematic illustrating the two types of biligand screen.  (A) In situ screen 
for a secondary (2°) ligand.  (B) The on-bead screen for a secondary (2°) ligand was 
utilized as confirmation that the in situ screen was performing its designed function. 
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            In situ click/OBOC biligand screen.  Based on the protein-catalyzed in situ 
click reactions reported by the Sharpless group17–21 only those 2° ligands that bind with 
bCAII and are in close proximity with the 1° ligand, and are in the correct orientation, 
will react to form the 1,2,3-triazole product.  Figure 2.7A illustrates the result of the 
first-generation in situ biligand screen Bi1 against bCAII, which utilized 100 µM lklwfk-
(D-Pra) as the 1° ligand and a comprehensive azide-modified Library C.  From 
histogram and raw analysis of hits, a 2° ligand Az4-kiwiG emerged as the best 
candidate, since its inherent motif was repeated several times.  Figure 2.7B shows an 
abbreviated list of the hit sequences isolated from screening Library C against 50 nM 
bCAII-Alexa647 (Bi1).  A complete list of biligand hit sequences from the in situ 
click/OBOC screens can be found in Appendix B. 
The very high sequence homology observed here was not witnessed for the 1° 
ligand screens, but is characteristic of all of the in situ biligand and triligand (see Section 
2.3.3) screens discussed in this thesis.  Note also that all of the peptides in Figure 2.7B 
contain at least one azide group, although, statistically, over one-third of the OBOC 
library does not contain azide groups at positions 1 or 7.  The high sequence homology, 
coupled with the persistence of azide groups in the selected 2° ligands, provides strong 
circumstantial evidence that the in situ click/OBOC screen worked to produce a biligand. 
 
On-bead biligand screen.  On-bead biligand screens (Bi2a and Bi2b) were 
carried out utilizing a focused CuAAC biligand library (Library D) that was prepared 
based on the sequencing results from screen Bi1.  All 2° ligand sequences obtained by 
screens Bi2a and Bi2b (Table 2.2) also display striking sequence homology.  Several 
sequences were repeated more than once, including kwlwGl and kwiwGw.  A residue- 
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     (A)          (B) 
Figure 2.7.  Identification of a 2° ligand by in situ click/OBOC screening against bCAII.  
(A) Diagram illustrating frequency (y-axis) of D-amino acids (x-axis) for 2° ligand 
candidates of a biligand isolated from screening Library C in the presence of the 1° 
ligand lklwfk-(D-Pra) and bCAII (screen Bi1).  (B) Abbreviated list of the 2° ligand 
sequences isolated from the screen of Figure 2.7A. 
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by-residue histogram analysis (Figure 2.8) of all 2° ligand hits illustrates a strong 
preference for only one particular amino acid at each residue position—1 (k), 2 (w), 4 
(w), and 5 (G)—in the 2° ligand component of the biligand capture agent.  The 
distribution of D-amino acids illustrated in Figure 2.8, based on the analysis of 37 
biligand hit beads, suggests this consensus sequence k-w-x3-w-G (where x3 = 
hydrophobic amino acid).  A complete list of biligand hit sequences from the on-bead 
biligand screens can be found in Appendix B. 
Several methods were employed to characterize the properties of biligand 
candidates.  First, homology derived from the 2° ligand sequences from both the in situ 
click/OBOC and on-bead screens provided clues.  Second, the three candidate 
biligands—kwlwGl-Tz1-kfwlkl, kwiwGw-Tz1-kfwlkl, and lklwfk-Tz1-kiwiG—were 
synthesized in bulk, and their binding affinities for bCAII were measured by SPR.  
Chapter 3 will describe that an equilibrium dissociation constant of KD ≈ 3 µM (bCAII) 
was determined for the best-binding biligand kwlwGl-Tz1-kfwlkl.  This value is two 
orders of magnitude greater than the affinity for the 1° ligand alone, meeting our goal of 
affinity enhancement. 
 
Binary component screen for in situ biligand.  Finally, the in situ click/OBOC 
biligand screening method can be validated by a binary component screen.  The 1° 
ligand lklwfk-(D-Pra) and 2° ligand Az4-kiwiG were combined in solution in the 
presence of protein target.  The bCAII-catalyzed assembly of biligand is typically 
monitored by analytical methods such as LC/MS.17–21  Here, MALDI-MS was used to 
monitor the extent of this reaction over several days (Figure 2.9).  The bCAII-catalyzed 
biligand product is marked with an arrow.  While it was encouraging that the 
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Figure 2.8.  Distribution of D-amino acids found in positions 1 to 6 based on the 
analysis of 37 biligand hit beads from screens Bi2a and Bi2b. 
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Figure 2.9.  Binary component in situ click chemistry screen of 1° ligand lklwfk-(D-Pra) 
and 2° ligand Az4-kiwiG, illustrating bCAII-catalyzed formation of biligand (marked by 
arrow).  (A) Bovine carbonic anhydrase II (bCAII).  (B) Bovine serum albumin (BSA) 
control.  (C) Buffer-only (no protein) control. 
(B) 
(A) 
(C) 
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background reactions (BSA, no protein) were less, the MALDI-MS result did not 
provide quantitative measurement of the signal-to-noise ratio and overall yield for the 
bCAII-catalyzed reaction.  Methods to quantitatively assess these were developed at the 
triligand level and are discussed in detail in Chapter 4. 
 
2.3.3  Identification of Tertiary (3°) Ligands:  Triligand Screens 
Once a biligand is identified, that biligand can serve as the new anchor ligand, as 
illustrated in Figure 2.1, and the same OBOC library may be employed to identify a 
triligand.  This process may be repeated with the same OBOC library until a multi-ligand 
with the desired affinity and specificity is reached.  With the biligand (D-Pra)-kwlwGl-
Tz1-kfwlkl serving as the anchor ligand, the Figure 2.1 in situ click/OBOC screen was 
repeated with Library C (Table 2.1) to identify a triligand rfviln-Tz2-kwlwGl-Tz1-
kfwlkl (Figure 2.4C).  It is crucial to note that the comprehensive Library C was applied 
again here, demonstrating the versatility of this type of general library. 
For the case of the triligand screens, a histogram charting the position-dependent 
frequency of amino acids observed in the hit beads was generated.  The consensus 
tertiary (3°) ligand was Az4-nlivfr (Figure 2.4A).  Figure 2.10 shows position-dependent 
histograms for the first-generation in situ click/OBOC screens, for peptides (a) with and 
(c) without an azide-containing amino acid, to generate a triligand.  For the in situ screen 
(Tri1, Figure 2.10A), one-third of the beads had no azide at the x1 or x7 positions, but 
interestingly, all hit beads contained an azide.  On the other hand, the first- and second-
generation on-bead CuAAC library screens (Tri2 and Tri4, Figure 2.10B), where the 3° 
ligand variable region was coupled via CuAAC (Tz2) to the biligand, yielded 
independent validation of the in situ result.  The final, consensus triligand sequence is  
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(C) No azide screen (no consensus)
(B) On-bead screen      
(A) In situ click/OBOC screen
 
Figure 2.10.  Method to validate protein-templated formation of a multi-ligand capture 
agent.  Position-dependent histograms are illustrated for the first-generation in situ 
click/OBOC screens, for tertiary ligands (A) with and (C) without an azide-containing 
amino acid, to generate a triligand.  First- and second-generation on-bead CuAAC 
library screens (B) independently confirmed the in situ result.  The final consensus 
triligand sequence is indicated in red.  Sample size: in situ = 25 hits; in situ no azide = 24 
hits; CuAAC library = 21 hits. 
a CuAAC conditions: Fully protected (D-Pra)-kwlwGl-Tz1-kfwlkl (0.274 g, 0.1 mmol, 
>98% HPLC), 0.03 mmol Library C, CuI (0.021 g, 0.1 mmol), and L-ascorbic acid 
(0.020 g, 0.1 mmol) were stirred in DMF/piperidine (8/2) overnight at 25 °C. 
 
 
 
 
 
52 
indicated by red font.  Both this on-bead triligand screen, and the in situ click/OBOC 
screen, yielded the same consensus sequence and confirmed the equivalence of the two 
types of screens. 
In the absence of azide (Figure 2.10C), the in situ triligand screens yielded 
completely different, and much less homologous, hit sequences.  This phenomenon 
resulted from the prevention of triligand capture agent formation by click chemistry 
(control screen TriX).  This screen illustrates the importance of the azide and acetylene 
functional groups, and their specific interaction on the surface of the target to produce a 
multi-ligand capture agent. 
The consensus 3° ligand obtained by second-generation in situ screen Tri3 
resembles almost exactly the 3° ligand isolated by the first-generation screen (Tri1).  
Such sequence homology is unique to the in situ screens, which display target-guided 
selection.  A complete list of triligand hit sequences from the in situ click/OBOC screens 
and on-bead triligand screens can be found in Appendix B. 
 The interaction between bCAII and triligand rfviln-Tz2-kwlwGl-Tz1-kfwlkl 
(Figure 2.4C) was measured by SPR.  Chapter 3 will describe that equilibrium 
dissociation constants of KD ≈ 45 nM (hCAII) and KD ≈ 64 nM (bCAII) were determined, 
and represent a fifty-fold affinity enhancement from the protein/biligand interaction. 
 
2.4  CONCLUSIONS 
It was our goal to develop a high-affinity protein capture agent with high affinity 
and specificity through the iterative conjugation of modest affinity peptides using in situ 
click chemistry.  An affinity enhancement due to in situ click conjugation was apparent 
at each screening level.  Even for a weakly binding anchor ligand (KD ≈ 500 µM), the 
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hits from biligand screens displayed high sequence homologies and affinities (KD ≈ 3 to 
10 µM).  Both types of biligand screens, in situ and on-bead, demonstrated this effect, 
suggesting that although the mechanism of the selection is different, the hits identified 
are essentially equivalent. 
At the triligand level, a similar concept was explored.  When the peptide ligand 
became approximately larger than a 15-mer, the OBOC library size was practically 
limited to <5 million sequences, and the in situ screen (Tri1) became the only way to 
sample increasing diversity and length.  Based on analysis of sequence homology, we 
discovered that the final triligand capture agent reflected in situ assembly, as the on-bead 
CuAAC triligand library (Table 2.2, Library E) was not comprehensive. 
The final triligand capture agent (Figure 2.4C) was demonstrated to bind to 
bCAII and hCAII with affinities of KD ≈ 64 nM and KD ≈ 45 nM, respectively, and in 
Chapter 3, we will provide evidence that it is a specific binder for the enzyme. 
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Chapter 3 
Affinities, Specificities, and Implementation of Multi-ligand Capture Agents in Standard 
Assays of Protein Detection 
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3.1  INTRODUCTION 
In Chapter 2, the screening methodology for discovery of a triligand capture 
agent for a specific target, namely human and bovine carbonic anhydrase II (hCAII and 
bCAII, respectively), was explored as a proof of concept.  During the course of multi-
ligand development, measurements of binding affinity, specificity, and other 
physicochemical properties for the isolated ligands were performed.  Characterization of 
hit-derived compounds provided guidance on selecting the most suitable anchor 
ligand(s), evaluating the quality of the screen, and deciding how many screens to 
perform.  The resultant triligand rfviln-Tz2-kwlwGl-Tz1-kfwlkl was further studied for 
efficacy as a capture and detection reagent in standard assays including dot blot, Western 
blot, and sandwich (ELISA-like) assay.  Through their potential to remove reliance on 
antibodies, multi-ligand capture agents may directly impact quantitative biology through 
such implementation in standard assays for protein detection. 
The binding affinities describing the interaction between b(h)CAII and the 
anchor ligands, biligands, and triligands have been characterized via several techniques, 
including fluorescence polarization and surface plasmon resonance (SPR).  The terms 
“binding affinity” or “affinity” as used herein indicate the strength of the binding 
between a ligand and protein target (CA II), and is expressed as an equilibrium 
dissociation constant (KD).  Binding affinities are influenced by non-covalent 
intermolecular interactions between the two molecules such as hydrogen bonding, 
electrostatic interactions, hydrophobic interactions, and van der Waals forces.  The 
smaller the dissociation constant, the more tightly bound is the ligand, or the better the 
binding affinity between the two molecules. 
61 
Specificities of multi-ligands have been demonstrated and optimized in one case 
(dot blot).  The term “specificity,” with reference to the binding of a ligand to a protein 
target (CA II), refers to the recognition, contact, and formation of a stable complex 
between the first molecule and the second molecule, together with substantially less to 
no binding interaction with other molecules that may be present.  With the protein target 
spiked in serum, dot blots, Western blots, and sandwich (ELISA-like) assays were 
employed to compare specificities of antibody vs. multi-ligand.  Detection sensitivities 
of triligand vs. biligand vs. anchor ligand were also studied.  As anticipated, the triligand 
rfviln-Tz2-kwlwGl-Tz1-kfwlkl was the most sensitive, detecting CA II at the ≥20 ng 
level from 10% porcine serum. 
Physicochemical properties of multi-ligands provide additional information on 
utility of capture agents in various biological assays.  Circular dichroism (CD) 
measurements indicated that the 1,2,3-triazole linker (Tz1 and Tz2) in a multi-ligand 
induces formation of a random coil structure, which is likely to influence the mechanism 
of binding to the protein target.  On the other hand, an activity assay of bCAII was 
utilized to assess capacity for active site binding by multi-ligands.  In addition, non-
natural amino acids in the form of D-stereoisomers were found to be useful ligand 
building blocks because they are not susceptible to enzymatic degradation.  Because the 
multi-ligands can be chemically synthesized and stored as a lyophilized powder, they 
have long shelf lives (>1 yr).  Since we have highly modular chemical control over 
capture agent synthesis, additional molecules or functional groups (e.g., fluorophores, 
small molecules, oligonucleotides, haptens, and other proteins) can be installed in 
desired locations to provide desired chemical or biological activity.  Similarly, if ultra-
62 
high affinity (e.g., KD ≈ pM) is a desired goal, the triligand can potentially be matured 
into a tetraligand capture agent via another iteration of the in situ click/OBOC screen. 
 
3.2  MATERIALS AND EXPERIMENTAL METHODS 
3.2.1  Chemicals 
For bulk biligand and triligand synthesis (see Chapter 2), acetylation reagents 
(acetic anhydride, 2,6-lutidine, and N,N-dimethylformamide) were purchased from 
Sigma-Aldrich (St. Louis, MO).  For the on-bead Cu(I)-catalyzed click reaction, 
copper(I) iodide, L-ascorbic acid, and sodium diethyldithiocarbamate trihydrate were 
purchased from Sigma-Aldrich (St. Louis, MO). 
Fluorescein isothiocyanate (FITC) was obtained from AnaSpec.  D-biotin and 4-
nitrophenyl acetate were obtained from Sigma-Aldrich (St. Louis, MO). 
 
3.2.2  Characterization of Affinity by Fluorescence Polarization  
The N-terminus of the anchor ligand was labeled with FITC following published 
protocols.1  After resin cleavage, the crude fluoresceinated anchor ligand was 
precipitated with ether and then purified to >95% by C18 reversed phase HPLC. 
Luminescence spectra were recorded by Fluorolog2 spectrofluorimeter (Jobin 
Yvon, Longjumeau, France) in the Beckman Institute Laser Resource Center (Pasadena, 
CA).  All samples contained 6 μM fluoresceinated anchor ligand and a concentration 
gradient of bCAII (0.2 to 800 μM) in PBS (pH 7.4) + 3% (v/v) DMSO.  Stock protein 
and anchor ligand concentrations were verified by UV-Vis using ε280 (bCAII) =  
57,000 M–1cm–1 or ε494 (FITC, 0.1 N NaOH) = 68,000 M–1cm–1 for fluoresceinated 
anchor ligand.  After incubation for 1 h at 25 °C in the dark, samples were excited at  
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488 nm (2-nm band-pass), and luminescence spectra were obtained between 500 and  
700 nm (4-nm band-pass).  All measurements were taken at 2-nm intervals with 0.5 s 
integration times at 25 °C.  All luminescence spectra were subjected to background 
subtraction. 
The ratio of sensitivities (G) for the vertically and horizontally plane-polarized 
light in the system was calculated by the equation G=IHH/IHV using the IHH and IHV 
luminescence spectra obtained from a peptide-only sample.  The luminescence spectra 
IVV and IVH were integrated, and the fluorescence polarization value (P) was calculated 
by applying Equation (1).  The polarization value, P, being a ratio of light intensities, is 
dimensionless, and is sometimes expressed in millipolarization units (1 polarization unit 
= 1000 mP Units). 
VHVV
VHVV
GII
GII
P +
−=            (1) 
The polarization values were fitted with a sigmoidal dose-response curve using Origin 
6.1 (Northampton, MA). 
 
3.2.3  Characterization of Affinity by Surface Plasmon Resonance 
Affinity measurements were performed using a Biacore T100 SPR (Caltech 
Protein Expression Center, Pasadena, CA) and research grade CM5 sensor chips (GE 
Heathcare).  The instrument was first primed with HBS-P+ [10 mM HEPES, 150 mM 
NaCl, 0.05% Tween20 (pH 7.4)] + 3% DMSO.  Flow cell 1 was used as a reference to 
subtract nonspecific binding, drift, and the bulk refractive index, while flow cell 2 (or 3) 
was immobilized with bCAII (or hCAII) following standard procedures.  A 1:1 mixture 
of 0.4 M EDC and 0.1 M NHS was used to activate flow cell 2, and 0.25 mg/mL bCAII 
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solution [prepared in 10 mM sodium acetate (pH 5.0)] was injected.2  Similarly, flow 
cell 3 was immobilized with hCAII following standard procedures using 0.25 mg/mL 
hCAII prepared in 10 mM sodium acetate (pH 5.5) buffer.3  Immobilization levels of 
~4000 RU were achieved using a flow rate of 100 µL/min over 420 s.  The instrument 
was then primed using running buffer (HBS-P+ + 3% DMSO).  Prior to the peptide 
analyte experiment, 8 buffer-alone cycles were completed to establish baseline 
stabilization. 
Triligands were dissolved in HBS-P+ + 3% DMSO buffer to produce 2 µM 
peptide stock solutions for each peptide, which were serially diluted by a factor of 2 to 
produce a concentration series down to 0.1 nM.  Biligands were dissolved in HBS-P+ + 
3% DMSO buffer to produce 5 µM peptide stock solutions for each peptide, which were 
serially diluted by a factor of 2 to produce a concentration series down to 2 nM.  Anchor 
(1°) ligands were dissolved in HBS-P+ + 3% DMSO buffer to produce ~10 µM peptide 
stock solutions for each peptide, which were serially diluted by a factor of 2 to produce a 
concentration series down to 300 nM.  For a given affinity measurement, these series of 
peptide solutions successively were injected into flow cell 2 (or 3) for 120 to 180 s of 
contact time, 300 s of dissociation time, and 200 s of stabilization time using a flow rate 
of 100 μL/min at 25 °C.  Data processing and affinity analysis, including background 
subtraction, was performed using Biacore T100 evaluation software (Version 2.0.1, 
Biacore).  Equilibrium dissociation constant (KD) values for 1:1 binding were extracted 
by nonlinear regression fitting of the data to Equation (2). 
RUeq = RUmax[peptide]/(KD + [peptide]),         (2) 
where RUeq is the measured response unit at a certain peptide analyte concentration and 
RUmax is the maximum response unit. 
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3.2.4  Enzymatic Activity Assay of Carbonic Anhydrase II 
Following previous methods,4 solution assays for esterase activity were 
conducted with 1.4 µM bCAII, 5 µM triligand rfviln-Tz2-kwlwGl-Tz1-kfwlkl, and  
50 µM 4-nitrophenyl acetate (4-NPA) in Tris buffer composed of 9 mM Tris-HCl and  
81 mM NaCl + 9% acetonitrile (v/v) + 1% DMSO (v/v).  Control assays were conducted 
in the absence of triligand, and in the absence of protein.  The hydrolysis of 4-NPA was 
monitored over a time course of 60 min, with absorbance measurements taken every  
6 min. 
 
3.2.5  Circular Dichroism of Triligand 
Circular dichroism spectra were measured by Aviv 62AD Spectropolarimeter 
(Aviv Associates, Lakewood, NJ) in a 1 mm cuvette at 25 °C.  Measurements of 15 μM 
triligand rfviln-Tz2-kwlwGl-Tz1-kfwlkl in 100 mM Tris-HCl (pH 7.5) were recorded 
between 200 and 260 nm with a band-pass of 1.5 nm. 
 
3.2.6  Dot Blot Specificity/Sensitivity Assays of Biligand and Triligand in Serum 
For these tests, Biotin-PEG-NovaTag resin (0.48 mmol/g; Novabiochem) was 
utilized for bulk synthesis of C-terminal biotin-labeled multi-ligands (Figure 3.7).  After 
resin cleavage, the crude biotinylated multi-ligand was precipitated with ether and then 
purified to >95% by C18 reversed phase HPLC. 
The b(h)CAII antigens were prepared as 1 mg/mL stocks in PBS (pH 7.4).  A 
dilution series of antigen was applied to a nitrocellulose membrane, typically ranging 
from 2 µg to 0.5 ng per spot.  The membrane was blocked at 4 °C overnight in 5% milk 
in Tris-buffered saline (TBS) [25 mM Tris, 150 mM NaCl, 2 mM KCl (pH 8.0)].  The 
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membrane was then washed with TBS.  The biotinylated multi-ligand was prepared at  
1 µM in 10% porcine serum in TBS + 0.1% DMSO (v/v) and incubated over the 
membrane at 4 °C overnight.  After washing with TBS for 1 h, 1:3000 Streptavidin-HRP 
(Abcam, Cambridge, MA) prepared in 0.5% milk/TBS was added to the membrane and 
incubated for 1 h.  After washing with TBS for 1 h, the membrane was developed with 
SuperSignal West Pico Chemiluminescent Enhancer and Substrate Solutions (Pierce, 
Rockford, IL) and then immediately exposed to HyBlot CL AR film. 
 
3.2.7  Western Blot Analysis Using Triligand 
For denaturing Western blot analysis, bCAII-spiked porcine serum was 
electrophoresed on a 12% Tris-HCl PAGE gel (Bio-Rad; Hercules, CA) in 1 × TGS  
[25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, pH 8.3].  Samples were prepared in 
Laemmli Sample Buffer (Bio-Rad) containing 0.05% (v/v) 2-mercaptoethanol, and 
boiled before electrophoresis.  Gels were transferred to nitrocellulose in 1 × TGS 
containing 20% methanol, over 1 h at 100 V. 
For native Western blot analysis, bCAII-spiked porcine serum was 
electrophoresed on a 12% Tris-HCl PAGE gel (Bio-Rad; Hercules, CA) in 1 × TG  
[25 mM Tris, 192 mM glycine, pH 8.3].  Samples were prepared in Native Sample 
Buffer (Bio-Rad) for electrophoresis.  Gels were transferred to nitrocellulose in 1 × TG 
containing 20% methanol, over 3 h at 100 V. 
After transfer, the nitrocellulose membrane was blocked at 4 °C overnight in 5% 
milk/TBS.  The membrane was then washed with TBS.  The biotinylated triligand  
rfviln-Tz2-kwlwGl-Tz1-kfwlkl-(EG)3-Biotin was prepared at 1 µM in 0.5% milk/TBS + 
0.1% (v/v) DMSO and incubated over the membrane overnight at 4 °C.  Alternately, a 
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separate membrane was probed with 1:4000 primary antibody (biotinylated anti-bCAII; 
Rockland Immunochemicals, PA) for 1 h at 4 °C.  After washing with TBS for 1 h, 
1:3000 Streptavidin-HRP prepared in 0.5% milk/TBS was added to the membranes and 
incubated for 1 h.  After washing with TBS for 1 h, the membranes were developed with 
SuperSignal West Pico Chemiluminescent Enhancer and Substrate Solutions (Pierce; 
Rockford, IL) and then immediately exposed to HyBlot CL AR film. 
 
3.2.8  Sandwich (ELISA-like) Assays Using Triligand 
Reacti-Bind Streptavidin high binding capacity coated 96-well plates (~125 pmol 
biotin/well; Pierce, Rockford, IL) were utilized for this experiment.  The biotinylated 
multi-ligand was prepared at 3 µM in 0.5% milk/TBS, and incubated for 1 h at 25 °C.  
After washing each well with 5% milk/TBS (3 ×), the plate was filled with 5% milk/TBS 
and blocked for 1 h at 25 °C.  A serial dilution of bCAII antigen was prepared in 10% 
porcine serum, ranging from 1 mM to 1 pM, and incubated for 1 h at 25 °C.  After 
washing each well with 5% milk/TBS (3 ×), 1:1000 polyclonal anti-bCAII, HRP 
conjugate (Abcam, Cambridge, MA) was added to each well in blocking buffer and 
incubated for 30 min at 25 °C.  After washing each well with 5% milk/TBS (3 ×), 
chromogenic substrate TMB (3,3’,5,5’-tetramethylbenzidine) was supplied to each well.  
After 20 min, the reaction was quenched with 1 M H2SO4 and analyzed by absorbance at 
450 nm on a plate reader. 
 
3.3  RESULTS AND DISCUSSION 
With the addition of each ligand to the capture agent, the affinity and the 
specificity of that capture agent for its cognate protein rapidly increase.  The screen 
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illustrated by Figure 2.1 was used to identify lklwfk-(D-Pra) as the anchor ligand and 
kwlwGl-Tz1-kfwlkl as the biligand, and ultimately implemented (D-Pra)-kwlwGl-Tz1-
kfwlkl as the new anchor ligand for identification of a triligand rfviln-Tz2-kwlwGl-Tz1-
kfwlkl against bCAII, according to the methods described in Chapter 2. 
 
3.3.1  Characterization of Anchor (1°) Ligand Affinities 
Fluorescence polarization.  To determine the binding affinity of the anchor (1°) 
ligands lklwfk-(D-Pra) and Az4-kfwlkl, fluorescence polarization was employed.  
Fluorescence polarization is a measure of the extent of molecular rotation by a 
fluorescent ligand during the period between excitation and emission with plane 
polarized light.5  Free ligands rotate quickly and tumble in and out of plane during their 
excited states.  Therefore, they have low polarization values upon excitation.  When a 
ligand is bound to a receptor (i.e., protein), the molecule remains largely stationary, and 
so the rotation of the ligand is smaller in its excited state, and hence high polarization 
values are observed.  In these experiments, ligands are typically labeled with a 
fluorescent dye of a high quantum yield, such as FITC (~4 ns excited lifetime). 
The results of a fluorescence polarization experiment to characterize the 
interaction between bCAII and a fluoresceinated lklwfk-(D-Pra) are shown in Figure 3.1.  
The fluoresceinated anchor ligand was titrated with increasing concentrations of the 
protein target (0.2 to 800 µM).  In high bCAII concentration, most fluoresceinated 
anchor ligands are bound to the protein.  This fluorescent ligand-protein complex will 
exhibit high fluorescence polarization.  However, as less bCAII is titrated, increasing 
amounts of free fluoresceinated anchor ligand will exist in the solution.  These unbound 
anchor ligands will contribute to a low fluorescence polarization reading.  Therefore, by  
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Figure 3.1.  Fluorescence polarization binding isotherm for the anchor ligand lklwfk-(D-
Pra), showing KD ≈ 500 μM.  For fluorescence polarization experiments, the anchor 
ligand was labeled with FITC at the N-terminus.  All samples contained 6 μM FITC-
anchor ligand and varying concentrations of bCAII (0.2 to 800 μM). 
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fitting the fluorescence polarization against the protein concentration, a value of KD ≈ 
500 μM was extrapolated to describe the strength of the bCAII/anchor ligand interaction. 
 
Surface plasmon resonance.  The binding affinities of 1° ligands lklwfk-(D-Pra) 
and Az4-kfwlkl were also determined by SPR, and confirm the previous fluorescence 
polarization result.  In SPR, real-time, label-free optical sensing of biomolecular binding 
events may be achieved through measurements of thickness (and refractive index) of 
films adsorbed on gold substrates.6  A transducing medium is usually formed on the gold 
substrate film through surface-immobilized biomolecules (e.g., receptors).  Changes in 
the refractive index of this transducing layer are induced by the binding of analyte to the 
biomolecule.  Measurement in binding response over time yields sensorgrams which can 
be fitted for KD and kinetics following a Langmuir binding isotherm. 
In Figure 3.2, sensorgrams depict the interaction of surface-immobilized bCAII 
with increasing concentration (300 nM to ~10 µM) of 1° ligands (A) lklwfk-(D-Pra) and 
(B) Az4-kfwlkl.  The analyte responses were quite weak, demonstrating KD >10–5 µM 
binding affinities for both 1° ligands, and represent a limit for Biacore analysis.  Since 
weak affinities are hard to quantify, this value is only an estimate. 
 
3.3.2  Characterization of Biligand Affinities 
Three candidate biligands were obtained by screening bCAII.  One biligand 
(lklwfk-Tz1-kiwiG) is the result of an in situ click/OBOC screen between a 
comprehensive bead library of azides, anchor ligand lklwfk-(D-Pra), and bCAII.  Two 
biligands (kwlwGl-Tz1-kfwlkl and kwiwGw-Tz1-kfwlkl) are the result of an on-bead  
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Figure 3.2.  SPR response sensorgrams obtained with increasing concentration (300 nM 
to ~10 µM) of 1° ligands (A) lklwfk-(D-Pra) and (B) Az4-kfwlkl demonstrate KD >10-
µM binding affinities to immobilized bCAII. 
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CuAAC biligand library screen.  These three biligands were synthesized in bulk, and 
their binding affinities for bCAII were measured using SPR. 
The binding responses (Figure 3.3A-B) reveal KD ≈ 10–6 M affinity of two 
biligands toward bCAII.  In particular, sensorgrams obtained with increasing 
concentration (2 nM to 5 µM) of the biligands (A) kwlwGl-Tz1-kfwlkl and (B) lklwfk-
Tz1-kiwiG demonstrate 3-μM and 11-µM binding affinities, respectively.  This proves 
that the in situ click/OBOC screen, whose selected biligand is depicted in Figure 3.3B, 
and the on bead CuAAC biligand library screen, whose selected biligand is depicted in 
Figure 3.3A, converge on similar biligand sequences with similar affinities, further 
validating our selection approach.  Furthermore, the SPR data for the best-binding 
biligand kwlwGl-Tz2-kfwlkl (Figure 3.3A), with an extrapolated affinity of KD ≈ 3 µM, 
represents a ~100-fold improvement over the binding affinity for 1o ligand interaction 
with the same protein. 
In Figure 3.3C, SPR response sensorgrams for biligand kwiwGw-Tz1-kfwlkl are 
represented.  These data were irregular and illustrated a significant amount of non-
specific binding at high analyte concentrations (i.e., evidenced by RU exceeding Rmax 
and high background binding on flow cell 1, data not shown).  As this biligand sequence 
differs from the best-binding biligand of Figure 3.3A by only two residues (Res3: l?i 
and Res6: l?w), we have indirect evidence of the apparently high binding specificity of 
bCAII for only certain sequences. 
In view of the above considerations, the biligand anchor (D-Pra)-kwlwGl-Tz1-
kfwlkl was synthesized.  The D-propargylglycine linker was installed at the N-terminus 
of the peptide, to minimize perturbation to the linear biligand sequence.  In the presence  
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Figure 3.3.  SPR response sensorgrams obtained with increasing concentration (2 nM to 
5 µM) of the biligands (A) kwlwGl-Tz1-kfwlkl and (B) lklwfk-Tz1-kiwiG demonstrate 
3-μM and 11-µM binding affinities, respectively, to immobilized bCAII.   
(C) Sensorgrams for biligand kwiwGw-Tz1-kfwlkl were irregular and illustrated a 
significant amount of non-specific binding. 
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of this new anchor unit, an in situ click/OBOC screen between bCAII and the same bead 
library of azides was performed to identify triligand candidates. 
 
3.3.3  Characterization of Triligand Affinities 
Only one candidate triligand was obtained by screening bCAII, because the 
sequence rfviln-Tz2-kwlwGl-Tz1-kfwlkl was repeated several times in both generations 
of in situ click/OBOC screen.  This consensus triligand (Figure 3.4A) was synthesized in 
bulk and its binding affinity for both bCAII and hCAII was measured using SPR.  The 
binding responses (Figure 3.4B-C) reveal KD ≈ 45 nM (for hCAII) and KD ≈ 64 nM (for 
bCAII).  These equilibrium dissociation constants represent a 50-fold affinity 
enhancement compared to the interaction between biligand and target, and >103-fold 
affinity enhancement compared to the binding of 1° ligand and target (see Figures 3.1-
3.3, for comparison). 
 
3.3.4  Enzymatic Activity Assay of Carbonic Anhydrase II 
 Nature of triligand binding to bCAII.  The active site of bCAII possesses an 
intrinsic esterase activity which can be monitored spectrophotometrically.4  Specifically, 
bCAII catalyzes the hydrolysis of 4-nitrophenyl acetate (4-NPA) to 4-nitrophenol (4-NP), 
whose absorption can be monitored at 400 nm.  The enzyme-catalyzed hydrolysis 
proceeds at a range of pH and serves as a test for active site binding by common 
inhibitors (Scheme 3.1).  We utilized this assay to study the functional activity of bCAII 
as an esterase in the presence and absence of the triligand rfviln-Tz2-kwlwGl-Tz1-
kfwlkl.  The activity assay was performed to qualitatively assess the possibility of active 
site binding by the triligand. 
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Figure 3.4.  (A) Triligand capture agent, rfviln-Tz2-kwlwGl-Tz1-kfwlkl.  SPR response 
sensorgrams with increasing peptide concentration (0.1 to 162 nM) characterize triligand 
binding to immobilized human (B) and bovine (C) CA II targets, respectively.  Data 
analysis of this biomolecular interaction provided values of KD ≈ 45 nM (hCAII) and KD 
≈ 64 nM (bCAII). 
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Scheme 3.1.  Esterase activity of bCAII, using 4-NPA as the hydrolytic substrate. 
 
 
 
 
Figure 3.5.  Enzymatic activity of bCAII in the presence of the triligand rfviln-Tz2-
kwlwGl-Tz1-kfwlkl.  Absorbance data monitor the bCAII-catalyzed hydrolysis of  
4-NPA to 4-NP (ε = 18,400 M–1cm–1 at 400 nm) at the protein active site.  Experiments 
were performed with (red) and without (black) capture agent.  Additionally, an assay 
was performed in the presence of 4-NPA alone (blue) to determine the slow background 
hydrolysis of the ester in aqueous solution.  [bCAII] = 1.4 µM, [Triligand] = 5 µM, and 
[4-NPA] = 50 µM in Tris buffer [9 mM Tris-HCl, 81 mM NaCl, 9% acetonitrile (v/v), 
1% DMSO (v/v)]. 
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The experimental results are presented in Figure 3.5.  Regardless of whether the 
assay contained triligand, there was an initial “burst” in 4-NP formation, followed by a 
slow increase in the product formation over the 60 min.  Because there were no 
appreciable changes in the bCAII esterase activity when the triligand capture agent was 
included in the assay, apparently this peptide binds to an epitope distinct from the bCAII 
active site. 
 
3.3.5  Circular Dichroism of Triligand 
 Circular dichroism (CD) measures the differential absorption of left- and right-
handed circularly polarized light in solutions of optically active molecules such as 
peptides, proteins, and nucleic acids.  For peptides and proteins, secondary structures 
such as α-helix and β-sheet are easily resolved by CD.  The signature peaks for an α-
helix and β-sheet can be found at 222 and 208 nm, respectively.7 
The triligand rfviln-Tz2-kwlwGl-Tz1-kfwlkl was characterized as a random coil 
by CD (Figure 3.6).  The unfolded random coil structure may be a reflection that this 
oligopeptide was assembled linearly through successive protein-templated in situ click 
screens.  Since the random coil is not one specific shape, but a statistical distribution of 
shapes, this conformation suggests the idea that, in the absence of specific, stabilizing 
interactions with the protein target, the oligopeptide will "sample" all possible 
conformations randomly.8 
 
3.3.6  Dot Blot Specificity/Sensitivity Assays of Biligand and Triligand in Serum 
Dot blots are a common method for detecting proteins.  The sensitivity and  
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Figure 3.6.  CD spectrum for triligand rfviln-Tz2-kwlwGl-Tz1-kfwlkl, acquired at  
15 µM in 100 mM Tris-HCl (pH 7.5).  Lack of signature peaks at 222 nm (for α-helix) 
and 208 nm (for β-sheet) indicates that the peptide structure is that of a random coil. 
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specificity of multi-ligand capture agents for detecting b(h)CAII in complex 
environments were demonstrated through the use of dot blot experiments in 10% porcine 
serum.  For a dot blot, the solution containing the protein of interest is simply deposited 
onto an absorbent membrane material (typically nitrocellulose).  The capture agent 
(typically an antibody, or one of the multi-ligands of Figure 3.7) is labeled with biotin, 
and then exposed to the entire nitrocellulose membrane.  The membrane is washed to 
remove unbound material, and then horseradish peroxidase (HRP)-labeled streptavidin is 
added, attaching to the protein-bound biotin.  Optical methods are typically utilized to 
detect this binding.  Because we conducted dot blots experiments with the multi-ligand 
capture agent in dilute serum, both sensitivity and specificity may be addressed in a 
single assay. 
Results for the dot blot to use the triligand (Figure 3.7A) and the biligand anchor 
(Figure 3.7B) to detect hCAII and bCAII from dilute porcine serum are shown in Figure 
3.8.  It is noted that bCAII and hCAII are >80% identical by sequence (PDB ID: 1CA2, 
1V9E), and so both proteins were expected to be captured in this assay.  The results of 
this assay illustrate ~20 ng b(h)CAII detection sensitivity by the triligand in 10% porcine 
serum, while ~0.2 µg hCAII detection sensitivity is attained by the biligand anchor when 
the assay is performed under similar conditions.  We reason that the sensitivity correlates 
with overall affinity of the capture agent, and so it is no surprise that the triligand is the 
more sensitive binder.  Similarly, these results suggest that through the in situ 
click/OBOC screening method, we build specificity into our multi-ligands with each 
screening iteration. 
We also wanted to directly compare binding specificity of the triligand (Figure 
3.7A) against a commercially available antibody.  Figure 3.9 shows the results of dot  
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Figure 3.7.  Biotin conjugates of the (A) triligand rfviln-Tz2-kwlwGl-Tz1-kfwlkl and 
(B) biligand anchor (D-Pra)-kwlwGl-Tz1-kfwlkl.  These capture agents were 
implemented in dot blots, Western blots, and sandwich (ELISA-like) assays of bCAII. 
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Figure 3.8.  (A) Dot blot illustrating ~20 ng b(h)CAII detection sensitivity by the 
triligand of Figure 3.7A in 10% porcine serum.  When the biligand anchor of Figure 
3.7B is used as the primary capture agent in 0.1% serum (B), the sensitivity is reduced 
by more than 10-fold. 
(A) 
(B) 
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Figure 3.9.  Results of dot blots performed in 0.5% milk/TBS where the (A) triligand of 
Figure 3.7A or (B) polyclonal anti-bCAII were utilized as the primary capture agent.   
(A) The triligand appears to be specific for CA II.  (B) The polyclonal antibody displays 
an apparent cross-reactivity with unrelated proteins.  Proteins = 2 µg per spot. 
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blots performed in 0.5% milk/TBS where the (A) triligand (Figure 3.7A) or  
(B) polyclonal anti-bCAII were utilized as the primary capture agent.  Besides bCAII 
and hCAII, two human secreted proteins interleukin-2 (IL-2) and TNFα were included in 
the protein panel.  We also tested bovine serum albumin (BSA) as the spotted antigen in 
a separate blot, and neither triligand nor antibody displayed detectable cross-reactivity 
(data not shown).  While the triligand displayed a high degree of specificity for CA II in 
the blot of Figure 3.9, the antibody showed an apparent cross-reactivity for the unrelated 
human proteins.  This result is not surprising, as polyclonal antibodies generally sample 
diffuse epitopes.  However, qualitative analysis of spot intensity suggests that the 
antibody is the more sensitive capture agent.  From the results of Figures 3.8-3.9, we 
conclude that the triligand capture agent displays a comparable, or even better, 
specificity for b(h)CAII than the antibody, but the sensitivity remains to be optimized. 
 
3.3.7  Western Blot Analysis Using Triligand 
The Western blot is another common method for detecting proteins.  For the 
standard Western blot, proteins are subjected to denaturing gel electrophoresis and 
transfer to nitrocellulose.  For the native Western blot, proteins are exposed to non-
denaturing conditions for both electrophoresis and transfer.  Antibody or multi-ligand 
capture agents are then used to interrogate the proteins on the nitrocellulose membrane.  
After specific binding of the capture agent to the target, a secondary detection agent is 
added to specifically bind to the capture agent.  The secondary detection agent (e.g., 
streptavidin-HRP) often exhibits chemiluminescence which allows visualization of the 
results on film. 
84 
Demonstrations of Western blots to detect bCAII, with direct comparisons 
between the triligand (Figure 3.7A) and a commercial antibody, are shown in Figure 
3.10.  The denaturing Western blot of Figure 3.10A, utilizing polyclonal anti-bCAII as 
the primary capture agent, shows ~50 ng bCAII detection sensitivity.  Curiously, on the 
same gel (Figure 3.10B), bCAII was not detected by the triligand.  This result suggests 
that the triligand capture agent recognizes a 3-D protein epitope that is destroyed when 
the protein is subjected to denaturing conditions. 
To test this hypothesis, native Western blots were performed under similar, but 
non-denaturing, conditions.  We also took this opportunity to interrogate specificity by 
utilizing the antibody and triligand capture agents as probes against bCAII spiked in 
dilute serum.  The native gel of Figure 3.10C details the electrophoresed bCAII and 
serum proteins.  When this native gel was transferred and probed with polyclonal anti-
bCAII (Figure 3.10D), bCAII and a serum protein (MW ≈ 30-35 kDa) are detected.  We 
hypothesize that this upper band may be one of the related isozymes CA I or CA III, 
which show 58%-60% identity with each other and with CA II in amino acids at similar 
positions.9  Furthermore, CA I is five to six times as abundant as CA II in erythrocytes.9  
When the same native blot is probed with the triligand of Figure 3.7A (Figure 3.10E), 
only bCAII is detected, illustrating triligand specificity for native bCAII epitopes.  Even 
in the presence of serum, native Western analysis suggests that the triligand is 
potentially more specific than the commercial anti-bCAII antibody, and this result 
confirms our previous dot blot analysis. 
It should be noted that the detection sensitivity for the triligand in the native 
Western blot is not as high as in the dot blot (1 µg vs. 20 ng bCAII).  Under non-
denaturing conditions, the gel transfer step requires high voltage and is still inefficient,  
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Figure 3.10.  Results of Western blots performed under denaturing (A, B) and non-
denaturing conditions (C, D, E).  (A) The denaturing Western blot, utilizing polyclonal 
anti-bCAII as the primary capture agent, shows ~50 ng bCAII detection sensitivity.   
(B) On the same gel, bCAII was not detected by the triligand of Figure 3.7A.  (C) The 
native PAGE gel was stained with Coomassie, and details total protein content.   
(D) When this native gel is transferred and probed with polyclonal anti-bCAII, bCAII 
and a serum protein (MW ≈ 30-35 kDa) are detected.  (E) When the same native blot is 
probed with the triligand of Figure 3.7A, only bCAII is detected, illustrating triligand 
specificity for native bCAII epitopes.  bCAII loading (C, D, E) = 1 µg per lane. 
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as the proteins are only natively charged.  The poor transfer leads to the perceived 
reduction in sensitivity by the triligand in the native Western blot. 
 
3.3.8  Sandwich (ELISA-like) Assays Using Triligand 
The sandwich assay is a third common method for detecting proteins.  Sandwich 
assays typically rely on two antibodies, a primary capture antibody (1°) and a labeled 
detection antibody (2° antibody), for detecting the protein of interest.  In a typical ELISA 
sandwich assay, the 1° antibody is typically coated onto a surface, such as the surface of 
a well within a 96-well plate.  A solution (e.g., serum, urine, etc.) expected to contain a 
particular target protein is added to the well.  The target protein is then allowed to 
diffuse to the surface where it is captured by the 1° antibody.  The 2° antibody is then 
added to the same well.  This antibody is designed to bind to an orthogonal binding site, 
or epitope, of the target protein.  Furthermore, this 2° antibody is labeled in a way that 
allows for the antibody/protein/antibody sandwich to be detected optically or by some 
other means. 
For optical detection, the label is often an optically absorbent chromophore or a 
fluorescent dye molecule, and that label is often attached to the 2° antibody directly.  
The label is then detected by absorbance or fluorescence, and the signal intensity is 
proportional to the amount of protein captured in the assay.  Alternatively, the 2° 
antibody may be conjugated to biotin, and in that case, a labeled protein (e.g., 
streptavidin-HRP) is added subsequently to visualize the biotin.  Other methods are 
possible, such utilizing a gold nanoparticle as a label instead of the fluorescent or 
optically absorbent molecule, or using a radioactive molecule as the label, where the 
final detection is completed using a scintillation counter or appropriately sensitized film. 
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Figure 3.11.  (A) Schematic illustration of the structure of fully assembled ELISA-like 
sandwich absorbance assays using the triligand of Figure 3.7A to detect bCAII protein.  
(B) Experimental data of ELISA assays at varying concentrations of bCAII as performed 
in the wells of a 96-well plate.  Increasing bCAII concentration is detected as an 
increasing yellow color.  (C) Diagrams illustrating two assay conditions.  The target is 
presented in 0.5% milk/TBS (red curve) or in 10% porcine serum (black curve) to yield 
a sandwich assay with an analytical sensitivity of ~10 µM (~300 µg/mL). 
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Demonstration of sandwich-type ELISA assays on streptavidin-functionalized 
microtiter plates to detect bCAII using a combined commercial antibody (2° capture 
agent) and triligand of Figure 3.7A (as the 1° capture agent) is shown in Figure 3.11.  
Two assay conditions were used to compare the detection sensitivity for bCAII in 
buffered solution vs. a background of dilute serum (Figure 3.11C).  For the sandwich 
assay performed with bCAII presented in 0.5% milk/TBS (red curve), the analytical 
sensitivity is ~10 µM (~300 µg/mL).  This result is similar to the sandwich assay 
performed with bCAII presented in dilute serum (black curve), which further illustrates 
the utility of multi-ligand capture agents in standard assays of protein detection. 
Our triligand sandwich (ELISA-like) assay, however, does not yet approach the 
analytical sensitivity expected for most commercial sandwich assays (~1 pg/mL).  There 
are several areas for optimization of the Figure 3.11 assay.  First, it is possible that the 
triligand of Figure 3.7A and the commercial polyclonal anti-bCAII (HRP conjugate) are 
not an optimized reagent pair.  We did not test whether these two capture agents 
compete for similar (or the same) binding epitopes on bCAII before performing the 
sandwich assay.  Competition of this kind would translate to reduced sensitivity.  Second, 
our sandwich assay was an absorbance assay using TMB (3,3’,5,5’-tetramethylbenzidine) 
as the chromophore to visualize bound proteins.  Absorbance ELISAs are not nearly as 
sensitive as fluorescence ELISAs.  It has been reported that a five- to six-fold 
enhancement in signal-to-noise ratio at a given analyte concentration and a two- to five-
fold enhancement in sensitivity, as reflected by relative limits of detection, may be 
achieved with fluorogenic substrates.10  Third, the background absorbance is high (0.6 
Abs units), potentially masking sensitivity for the lower bCAII concentrations.  This 
background may be caused by insufficient washing during the assay, or possibly use of 
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too much polyclonal anti-bCAII (HRP conjugate).  Polyclonal antibodies display a 
higher risk of cross-reactivity since their epitopes are less precisely defined, and so there 
may have been some background binding to the serum- or milk-based proteins present in 
our assay. 
 
3.4  CONCLUSIONS 
As a companion to Chapter 2, this chapter focused on the properties and results 
of using multi-ligand capture agents in standard assays of protein detection.  
Measurements by fluorescence polarization and SPR served as direct evidence of the 
kind of affinity enhancement that one can achieve through multivalent binding 
interactions.  Starting from lklwfk-(D-Pra) (KD ≈ 500 µM) as the anchor (1°) ligand, 
moderate affinity biligands such as kwlwGl-Tz1-kfwlkl (KD ≈ 3 µM) were assembled by 
in situ click chemistry and represent a ~100-fold affinity improvement.  Using biligand 
(D-Pra)-kwlwGl-Tz1-kfwlkl as the new anchor unit, a triligand capture agent (rfviln-
Tz2-kwlwGl-Tz1-kfwlkl, KD ≈ 50 nM) was isolated by in situ click/OBOC selection and 
represents a 50-fold affinity enhancement compared to the interaction between biligand 
and target, and a >103-fold overall affinity enhancement compared to the binding of 1° 
ligand and target.  Interestingly, this triligand does not bind the active site of bCAII, but 
rather to a separate generalized epitope, and apparently the random coil structure of this 
peptide may become stabilized by specific binding with the target. 
Protein capture agents should exhibit both an affinity for their cognate protein, as 
well as a specificity for detecting that protein in complex environments.  Multi-ligands 
show initial efficacy as capture agents in standard assays including dot blot, Western 
blot, and sandwich (ELISA-like) assay.  The triligand was found to detect ≥ 20 ng CA II 
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in porcine serum as illustrated by dot blot.  The triligand was also found to detect ≥ 1 µg 
CA II from porcine serum in a non-optimized native Western blot.  Curiously, the 
triligand only recognizes a 3-D (native) protein epitope which argues for the exquisite 
nature of the in situ click/OBOC discovery process.  Non-optimized sandwich (ELISA-
like) absorbance assays using the triligand for bCAII capture and a polyclonal anti-
bCAII for detection yield an analytical sensitivity of ~10 µM (~300 µg/mL).  These 
feasibility demonstrations show great promise toward the routine implementation of 
protein capture agents in basic research and as medical diagnostic tools. 
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Chapter 4 
Assays for Quantifying Protein-Catalyzed Multi-ligands and  
Extensions to Other Proteins 
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4.1  INTRODUCTION 
Protein-templated in situ click chemistry is a low-yielding reaction, as it requires 
precise alignment of the azide and alkyne with respect to each other and the protein.  
Therefore, only a small fraction (<<1%) of the peptides on a particular bead will be 
converted to multi-ligands.  Previously in Chapters 2 and 3, I discussed the discovery of 
a triligand capture agent, possessing antibody-like attributes, for the model protein, 
bCAII.  We initially validated the in situ click assembly by analysis of sequence 
homology and binary component screens (monitored by MALDI-MS).  However, 
challenges remained in developing direct, quantitative assays to assess the yield of multi-
ligand capture agent following the in situ click/OBOC screen.  Such quantitative assays 
define the signal-to-noise ratio for the in situ click/OBOC selection, since background 
chemical processes can also contribute to “false” hits.  In this chapter, we will explore 
different assays for detecting on-bead, protein-templated triligand, such as colorimetric 
and quantitative polymerase chain reaction (QPCR) assays.  The low but detectable yield 
per protein-catalyzed in situ click reaction—approximately 0.000005% for bCAII—
confirms the exquisite demands of the process, and also provides guidance for the types 
of methods that can improve the signal-to-noise ratio for the in situ click/OBOC 
screening process. 
This result encouraged us to develop more sophisticated screening strategies for 
improving signal-to-noise ratio during in situ click/OBOC screens.  Such strategies 
incorporated anti-selections (following the selections) so as to remove hits that resulted 
from potential side reactions.  The strategies also included the direct detection of the 
bead-bound products of the protein-catalyzed click reaction.  Such product-based screens 
provide information that is highly complementary to that obtained from screens in which 
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hits are identified according to the presence of the target (i.e., the fluorescently labeled 
protein) on bead.  These strategies were able to take advantage of the modular 
construction of the multi-ligand capture agents.  As one example, by site-specific 
labeling the anchor (1°) ligand with biotin, we have a label that permits the direct 
monitoring of the in situ click reaction between 1° ligand and bead-bound 2° ligands.  
The use of this label is described in some detail within this chapter.  In a second example, 
through the use of a labeled antibody, we can probe for bead-bound proteins during an in 
situ click/OBOC screen.  These new screening strategies were applied toward the in situ 
click/OBOC selection of a biligand capture agent (KD ≈ 140 nM) against the blood-based 
protein biomarker prostate-specific antigen (PSA).  The rapid assembly of the biligand 
capture agent by the protein-catalyzed process was expedited to two weeks by utilization 
of a previously reported anchor ligand1 and the new selection/anti-selection strategies, 
and demonstrates the feasibility of a high-throughput route toward production of high-
affinity, high-specificity protein capture agents. 
 
4.2 MATERIALS AND EXPERIMENTAL METHODS 
4.2.1  Materials 
Proteins.  Bovine and human carbonic anhydrase II (bCAII, C2522; hCAII, 
C6165), from erythrocytes, lyophilized powder, were obtained (Sigma-Aldrich; St. Louis, 
MO) and used as received.  Human transferrin (Tf) and bovine serum albumin (BSA, 
≥98%) were also purchased from Sigma-Aldrich as lyophilized powders.  Prostate-
specific antigen (PSA) was isolated by Scripps Laboratories (San Diego, CA) and 
shipped as a lyophilized powder.  PSA activity was confirmed by an optical assay 
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employing the chymotrypsin substrate Suc-Arg-Pro-Tyr-pNA (AnaSpec, San Jose, CA; 
pNA = p-nitroaniline) as a chromogenic substrate. 
 
4.2.2  On-Bead Detection of In Situ Triazole Formation 
 A biotin conjugate of the biligand anchor was prepared by modifying the N-
terminus with an ethylene glycol linker (Fmoc-NH-(PEG)5-COOH, EMD Biosciences) 
followed by biotin, by standard SPPS.  A stock solution of this biotinylated biligand 
anchor Biotin-(EG)5-(D-Pra)-kwlwGl-Tz1-kfwlkl (1.25 mM, alkyne) was prepared in 
DMSO (EG = ethylene glycol).  Stock solutions of bCAII (30 µM) and hCAII (30 µM) 
were prepared in 50 mM Tris-Cl buffer (pH 7.2).  For control experiments, stock 
solutions of human transferrin (Tf, 30 µM) and bovine serum albumin (BSA, 30 µM) 
were prepared in 50 mM Tris-Cl buffer (pH 7.2), and Biotin-RPRAAA-Pra (1.25 mM, 
alkyne with no documented affinity for CA II) was prepared in DMSO.  The consensus 
3° ligand Az4-nlivfr (azide) was synthesized in bulk on TentaGel S-NH2 beads.  Each in 
situ click reaction contained 0.5 mg beads appended with 3° ligand, 30 μM biotinylated 
peptide-alkyne, and 15 μM protein in a final volume of 50 μL 50 mM Tris-Cl buffer  
(pH 7.2) + 2.5% DMSO (v/v).  In situ click reactions proceeded for 24 h at 25 °C with 
shaking.  Reactions were quenched with 50 μL 7.5 M guanidine hydrochloride (GuHCl, 
pH 2.0).  Following incubation with GuHCl (pH 2.0) for 1 h, the beads were washed 
with 10 × 200 µL water, leaving only covalently bound peptides (3° ligand and 
biotinylated in situ triligand) on the bead. 
 To prepare for the enzyme-linked, colorimetric assay,2 beads were washed with  
3 × 100 µL Blocking Buffer (25 mM Tris-Cl, 10 mM MgCl2, 150 mM NaCl, 14 mM 2-
mercaptoethanol, 0.1% (w/v) BSA, 0.1% (v/v) Tween 20, pH 7.5).  Beads were then 
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incubated in Blocking Buffer for 1 h with shaking.  Alkaline phosphatase-streptavidin 
(AP-SA, Promega) was introduced at 1:300 dilution in Blocking Buffer to bind to any 
potential bead-bound biotinylated triligand.  This AP-SA solution was incubated for 1 h 
with shaking.  Excess AP-SA was then removed by washing the beads with 3 × 300 µL 
Wash 1 Buffer (25 mM Tris-Cl, 10 mM MgCl2, 150 mM NaCl, 14 mM 2-
mercaptoethanol, pH 7.5), followed by 2 × 250 µL Wash 2 Buffer (25 mM Tris-Cl,  
14 mM 2-mercaptoethanol, pH 7.5).  Beads were developed for 2 h in 50 µL of the 
chromogenic substrate BCIP (5-bromo-4-chloro-3-indoyl phosphate, Promega). 
 
4.2.3  QPCR Assay for the Detection and Quantitation of the Formation of On-
Bead, Protein-Catalyzed Triligand Capture Agent 
The Streptavidin-oligo reagent was prepared as described below: SAC expression 
was performed according to previously published protocols.3  Prior to use, stock SAC 
(streptavidin-cysteine) was buffer exchanged to Tris buffered saline (TBS) containing  
5 mM Tris(2-carboxyethyl) phosphine hydrochloride (TCEP) using desalting columns 
(Pierce).  MHPH (3-N-Maleimido-6-hydraziniumpyridine hydrochloride, Solulink) in 
DMF was added to SAC at a molar excess of 300:1.  In parallel, SFB in DMF 
(succinimidyl 4-formylbenzoate, Solulink) was added in a 40:1 molar excess to the 5’ 
aminated oligo.  The mixtures were allowed to react at room temperature for 3 to 4 h.  
Excess MHPH and SFB were removed and samples were buffer exchanged to citrate 
buffer (50 mM sodium citrate, 150 mM NaCl, pH 6.0) using Zeba desalting spin 
columns (Pierce).  The SFB-labeled oligo was then combined in a 20:1 molar excess 
with the derivatized SAC and allowed to react for 2 to 3 h at room temperature before 
transferring to overnight incubation at 4 oC.  Unreacted oligos were removed using a 
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Pharmacia Superdex 200 gel filtration column at 0.5 mL/min isocratic flow of PBS.  
Fractions containing the SAC-oligo conjugates were concentrated using 10K MWCO 
concentration filters (Millipore).  The synthesis of SAC-oligo constructs was verified by 
non-reducing 8% Tris-HCl SDS-PAGE. 
The triligand-containing beads were prepared as described in Section 4.2.2.  
After dissociation of the target, 0.5 mg beads were washed 10 times in water and 
resuspended in Blocking Buffer (0.15% BSA (w/v), 0.1% Tween-20, 150 µg/mL 
sheared salmon sperm DNA, in PBS pH 7.4).  The beads were washed with 3 × 100 µL 
Blocking Buffer and incubated for 1 h at 25 °C in 100 µL Blocking Buffer.  The beads 
were then filtered and washed twice more in 100 µL Blocking Buffer.  Streptavidin-
oligo (100 µL of 170 ng/mL dilution prepared in Blocking Buffer) was added and the 
beads were incubated for 1 h at 25 °C.  The beads were washed 5 times in 250 µL 
Blocking Buffer followed by 3 washes in 250 µL PBS.  The beads were resuspended in 
dH2O and spotted on a glass slide.  After evaporation, the beads were manually picked 
and placed in thin-walled PCR tubes. 
Quantitative PCR (QPCR) was carried out on a Bio-Rad Real-Time PCR system.  
To each tube containing 1 to 5 individual beads was added 12.5 µL iQ SYBR Green 
Supermix (Bio-Rad), 11.5 µL dH2O, 100 nM Forward Primer 
(5’…TAATACGACTCACTATAGGGACAATTACTATTTACAATTACA…3’ –SEQ 
ID NO: 2), and 100 nM Reverse Primer (5’…ACCGCTGCCAGACCCCGATT 
TGGCCTGGGAGACGAACTCG…3’ –SEQ ID NO: 3).  Real-time PCR was carried 
out for 30 cycles with the following thermal profile: 94 ºC, 30 s, 50 ºC, 45 s, 72 ºC, 60 s.  
A standard curve was generated using known template concentrations ranging from  
0.01 nM to 0.01 pM.  The Ct values for each of the known concentrations were plotted 
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against the log of the template concentration to generate a linear standard curve which 
was then used to determine the concentration of oligo in each of the sample tubes.  This 
was adjusted based on the number of oligonucleotide templates present per streptavidin 
tetramer as estimated by SDS-PAGE. 
 
4.2.4  Selection of Biligand Capture Agent for Prostate-Specific Antigen 
Two-stage in situ click/OBOC screen with biotinylated cyclic anchor.  The 
comprehensive 5-mer Library X, displaying an N-terminal azidoalkyl amino acid, is first 
blocked overnight (0.2 g TentaGel scale) at 25 °C in Blocking Buffer (25 mM Tris-Cl, 
10 mM MgCl2, 150 mM NaCl, 0.1% (w/v) BSA, 0.1% (v/v) Tween 20, pH 7.5).  Then,  
5 to 40 nM PSA is prepared with 2.5 µM biotin-labeled cyclic anchor (Biotin-(EG)5-Pra-
cy(CVFAHNYDYLVC), Figure 4.7A) in 1 to 3 mL Blocking Buffer.  The protein and 
cyclic anchor were allowed to incubate for 1 h at 25 °C.  This solution was subsequently 
combined with the blocked portion of Library X.  After screening for 1 h at 25 °C, the 
library/PSA complex was washed with 5 × 3 mL Blocking Buffer to remove excess 
target and then incubated with a primary antibody for 1 h at 25 °C [mouse monoclonal 
anti-PSA, clone PS2 or PS6 (#M86433M or #M86111M, Meridian Life Science, Saco, 
ME)].  Primary antibodies were prepared at 1:5000 to 1:50,000 dilution in Blocking 
Buffer.  Beads were then washed with 5 × 3 mL Blocking Buffer to remove excess 
primary antibody, and then incubated with a secondary antibody [anti-mouse IgG, 
alkaline phosphatase (AP)-conjugated, at 1:5000 dilution in Blocking Buffer; Cell 
Signaling] in Blocking Buffer for 30 min at 25 °C.  Excess secondary antibody was 
removed by washing the beads with 5 × 3 mL Blocking Buffer, followed by 5 × 3 mL 
Wash 1 Buffer (25 mM Tris-Cl, 10 mM MgCl2, 700 mM NaCl, pH 7.5), and last by  
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5 × 3 mL Wash 2 Buffer (25 mM Tris-Cl, pH 7.5).  Beads were developed for 30 to  
90 min in the chromogenic substrate BCIP:NBT (Promega, #S3771), freshly prepared in 
Alkaline Phosphatase Buffer [100 mM Tris-HCl (pH 9.0), 150 mM NaCl, 1 mM MgCl2], 
as recommended by the vendor.  The darkest purple beads (“initial hits”) are selected by 
micropipette, washed with 7.5 M guanidine hydrochloride (GuHCl pH 2.0) for 1 h to 
remove bound protein, then with 10 × 500 µL water.  Beads are then decolorized 
overnight by incubation in DMF.  After the purple dye has completely dissociated from 
the beads, the initial hits are re-swollen for at least 12 h in Blocking Buffer before 
moving on to the next step. 
 The second screen for direct detection of on-bead protein-templated biligand is 
achieved by incubating the initial hits with AP-SA (Promega) at 1:300 dilution in 
Blocking Buffer for 45 min at 25 °C.  Excess AP-SA is removed by washing the beads 
with 5 × 3 mL Blocking Buffer, followed by 5 × 3 mL Wash 1 Buffer (25 mM Tris-Cl, 
10 mM MgCl2, 700 mM NaCl, pH 7.5), and last by 5 × 3 mL Wash 2 Buffer (25 mM 
Tris-Cl, pH 7.5).  Beads are developed for 30 to 90 min in the chromogenic substrate 
BCIP:NBT as described above.  The darkest purple beads (“true hits”) are selected by 
micropipette, washed with 7.5 M GuHCl (pH 2.0) for 1 h to remove bound protein, then 
with 10 × 500 µL water.  Following this wash, the purple hit beads are analyzed directly 
by Edman degradation, and the sequences of the candidate 2° ligands are determined. 
 
Synthesis of cyclic biligand candidates.  Click reactions were performed in 
solution between cyclic anchor and 2° ligand.  To begin, HPLC-purified cyclic anchor 
Biotin-(EG)5-Pra-cy(CVFAHNYDYLVC) (EG = ethylene glycol, cy = denotes cyclized 
sequence) was dissolved in DMF to make a stock of 15 to 30 mM.  Similarly, HPLC-
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purified 2° ligands (Az8-iyydt, Az8-kyydt, and Az8-iyiet) were each dissolved in DMF 
to make a stock of 15 to 30 mM.  In 200 µL of 4:1 DMF:H2O, the in-solution reaction 
was set up with the following final concentrations:  2 mM Cyclic anchor, 3 mM 2° 
ligand, 3 mM CuI, 10 mM Ascorbic acid, 10 mM TBTA [Tris-
(benzyltriazolylmethyl)amine].  TBTA is a ligand which accelerates catalysis while 
simultaneously protecting and stabilizing the copper(I) from oxidation, thus further 
improving the efficiency of the CuAAC.4  After overnight reaction at 25 °C, the entire 
crude mixture was loaded onto the HPLC, and cyclic biligands were isolated at 
approximately 30% B (where A = H2O/0.1% TFA and B = ACN/0.1% TFA).  Non-
optimized yield was >25%. 
It should be noted that the protein-templated in situ click reaction may yield 
product regioisomers that are either anti (1,4), syn (1,5), or a mixture of the two 
geometries.  Although we have not yet determined which regioisomers of the in situ 
click products were formed, the authentic multi-ligands synthesized by CuAAC were 
definitely the 1,4-triazole [Tz1 = triazole formed between Pra (appended from the cyclic 
anchor) and Az8 (on the 2° ligand)].  After bulk synthesis, cyclic biligands were purified 
by HPLC and analyzed by MS prior to use.  Their characterization is as follows: 
Biotin-(EG)5-Tz1-cy(CVFAHNYDYLVC)-iyydt.  MALDI-MS of the purified 
biotinylated cyclic biligand gave a peak at m/z 2982.9 for [M + H]+. 
Biotin-(EG)5-Tz1-cy(CVFAHNYDYLVC)-kyydt (Figure 4.7B).  MALDI-MS of 
the purified biotinylated cyclic biligand gave a peak at m/z 2998.9 for [M + H]+. 
Biotin-(EG)5-Tz1-cy(CVFAHNYDYLVC)-iyiet.  MALDI-MS of the purified 
biotinylated cyclic biligand gave a peak at m/z 2946.0 for [M + H]+. 
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Characterization of affinity by surface plasmon resonance.  SPR experiments 
were performed as described in Chapter 3, with a few minor modifications.  Here, PSA 
[30 to 60 µg/mL in 10 mM sodium acetate (pH 5.5)] was immobilized to ~3000 RU on 
the CM5 chip using a running buffer of HBS-P+ [10 mM HEPES, 150 mM NaCl, 0.05% 
Tween20 (pH 7.4)].  Cyclic biligands were dissolved in HBS-P+ buffer to produce  
2.5 µM stock solutions for each peptide, which were then serially diluted by a factor of 2 
to produce a concentration series down to 0.3 nM.  Cyclic anchor ligands were dissolved 
in HBS-P+ buffer to produce 10 µM stock solutions for each peptide, which were then 
serially diluted by a factor of 2 to produce a concentration series down to 1 nM.  For a 
given affinity measurement, these series of peptide solutions successively were injected 
into flow cell 2 (or 3) for 360 s of contact time, 300 s of dissociation time, and 200 s of 
stabilization time using a flow rate of 50 μL/min at 25 °C.  Data processing and affinity 
analysis, including background subtraction, was performed using Biacore T100 
evaluation software (Version 2.0.1, Biacore) as before. 
 
4.3 RESULTS AND DISCUSSION 
4.3.1  Initial Validation of Protein-Catalyzed Multi-ligand Product 
Protein catalyzed, multi-ligand capture agents were prepared according to the 
scheme of Figure 2.1.  When an in situ multi-ligand screen was carried out as illustrated 
in Figure 2.1, only a very small fraction of the on-bead n-order ligands were covalently 
coupled to the solution-phase 1° ligand by the protein.  Analysis of the n-order ligands 
on the bead using standard methods yields information largely about the sequences of 
the n-order ligands themselves, since they comprise >99% of the molecules bound to the 
bead, and not the complete multi-ligand.  For previously published in situ click 
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chemistry screens, the triazole product was identified using chromatographic separation 
followed by mass spectrometry.5–9  For the case of the in situ click/OBOC biligand 
screens (Figure 2.1), the binary component screen was adopted.  This was not a broadly 
applicable method, but showed efficacy in one exemplary case, which was discussed in 
Chapter 2 (Figure 2.9).  Thus, alternative strategies were developed for demonstrating 
that the protein-catalyzed multi-ligand capture agent selections are indeed successful. 
Two alternative strategies include: sequence homology analysis, and assays 
involving amplification of one or more labeled ligands.  For both the first-generation 
biligand and triligand screens, a striking result was the extremely high sequence 
homology that was observed for the hit beads.  For example, for the first 17 hit beads 
sequenced from screen Bi1, two peptides were identical, and a third peptide varied by 
only a single amino acid (see Appendix B).  For screen Tri1 (against the same library), 
the most commonly observed amino acids by position almost exactly reflect the 
consensus sequence identified in the second generation (focused) screen Tri3 (see 
Appendix B).  Such sequence homology was unique to in situ click/OBOC screens, and 
argues that these screens generate highly selective hits. 
 
4.3.2  Direct Detection of Protein-Catalyzed In Situ Multi-ligand 
Assays with labeled ligands.  An enzyme-linked, colorimetric assay was 
developed for detecting on-bead, protein-templated multi-ligand (Figure 4.1).  This 
approach relies upon appending a small molecule, such as biotin, to the solution-phase 
anchor (1°) ligand that is used in the screen.  Once the screen has been completed, the 
small molecule will be covalently functionalized on only those beads that contain the 
protein-catalyzed multi-ligand.  That small molecule can then provide a handle for  
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Figure 4.1.  (A) Schematic of in situ click assay for on-bead triazole formation, using a 
biotinylated biligand anchor (D-Pra)-kwlwGl-Tz1-kfwlkl.  (B) Purple beads are 
visualized as a positive indicator of triazole formation. 
 
(A) 
(B) 
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building up a chemical construct that can generate some detectable signal.  The most 
successful approaches will rely on signals that can be amplified.  For example, if an 
enzyme is appended to the small molecule, and then that enzyme can be utilized to 
catalyze some chemical process, which in turn represents an amplified signature of the 
on-bead protein-catalyzed multi-ligand.  The product molecules from the enzymatic 
reaction can be uniquely colored, fluoresce or have some other unusual chemical or 
physical property that can be detected, thus providing evidence for the formation of the 
on-bead multi-ligand product.  Results of such an assay, utilized to detect the on-bead 
formation of the triligand shown as the product of the 3° ligand screen of Figure 2.1, are 
presented in Figure 4.1. 
In particular, the illustration of Figure 4.1A shows the schematic of in situ click 
assay for on-bead triazole formation, using a biotinylated biligand anchor Biotin-(EG)5-
(D-Pra)-kwlwGl-Tz1-kfwlkl.  After dissociation of the protein target, Figure 4.1B shows 
that treatment with alkaline phosphatase-streptavidin (AP-SA) then BCIP (5-bromo-4-
chloro-3-indoyl phosphate) yields purple beads as a positive indicator of multi-ligand 
formation.  In situ triligand was only formed in the presence of b(h)CAII protein, and not 
when the protein was human transferrin (Tf), BSA, or absent.  Also, triligand is not 
observed when the biligand anchor sequence is incorrect. 
 
QPCR assay for the detection and quantitation of the formation of on-bead, 
protein-catalyzed multi-ligand protein capture agent.  Quantitative polymerase chain 
reaction (QPCR) enables both detection and quantification of oligonucleotide templates 
(as an absolute or relative copy number) through real-time monitoring of the 
intercalation of double-stranded DNA-binding fluorescent dyes during template 
105 
amplification.  Fluorescence emission during the elongation step of each cycle is 
proportional to the amount of PCR product and enables direct monitoring of the PCR 
reaction.  The resulting PCR curve is used to define the exponential phase of the reaction, 
which is a prerequisite for accurate calculation of the initial copy number at the 
beginning of the reaction.10  Real-time PCR assays are characterized by a wide dynamic 
range of quantification, a high technical sensitivity (< 5 copies of template oligo) and a 
high precision (< 2% standard deviation).11,12 
To quantify the formation of on-bead, protein-catalyzed triligand obtained by the 
assay of Figure 4.1A, it was necessary to transform the biotin label into an 
oligonucleotide label.  The PCR-based assay shown in Figure 4.2 is a variation of the 
enzymatic assay where AP-SA is replaced with streptavidin conjugated to a small 
template oligonucleotide (5’…NH2–(CH2)6–GGGACAATTACTATTTACAATTAC 
AATGCTCACGTGGTACGAGTTCGTCTCCCAGG…3’ –SEQ ID NO: 1).  Binding of 
this reagent to biotinylated triligand results in the recruitment of the template 
oligonucleotide to the bead surface where it can be amplified by PCR.  The extent of 
amplification (i.e., number of PCR cycles required to produce a band) is directly 
proportional to the amount of oligonucleotide at the bead surface, providing a 
quantitative readout of the assembled triligand and hence the efficiency of the in situ 
click reaction. 
The results shown in Figure 4.2 are roughly in line with the colorimetric AP-SA 
assays.  The percent yield for the bCAII-catalyzed click reaction between biotinylated 
biligand anchor (D-Pra)-kwlwGl-Tz1-kfwlkl and 3° ligand Az4-nlivfr may be estimated 
as 0.000005% from the QPCR assay of Figure 4.2.  This takes into account a 
stoichiometry of 4 oligos per streptavidin tetramer, and estimates that single beads  
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Figure 4.2.  (A) General method for detecting on-bead multi-ligand by QPCR.  (B) In a 
specific example, the results of a QPCR assay quantifying the yield of biotinylated 
triligand from the protein-catalyzed in situ click reactions of Figure 4.1 are illustrated.  
Results are expressed by bar graph in units of mean amol triligand/bead for 5-bead 
samples (N = 3).  The Ct values for a series of known template concentrations were used 
to generate a linear standard curve (inset), from which the concentration of streptavidin-
oligo reagent in each 5-bead sample was extrapolated. 
(A) 
(B) 
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display a uniform loading of 100 pmol/bead.  It is interesting that while bCAII 
apparently makes 2 times more triligand product per QPCR assay than hCAII, the 
triligand displays a slightly higher binding affinity for hCAII (see Chapter 3).  Out of the 
controls, the “no protein” control displays the consistently higher background reaction 
than the BSA and Tf controls.  It is possible that BSA and Tf are blocking reactive 
azides on the bead and attenuating the background click reaction.  It is also interesting 
that the Akt1 peptide control displayed the least background, showing nearly no triligand 
formation, and is comparable with blank beads.  Here, bCAII is evidently binding to the 
bead but not to the Akt1 peptide, and azides on these beads are blocked more effectively 
with bCAII than with BSA or Tf. 
 
4.3.3  Strategies for Improving Signal-to-Noise Ratio during  
In Situ Click/OBOC Screens 
 Based on the success of the colorimetric assay in Figure 4.1, a new method for 
visualization of hits from the in situ click/OBOC screens emerged.  Rather than 
stratifying hit beads based on fluorescence (via binding of a fluorescently labeled protein 
target, see Chapter 2), it became apparent that the assay of Figure 4.1 could be easily 
modified to accommodate screening of an entire bead library rather than a single 
sequence.  This colorimetric approach removed dependence on a fluorescence 
microscope (or array scanner) for identification of hits, and allowed the researcher to 
pick the hits in real time while monitoring the BCIP development with a standard light 
microscope.  Furthermore, the intrinsic autofluorescence13,14 of TentaGel S-NH2 beads 
was no longer a potential challenge to the signal-to-noise ratio.  It also should be noted 
that the more delicate of protein targets (such as phospho-Akt), which were previously 
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intolerant to covalent modification with fluorophores, now became candidates for multi-
ligand capture agent development. 
We were surprised by the extremely low yield of the protein-catalyzed click 
reaction.  Such a low-frequency event may potentially be surrounded by a high level of 
background.  A major source of background would arise from the binding of protein 
target to the bead, but without any click reaction occurring.  Since our methods of 
Chapter 2 relied on protein detection (by way of the fluorophore), “background hits” 
would not have been distinguished from “true hits.”  Thus, the general concept of multi-
stage screening was explored (see Figures 4.3-4.4). 
For the most important cancer-specific protein biomarkers, antibodies are 
available.  Therefore, primary and AP-labeled secondary antibodies initially could serve 
as reagents to detect bead-bound protein from a simple OBOC screen, as shown in 
Figure 4.3A and Figure 4.4A, all the way to the in situ click/OBOC screen (see Figure 
4.5A for a specific example).  This antibody-based screening approach is essentially a 
sandwich (ELISA-like) assay, but with the solid support being a bead rather than a 
microwell of a 96-well plate.  As an added bonus, this approach also selects for those hit 
beads and peptides that can eventually form a multi-ligand capture agent that, together 
with the antibody, form an ELISA pair.   
The antibody-based screening approach also allowed for improvement of the 
signal-to-noise ratio, through pairing each screen with an anti-screen.  Figure 4.3B 
illustrates an anti-screen which would be performed following the 1° ligand screen of 
Figure 4.3A.  This screen eliminates “background hits” which would represent natural 
antibody-binding epitopes.  Figure 4.4B illustrates an anti-screen which would be 
performed following the epitope-targeted 1° ligand screen of Figure 4.4A.  This screen 
  
 
Figure 4.3.  General screening strategies to improve signal-to-noise ratio and reduce number of false positives in OBOC selections.  
(A) Colorimetric antibody screen for initial hits.  This screen can be used at any level of multi-ligand discovery (i.e., anchor, biligand, 
etc.), as only bound protein is detected.  (B) Anti-screen for removing background hits.  (C) Direct detection of on-bead biligand. 
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Figure 4.4.  (A) Screening and (B) anti-screening strategies to target a particular protein epitope or modification. 
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Figure 4.5.  Two-stage in situ/click OBOC screening strategy to identify a biligand capture agent for PSA using a previously 
identified cyclic peptide Biotin-(EG)5-Pra-cy(CVFAHNYDYLVC) as the anchoring unit.  It should be noted that this strategy is a 
specific application of Figures 4.3A,C.  (A) Probing for bound PSA.  (B) Probing for on-bead, protein-catalyzed biligand.  (C) True 
hits displaying a high degree of sequence homology. 
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eliminates “background hits” which would represent non-targeted peptides.  Figure 4.5B 
illustrates the specific case of an anti-screen that results in direct detection of the bead-
bound biligand products of the protein-catalyzed click reaction.  Through detection of the 
biotin label, we can parse out the false-positive beads which bind to PSA (in the Figure 
4.5A screen) but do not undergo in situ click reaction with the biotinylated anchor ligand.  
A general screen for direct detection of protein-catalyzed in situ hits is shown in Figure 
4.3C, and this is simply the whole-library extension of the Figure 4.1 assay. 
 
4.3.4  Selection of Biligand Capture Agent for Prostate-Specific Antigen 
 The in situ click/OBOC selection of an epitope-targeted biligand capture agent 
against prostate-specific antigen was explored as a feasibility demonstration for the 
antibody- and biotin-based multi-stage screening strategies. 
Prostate-specific antigen.  PSA is a 30-kDa serum glycoprotein and protein 
biomarker for detection and management of prostate cancer.  This protein is present in 
normal prostatic tissue, but increased levels of PSA are a reliable indicator of prostate 
cancer and are widely used as a marker of potential cancerous growths or disease status.15  
Differences in concentration between the active form of PSA and enzymatically inactive 
versions (e.g., proPSA, nicked inactive PSA, ACT-PSA complex) may provide 
distinguishing information between cancer and benign prostatic hyperplasia (BPH), 
which is a common misdiagnosis.  Additionally, PSA has a single N-oligosaccharide 
chain attached to Asn-45, and it has been reported that one can distinguish PSA origin 
(healthy vs. tumor) through differences in glycosylation patterns.16  Creating specific 
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multi-ligands that target these minor variants of PSA may potentially facilitate more 
accurate diagnosis of prostatic diseases. 
 
Preparation of anchor (1°) ligand.  Due to its relevance in the diagnosis and 
monitoring of human prostate cancer, PSA is a well studied protein target for ligand 
development.  Phage display,1,17 polysome selection,18 and in silico structure-guided 
design19,20 have all been used to isolate peptide ligands of µM to nM binding affinity 
against PSA.  It was our idea that the multi-ligand discovery process can be expedited 
through implementation of one of these peptides as the anchor (1°) ligand.  Indeed, the 1° 
ligand OBOC screen is the most challenging step of Figure 2.1 since only weak binding 
interactions are probed.  After evaluating several of these reported peptides, we chose the 
optimized phage-derived cyclic sequence cy(CVFAHNYDYLVC) as the 1° ligand for the 
rapid selection of a multi-ligand capture agent against PSA.1  SPR measurement 
determined that this peptide displays a binding affinity of KD ≈ 2.4 µM for its interaction 
with PSA.  As this KD value is approximately the same affinity as our biligand for bCAII, 
we concluded that cy(CVFAHNYDYLVC) was an excellent starting point for building a 
multi-ligand capture agent that specifically recognizes the active site of PSA. 
Cyclic peptides, due to their conformational rigidity, lose less entropy and free 
energy upon binding to targets than their linear counterparts.21  This translates to 
enhancements in receptor-binding affinity, specificity, and stability.  To illustrate this 
point, we determined that cy(CVFAHNYDYLVC) binds to the active site of PSA when 
cyclized, but does not bind as a linear sequence (SPR, data not shown). 
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In order to prepare the peptide cy(CVFAHNYDYLVC) for in situ click chemistry, 
the artifical amino acid L-propargylglycine was installed on the N-terminus during solid-
phase peptide synthesis of the linear sequence.  Following the coupling of L-
propargylglycine, two other chemical modifications were made.  First, Fmoc-NH-
(PEG)5-COOH (22 atoms) (Novabiochem) was installed to impart better water solubility 
to the cyclic anchor ligand.  Second, biotin was added to cap the N-terminus, thus 
providing the label for performing the two-stage in situ click/OBOC screen with direct 
detection of on-bead protein-catalyzed biligand.  Peptide cyclization by formation of a 
disulfide bond was achieved by an oxygen/Cu(II)(1,10-phenanthroline)3 system.22  The 
final structure of cyclic anchor ligand Biotin-(EG)5-Pra-cy(CVFAHNYDYLVC) is 
shown in Figure 4.7A.  Results from SPR determined that the addition of these linker 
moieties did not affect the overall binding affinity of the anchor to PSA.  It was found 
that this modified cyclic anchor ligand had an affinity of 2.1 µM (Figure 4.7C).  A kinetic 
fit of the data yielded kd = 0.09 s–1 and ka = 4.5 × 104 M–1s–1 (for 1:1 binding interaction). 
Binding specificity for the cyclic anchor ligand of Figure 4.7A was characterized 
by sandwich (ELISA-like) assays on streptavidin-functionalized microtiter plates.  
Similar to Chapter 3, the cyclic anchor (1° capture agent) was paired with a commercial 
mouse monoclonal anti-PSA antibody (2° capture agent) for quantification of captured 
PSA.  For a sandwich assay performed with PSA presented in 10% porcine serum, the 
analytical sensitivity was ~2 µM (~60 µg/mL), further confirming the SPR result of 
Figure 4.7C even in a high protein background. 
Cyclic peptides were prepared in bulk by solid-phase synthesis, purified by HPLC, 
and analyzed by MS prior to use.  Their characterization is as follows: 
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cy(CVFAHNYDYLVC).  MALDI-MS of the purified cyclic peptide gave a peak at 
m/z 1443.2 for [M + H]+. 
Biotin-(EG)5-Pra-cy(CVFAHNYDYLVC) (Figure 4.7A).  MALDI-MS of the 
purified biotinylated cyclic anchor gave a peak at m/z 2100.0 for [M + H]+. 
 
Two-stage in situ click/OBOC screen for biligand capture agent using a 
biotinylated anchor ligand.  The two-stage in situ click/OBOC screening approach for 
selection of a biligand capture agent against PSA is shown in detail in Figures 4.5A-B.  
Note that this screening procedure is an application of the general methods in Figure 4.3.  
For these screens, a single comprehensive library of 3 × 185 hexamers was used (Library 
X):  Az-X1X2X3X4X5-TentaGel, where Az = azidoalkyl amino acids Az2,23 Az4, or Az8, 
and X = all D-amino acids except D-Cys and D-Met.  In the first stage (Figure 4.5A), two 
antibodies were applied to detect and amplify the binding of PSA to the bead library 
during an in situ/click OBOC screen.  Binding of monoclonal anti-PSA antibody to the 
PSA-bound bead was visualized by probing with an AP-labeled secondary anti-IgG, 
followed by treatment with BCIP.  The percentage of hits (purple beads) following this 
first screen was 10%, a value which indicated that a significant number of “background 
hits” were likely selected along with the “true hits.”  This first screen may be optimized 
to achieve a more manageable number of hits, through modulating antibody and/or PSA 
concentrations, or by testing different blocking buffers.  Instead, we chose to perform a 
second screen, against only the initial hits from the first screen (Figure 4.5B).  Because a 
biotinylated cyclic anchor ligand was applied in the first screen, we have a label for direct 
monitoring of the in situ click hits, representing protein-catalyzed conjugation of 1° 
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ligand to bead-bound 2° ligands.  In the second screen, AP-SA followed by BCIP 
treatment allowed visualization of only the in situ click biligand hits.  Surprisingly, only 
10% of the initial hits were “true hits” in this assay.  This result confirms the practical 
importance of the multi-stage screening method to enrich for the best hits. 
A representative image of the beads in this second screen is depicted in Figure 4.6, 
and it illustrates the high signal-to-noise ratio that may be achieved by colorimetric 
detection.  Edman sequencing of the true hits (i.e., in situ click biligands) yielded the 
table of results shown in Figure 4.5C.  There is an incredible sequence homology 
displayed by these biligand hits.  All hits demonstrate an extremely high preference for 
X5 = t and significant propensity for Az = Az8.  Also, two sequences show the homology 
of “yy” in positions X2 and X3.  This motif was reinforced by two additional occurrences 
of y at these positions.  The 2° ligand motif Az8-X1yydt was observed twice (X1 = k, i). 
 
Validation of PSA-binding cyclic biligands.  Based on the Edman sequencing 
results (Figure 4.5C), the cyclic biligands comprised of Az8-iyydt, Az8-kyydt, and Az8-
iyiet were chosen as candidates to test for binding affinity by SPR.  The best-binding 
cyclic biligand was Biotin-(EG)5-Tz1-cy(CVFAHNYDYLVC)-kyydt, whose structure is 
shown in Figure 4.7B.  SPR measurement determined that this peptide displays a binding 
affinity of KD ≈ 140 nM for its interaction with PSA, which is a factor of ~15 
improvement from the cyclic anchor (Figure 4.7D).  Biligands Biotin-(EG)5-Tz1-
cy(CVFAHNYDYLVC)-iyydt and Biotin-(EG)5-Tz1-cy(CVFAHNYDYLVC)-iyiet 
displayed affinities of KD ≈ 480 nM and KD ≈ 5 µM, respectively (data not shown).  Thus,  
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Figure 4.6.  Representative image of an in situ click/OBOC screen with enzymatic 
amplification.  In a single assay, >106 TentaGel beads (90-µm diameter) present 
individual 2° ligands to a solution of PSA and the biotinylated cyclic anchor (of Figure 
4.7A).  Specific binding by PSA and formation of in situ click product (purple color) is 
visualized by treatment with AP-SA and the chromogenic substrate BCIP. 
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Figure 4.7.  Structures of active site targeted cyclic anchor (A) and cyclic biligand (B) 
against PSA.  Note that the anchor (black) is comprised of L-amino acids, while the 2° 
ligand (of the biligand) is composed of D-stereoisomers.  (C) SPR response sensorgrams 
obtained with increasing concentration (1 nM to 10 µM) of cyclic anchor demonstrate KD 
≈ 2.1 μM binding affinity to immobilized PSA.  (D) SPR response sensorgrams obtained 
with increasing concentration (0.3 nM to 2.5 µM) of cyclic biligand display KD ≈ 140 nM 
binding affinity to immobilized PSA. 
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it appears that the area proximal to the active site of PSA is negatively affected by 
binding of isoleucine. 
To further evaluate the cyclic biligand of Figure 4.7B as a suitable capture agent 
for PSA, a sandwich (ELISA-like) assay will be performed in parallel with the standard 
commercial 2-antibody ELISA kit for PSA capture and detection.  The analytical 
sensitivities will also be compared for cyclic anchor vs. cyclic biligand as 1° capture 
agents.  Based on the high specificity of the cyclic anchor, we expected that its 
corresponding biligand will have sufficient affinity and specificity to capture the PSA 
from even undiluted serum. 
 
4.4  CONCLUSIONS 
 To both qualitatively and quantitatively assess the formation of protein-templated 
multi-ligand products from in situ click/OBOC screens, two complementary assays were 
developed.  First, the colorimetric assay employing AP-SA and the chromogenic 
substrate BCIP allowed detection of on-bead multi-ligands by simple visual inspection.  
Second, the QPCR assay employing a novel streptavidin-oligo reagent allowed accurate 
and direct determination of the on-bead in situ click products.  The low-yielding, but 
detectable, products of in situ click chemistry inspired us to develop next-generation, 
multi-stage screening strategies to improve the signal-to-noise ratio and reduce the 
number of false positives in our screens.  Next-generation screening formats included 
colorimetric antibody-based screens for initial hits, anti-screens for removing background 
hits, and direct screening of on-bead biligand.  These methods dramatically improved the 
efficiency of the in situ click/OBOC multi-ligand discovery process.  Furthermore, these 
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new colorimetric methods were easier to perform as they did not require sophisticated 
instrumentation (e.g., fluorescent microscopes or array scanners). 
As a specific application of the multi-stage screening strategies, the rapid 
selection of a biligand capture agent for PSA was demonstrated.  The biligand selection 
process was expedited through both use of a previously reported, phage-derived cyclic 
anchor ligand and a two-stage in situ click/OBOC screening method.  The cyclic anchor 
was shown by SPR to have an affinity of KD ≈ 2.1 µM, and it was a viable capture agent 
in sandwich (ELISA-like) assays, pulling down 2 µM (~60 µg/mL) PSA from dilute 
serum.  After two screens, the initial pool of in situ click biligand hits was reduced to 
10% true hits, and we obtained an extremely high sequence homology in these cyclic 
biligand sequences.  The best cyclic biligand was shown by SPR to have an affinity of 
140 nM.  The sequence of this capture agent is unique in that it is a mixture of cyclic, L-
chirality, and D-chirality components.  Also, one can feasibly only obtain the resultant 
biligand from the in situ click/OBOC screening methodology described in this thesis.  
Using the cyclic biligand as a starting point, we next intend to synthesize a triligand 
capture agent of even higher affinity (e.g., KD ≈ 1 nM) and specificity for PSA. 
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Chapter 5 
A Non-Oxidative Approach toward Chemically and Electrochemically Functionalizing 
Si(111) 
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5.1  INTRODUCTION 
Semiconductor devices and semiconductor processing are playing an 
increasingly large role in biotechnology applications.  Examples include silicon 
nanowires (SiNWs)1 and nanocantilevers2,3 for label-free biomolecular sensors, 
nanofluidics for biomolecular separations,4–7 and microfabricated lab-on-a-chip 
technologies.8,9  Coupled with these developments has been the emergence of 
mechanical,10–12 chemical, and electrochemical approaches for functionalizing and/or 
selectively activating surfaces.  For sensing applications, electrochemical activation of 
surfaces is particularly relevant since it is only limited by the size of electronically 
addressable features (which can be much denser than what can be spotted with an inkjet, 
for example).  Electrochemical activation of metal surfaces has been pioneered by 
Mrksich and co-workers,13–16 and applications of that chemistry toward the spatially 
selective biofunctionalization of semiconductor nanowires has been demonstrated by at 
least two groups.17,18 
For silicon surfaces, the chemistry is particularly challenging because 
unprotected silicon forms a native oxide (SiO2) layer.  This native oxide layer can limit 
the use of silicon electrodes for electrochemical functionalization.  Moreover, the native 
oxide on silicon has a low isoelectric point (~2).  Therefore, SiO2 surfaces are negatively 
charged under physiological conditions (= pH 7.4).19 These surface charges can 
potentially limit the sensitivity of SiNW field effect biosensors through Debye 
screening20 by the localized ionic concentration at the sensor surface.  Additionally, the 
native oxide layer contains electrical defect sites at the Si-SiO2 interface.21  These 
electrical defect sites can detrimentally affect carrier recombination rates leading to 
decreased transistor or sensor performance in silicon-based nanoelectronic devices.22  
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For high surface area devices, such as SiNWs, this phenomenon can reduce charge 
carrier mobilities significantly.21  Thus, the ideal biofunctionalization strategy for 
electrochemically activating silicon surfaces should begin with non-oxidized silicon.  
For sensing applications, the functionalization approach should provide continued 
protection of the silicon surface against further oxidation and limit the number of surface 
defect sites that can increase carrier recombination rates. 
Several methods for attaching organic molecules onto non-oxidized silicon 
surfaces have been reported.  One class of schemes relies on the direct covalent 
attachment of terminal alkenes on hydrogen-terminated surfaces by thermal induction, 
ultraviolet (UV) light, or catalysis.23–30  The resulting alkyl monolayers reflect the 
atomic flatness of the underlying silicon,31,32 and they provide partial chemical 
passivation of silicon via the formation of a Si-C bond.  However, the alkyl monolayers 
prepared by the above strategies have not been demonstrated to give long-term 
protection to the silicon surface against oxidation due to limited molecular packing 
densities. 
The Lewis group has developed techniques to alkylate chlorine-terminated 
Si(111) surfaces using alkylmagnesium and alkyllithium reagents.33–38  A limitation of 
these methods is that a 100% surface coverage can only be obtained with a methylated 
Si(111) surface, as confirmed by low-temperature STM.34,39  By comparison, the surface 
coverage achieved by the ethylation of chlorine-terminated Si(111) is limited by steric 
effects and corresponds to 80% of the atop silicon sites.40  For more complex long-chain 
organic molecules, surface coverages will most certainly be lower, and the resistance to 
oxidation of the Si(111) surface will be reduced.  It is therefore necessary to develop a 
surface chemistry method that will fully passivate the Si(111) surface, provide resistance 
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to oxide growth, and offer a chemical handle for the attachment of a variety of molecules.  
No methods have yet been demonstrated that protect the more technologically relevant 
Si(100) surface against oxidation. 
This chapter describes the development of a versatile and robust strategy for 
chemically passivating Si(111) surfaces in a manner that stabilizes the underlying Si 
against native oxidation and allows for both chemical and electrochemical 
functionalization of the surface.  Based on our previous work on methylated and 
ethylated Si(111),33–40 the more chemically versatile acetylenylation of chlorine-
terminated Si(111) was explored.  Work by Nemanick41 and Lewis’ group42,43 indicated 
that the chlorination/alkylation chemistry for acetylenylating Si(111) could proceed to 
completion.  The footprint of the linear sp-hybridized acetylene group (-C≡CH) on 
Si(111) should be as small or smaller than the –CH3 group, and so a high surface 
coverage should be possible.  Equally important is that the -C≡CH group also provides a 
chemical handle for additional functionalization via the Cu(I) catalyzed Huisgen 1,3-
dipolar cycloaddition (‘click’ reaction44,45) between an azide and the surface-bound 
alkyne.  In particular, we designed an azide-functionalized, modified benzoquinone for 
attachment, via the click reaction, to the surface-bound acetylenyl groups to form a 
1,2,3-triazole.  The click reaction is useful because azides and acetylenes are 
synthetically easy to introduce, compatible with a variety of solvents and species, and 
tolerant against other functionalities (highly specific, coupling can only occur between 
these two groups).  Our work here follows reports that have demonstrated that different 
molecules can be clicked onto gold and SiO2 surfaces in a variety of solvent and pH 
conditions.46–54   
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We previously reported on the electrochemistry of hydroquinones on Si(111) and 
Si(100) surfaces, attached via the UV-activation of H-terminated Si.17  In that work, the 
hydroquinones could be reversibly oxidized to form benzoquinones (the ‘activated’ 
surface) which could then react by way of either Diels-Alder cycloaddition13,15 or 
Michael addition chemistries,55,56 leading to a selectively biofunctionalized silicon 
microwire or nanowire surface.  However, while the hydroquinone coverage on the 
Si(111) surface did yield at least some protection for that surface against oxidation, the 
electrochemical step to oxidize the hydroquinone also led to oxidation of the underlying 
Si(111).  Thus, in this work, we have designed and synthesized a benzoquinone that can 
be clicked onto the acetylenylated silicon surface.  The surface-bound benzoquinone 
may be then activated via electrochemical reduction to produce an amine terminus.14,57,58  
We demonstrate that the entire chemical process may be accomplished in a fashion that 
greatly reduces the oxidation of the underlying silicon.  We also demonstrate the 
selective attachment of ferrocene onto an electrochemically activated Si(111) surface, as 
well as the model biomolecule, biotin. 
 
5.2  MATERIALS AND EXPERIMENTAL METHODS 
5.2.1  Chemicals 
 Anhydrous methanol and anhydrous tetrahydrofuran (THF, inhibitor-free) were 
obtained from Aldrich and exclusively stored and used in a N2(g)-purged glove box.  
Chlorobenzene, benzoyl peroxide, and sodium acetylide (18 wt% in xylenes/light 
mineral oil) were purchased from Aldrich and were stored and used in the glove box.  
Phosphorus pentachloride (PCl5) was acquired from Riedel-de Haën (Seelze, Germany).  
The 40% NH4F(aq) solution was obtained from Transene Co. (Rowland, MA) and was 
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used as received.  The CuSO4·5H2O was obtained from Spectrum Chemical Mfg. Corp. 
(Gardena, CA).  Sodium ascorbate, ferrocene carboxylic acid, and anhydrous N,N′-
dimethylformamide (DMF) were obtained from Aldrich.  N,N′-Diisopropylcarbodiimide 
(DIC) was purchased from AnaSpec (San Jose, CA).  Dulbecco’s Phosphate Buffered 
Saline (DPBS) (2.7 mM KCl, 1.5 mM KH2PO4, 137 mM NaCl, 8 mM Na2HPO4) pH 7.4 
was purchased from Sigma.  EZ-Link NHS-Biotin was obtained from Pierce 
Biotechnology (Rockford, IL).  Nanogold Streptavidin was purchased from Invitrogen 
(Carlsbad, CA).  GoldEnhance-EM kit for Nanogold amplification was bought from 
Nanoprobes (Yaphank, NY). 
 
5.2.2  Acetylenylation of Si(111) 
Scheme 5.1 shows the strategy utilized for functionalization of Si(111), using a 
two-step chlorination/alkylation method followed by Cu(I)-catalyzed click chemistry.  
The acetylene passivation leads to a high coverage of atop sites on an unreconstructed 
Si(111) surface (97 ± 5 %), which resists native oxidation of the surface.39,40  Another 
advantage is the ability to use the terminal alkyne to attach a variety of molecules via 
click chemistry. 
The starting surfaces used in these experiments were single crystal, polished 
Si(111) wafers that were 500 to 550 µm thick, phosphorus-doped (n-type), with 0.005 to 
0.02 Ω-cm resistivity, and a miscut angle of 3°-4° (Montco Silicon Technologies; Spring 
City, PA).  Prior to use, the Si wafers (1 cm × 1 cm) were cleaned by successive 
sonications in acetone, methanol, and isopropanol.  Substrates were then rinsed with 
Millipore (18 MΩ) water and then placed into basic piranha solution (5:1:1 = H2O:H2O2: 
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Scheme 5.1.  Strategy for the functionalization of Si(111).  
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NH4OH  warning: caustic!) at 80 °C for 5 min.  The samples were removed from 
piranha solution, rinsed with copious amounts of Millipore water and dried under 
streaming N2(g).  The samples were immediately place in degassed NH4F(aq) solution 
for 15 min.  The samples were subsequently removed from the NH4F(aq), rinsed 
copiously with water, dried under streaming N2(g), and immediately loaded into a glove 
box. 
  Chlorination of the Si(111) surfaces (Scheme 5.1, Step 1) was carried out in a 
N2(g)-purged glove box, according to published methods.33–40  A saturated solution of 
PCl5 in chlorobenzene was prepared and heated for 1 h before use to ensure complete 
dissolution of the PCl5.  The Si substrate was added with a grain of benzoyl peroxide to 
this solution and heated to 90 °C for 50 min.  Subsequently, the samples were rinsed 
with anhydrous THF several times and immediately used for the acetylenylation step. 
Acetylenylation of the chlorinated Si(111) surfaces (Scheme 5.1, Step 2) was 
performed inside the N2(g)-purged glove box.  The chlorinated wafers were immersed in 
a sodium acetylide (18 wt% in xylenes/light mineral oil) suspension and heated to  
130 °C for 5 h.43  After reaction, the samples were removed from solution, rinsed 
copiously with anhydrous THF, and then rinsed with anhydrous methanol.  The samples 
were then immersed into a fresh volume of anhydrous methanol, removed from the 
glove box into air, sonicated for 10 min, and then dried in a stream of N2(g). 
 
5.2.3  Synthesis of Electroactive Benzoquinone 1 
Scheme 5.2 describes the synthetic procedure for making the electroactive 
benzoquinone 1 used for all surface click reactions.57  A 2,3,5-trimethylhydroquinone 
was treated with dimethylacrylic acid to give a lactone (a) by a Friedel-Crafts type  
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Scheme 5.2.  Synthesis of electroactive benzoquinone 1. 
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addition reaction.  The quinone acid (b) was prepared by oxidation of the resulting 
lactone (a) with aqueous N-bromosuccinimide (NBS).  The acid was activated with an 
N-hydroxysuccinimidyl (NHS) group to give (c), which was then subjected to 3-
azidopropylamine to afford 1. 
 6-Hydroxy-4,4,5,7,8-peptamethyl-chroman-2-one (a).  2,3,5-Trimethylhydro-
quinone (2 g, 13.1 mmol) was mixed with 3,3-dimethylacrylic acid (1.45 g, 14.5 mmol) 
and methanesulfonic acid (10 mL).  The mixture was stirred at 85 °C under nitrogen for 
3 h and then cooled to room temperature.  To the mixture, 100 g of ice was added with 
stirring.  The precipitate was extracted with ethyl acetate (4 × 50 mL).  The combined 
organic layer was washed with saturated NaHCO3 (2 × 50 mL) and water (2 × 50 mL), 
and dried over MgSO4.  After filtration and evaporation, an obtained residue was 
recrystallized from hexane and ethyl acetate (2:1, v/v) to give 2.6 g (84%) of the desired 
product as a white solid.  1H NMR 300 MHz (CDCl3) δ 4.69 (s, 1H), 2.56 (s, 2H), 2.37 
(s, 3H), 2.23 (s, 3H), 2.9 (s, 3H), 1.46 (s, 6H). 
 3-Methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanoic acid (b).  
To a solution of the lactone a (1.58 g, 6.74 mmol) in a mixture of acetonitrile (15 mL) 
and water (3 mL) was added N-bromosuccinimide (1.26 g, 7.08 mmol) in portions with 
stirring at room temperature.  After 30 min, the organic solvents were evaporated under 
reduced pressure, and the remaining solution was extracted with CH2Cl2 (2 × 30 mL).  
The combined organic layer was dried over MgSO4, and reduced solvent to give 1.65 g 
(98%) of a yellow oily product, which was used without further purification.  1H NMR 
300 MHz (CDCl3) δ 3.04 (s, 2H), 2.15 (s, 3H), 1.96 (m, 3H), 1.94 (m, 3H), 1.45 (s, 6H). 
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3-Methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanoic acid, N-
hydroxysuccinimidyl ester (c).  To a solution of acid b (326 mg, 1.30 mmol) and N-
hydroxysuccinimide (152 mg, 1.32 mmol) in CH2Cl2 (15 mL), was added 1,3-
dicyclohexylcarbodiimide (DCC, 270 mg, 1.31 mmol) portionwise, followed by a 
catalytic amount of N,N-dimethylaminopyridine (DMAP).  The reaction mixture was 
stirred for 1 h.  The white precipitate was filtered and the filtrate was concentrated.  The 
residue was redissolved in cold ethyl acetate (5 mL) and insoluble impurities were 
filtered.  Solvent was removed to give 419 mg (93%) of a yellow foamy solid product.  
1H NMR 300 MHz (CDCl3) δ 3.27 (s, 2H), 2.77 (s, 4H), 2.15 (s, 3H), 1.94 (s, 6H), 1.51 
(s, 6H).  
N-(3-azidopropyl)-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-
dienyl) butanamide (1).  To a solution of c (443 mg, 1.28 mmol) in DMF (5 mL) was 
added diisopropylethylamine (DIEA, 523 µL, 3.06 mmol), followed by 3-
azidopropylamine (153 mg, 1.53 mmol).  The reaction mixture was stirred overnight at 
50 °C, diluted with ethyl acetate (30 mL), washed with NH4Cl and brine, and dried over 
MgSO4.  Solvent was reduced and the residue was purified by silica gel chromatography 
(hex/EtOAc, 2:1) to give 370 mg (87%) of product as a yellow solid.  1H NMR 300 MHz 
(CDCl3) δ  3.30 (t, J = 6.6, 2H), 3.23 (q, J = 6.6, 2H), 2.81 (s, 2H), 2.12 (s, 3H), 1.96 (m, 
3H), 1.94 (m, 3H), 1.70 (quint, J = 6.6, 2H), 1.41 (s, 6H). Mass (ES) m/z 333.0 ([M + 
H]+). 
 
5.2.4  Click Reaction to Attach 1 onto Acetylene-Terminated Si(111) 
The click reaction of acetylene-terminated Si(111) (Scheme 5.1, Step 3) with 1 
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(Scheme 5.2) was carried out in anhydrous DMF.  Relative to the azide, 20 mol% 
sodium ascorbate was added, followed by 10 mol% of CuSO4·5H2O, and a 10 mM azide 
solution of 1 in DMF.  The reaction was run for 12 h in the glove box.  After the reaction, 
the surface was sonicated in DMF for 3 × 5 min and then rinsed with methanol and blow 
dried under N2(g). 
 
5.2.5  Electrochemical Activation to Attach Ferrocene Carboxylic Acid and Biotin 
1 was attached to acetylene-terminated Si(111) using the Cu(I)-catalyzed click 
reaction (Scheme 5.1, Step 3), to form 1s (Scheme 5.3).  Reductive electrochemistry  
(–800 mV referenced to Ag/AgCl) was performed to convert the modified benzoquinone 
to hydroquinone in degassed DPBS (pH 7.4).  The hydroquinone then underwent an 
intramolecular cyclization reaction, leaving a free amine on the surface (2s) and 
releasing a lactone species (2l).  This amine terminus allows for a variety of subsequent 
reactions, including amide coupling chemistry, which is commonly utilized to attach 
biomolecules to surfaces.  We first illustrated the use of this electrochemical reduction 
process to attach ferrocene carboxylic acid to the surface, to form 3s, via amide coupling 
chemistry.  Ferrocene carboxylic acid (0.02 M) and N,N′-diisopropylcarbodiimide (DIC) 
(0.13 M) in DMF were added to the free amine surface.  The amide coupling reaction 
was run overnight covered in an N2-purged glove box.  The surface was then sonicated 
three times in DMF, then MeOH, and then blown dry.  
 Similarly, biotin (0.02 M) and DIC (0.13 M) in DMF were added to the free 
amine surface 2s.  The amide coupling reaction was run overnight in an N2-purged glove 
box at 50 °C.  The surface was then sonicated three times in DMF, then MeOH, and 
blow dried.  Subsequently, the Nanogold streptavidin (10 pM in 0.05% Tween20/DPBS)  
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Scheme 5.3.  The chemical and electrochemical steps involved in non-oxidatively 
activating Si(111) surfaces.  The molecules or molecular components are colored to 
highlight their different functions.  1s represents the surface-bound benzoquinone that 
resulted from the click reaction of 1 to the acetylene-modified Si(111) surface (reacted 
acetylene group drawn in black).  Upon reduction at –800 mV (vs. Ag/AgCl) of the 
benzoquinone to the hydroquinone, an intramolecular cyclization reaction ensues to 
produce 2l (red lactone leaving group) and 2s (the green triazole ring with an amine 
terminus).  This represents the activated surface.  The ferrocene carboxylic acid (orange), 
a second electrochemically active molecule, is then coupled to the Si(111) surface. 
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was introduced for 15 min.  The surface was sonicated in 0.05% Tween20/DPBS for  
25 min and then water for 5 min.  The gold particles were then amplified with gold 
enhancement reagents for 10 min and then sonicated in water for 5 min. 
 
5.3  SURFACE CHARACTERIZATION 
5.3.1  X-ray Photoelectron Spectroscopy 
X-ray photoelectron spectroscopy (XPS) was utilized to characterize many of the 
steps of both Schemes 5.1 and 5.3.  All XPS measurements were performed in an ultra-
high vacuum chamber of an M-probe surface spectrometer that has been previously 
described.59  All measurements were taken on the center of the sample at room 
temperature.  Monochromatic Al Kα X-rays (1486.6 eV) were incident at 35° from the 
sample surface and were used to excite electrons from samples.  The emitted electrons 
were collected by a hemispherical analyzer at a take-off angle of 35° from the plane of 
the sample surface. 
ESCA-2000 software was employed to collect and analyze the data.  To get an 
overview of the species present in the sample, survey scans were run from 0 to 1000 
binding eV (BeV).  The Si 2p (97-106 BeV), Cl 2p (196-206 BeV), C 1s (282-292 BeV), 
N 1s (393-407 BeV), Fe 2p (695-745 BeV), and Au 4f (77-97 BeV) regions were 
investigated in detail. 
 
5.3.2  Contact Angle Goniometry 
The sessile contact angle of water on the functionalized Si(111) surface was 
utilized as a measurement of the fidelity of the monolayer for all surfaces of Schemes 
5.1 and 5.3 except H- and Cl-terminated Si(111).  Contact angle measurements were 
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obtained with an NRL C.A. Goniometer Model #100-00 (Rame-Hart) at room 
temperature.  Contact angles, θ, were measured from sessile drops by lowering a 1 µL 
drop from a syringe needle onto the surface.  This was repeated three times and averaged 
to obtain the θ for the surface. 
 
5.3.3  Electrochemical Characterization of Surface Coverages 
Reductive electrochemistry was performed on 1s in a custom-made cell using a 
VMP Multi-Potentiostat (Princeton Applied Research, Oak Ridge, TN) (Figure 5.3).  
Dulbecco’s Phosphate Buffered Saline (DPBS) was used as the electrolyte, with silicon 
as a working electrode, a Pt coil as a counter electrode, and an Ag/AgCl reference 
electrode.  Cyclic voltammetry was carried out at a rate of 100 mV/s.  Molecular 
coverage was obtained by integrating the cathodic peak of the first scan in which all the 
modified benzoquinone was reduced to hydroquinone. 
 
5.3.4  Fourier-Transform Infrared Spectroscopy 
The H- and H-C≡C-terminated Si(111) surfaces were characterized by 
Attenuated Total Reflection Fourier Transform Infrared Spectroscopy (ATR-FTIR).  The 
Si(111) surfaces were prepared from single-crystal, polished Si(111), miscut 3°-4°, 
boron-doped (p-type), 500 to 550 µm thick, and with 4 to 20 Ω-cm resistivity (Addison 
Engineering; San Jose, CA).  Samples were cut into (2 cm × 2 cm) pieces.  Samples 
underwent the acetylenylation and click reactions as described above.  Samples were 
mounted on a Germanium ATR crystal (GATR, Harrick Scientific Products) for a 
grazing angle of 65°.  The sample was placed in a Vertex 70 FT-IR spectrometer (Bruker 
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Optics) for measurements.  In an air-purged sample chamber, 512 or 1024 scans were 
taken, with background scans of air subtracted from the spectra.  Spectra were fitted with 
a linear baseline prior to analysis. 
 
5.4  RESULTS  
5.4.1  XPS Survey Scans and Contact Angle Measurements 
 XPS survey scans revealed the progression of the acetylenylation and click 
chemistry steps.  For a freshly prepared, H-terminated Si(111) surface (H-[Si(111)]), Si 
2p and Si 2s peaks were observed, at 100 BeV and 150 BeV, respectively.  Additional 
small C ls and O ls peaks, corresponding to adventitiously adsorbed carbon and oxygen 
on the surface, were also detected.  After chlorination of H-[Si(111)] by PCl5, two new 
peaks at 200 BeV and 270 BeV appeared in the XPS spectrum, representing the Cl 2p 
and Cl 2s electrons, respectively.  Upon a treatment with sodium acetylide, the chlorine 
peaks disappeared completely and a pronounced C 1s appeared at 285 BeV, verifying 
that the acetylene-terminated Si(111) surface (H-C≡C-[Si(111)]) has been generated.  
Other adsorbed carbon can contribute to the C 1s peak intensity for this scan.  After the 
click reaction with electroactive quinone 1, a new N 1s peak appears at 400 BeV. 
Sessile contact angles were also quantified for the various surface 
functionalization steps described in Schemes 5.1 and 5.3, and those values are listed in 
Table 5.1. 
 
5.4.2  High-Resolution XPS Measurements 
High-resolution XPS measurements were utilized to quantitate the chemical steps 
of Schemes 5.1 and 5.3.  In particular, the Si 2p region was used to monitor the growth  
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Table 5.1.  Measured contact angles for various Si(111) surfaces. 
Surfaces Contact Angle (°) 
H-C≡C-[Si(111)] 77 ± 2 
1s 68 ± 2 
2s 60 ± 2 
3s 59 ± 2 
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of silicon oxides as a function of exposure time to air (Figure 5.1) and as a function of 
the chemical and electrochemical steps of Scheme 5.3 (Figure 5.2A) in two sets of 
experiments.  For both measurements, a Shirley baseline was applied to each spectrum 
before the peaks were fitted.  Peak line shapes for bulk Si 2p3/2 and 2p1/2 were fitted to 
Voigt functions fixed at 95% Gaussian and 5% Lorentzian, with a 15% asymmetry.  The 
Si 2p1/2 and 2p3/2 peaks were fitted with the two peaks held 0.6 BeV apart, the full width 
at half maximum (FWHM) was fixed at 1, and the integrated area ratio of the 2p1/2/2p3/2 
peaks was fixed at 0.51, as has been previously described.33–35,42  The broad peak 
between 100 and 104 BeV was assigned as Si+ to Si4+ oxides and was fitted to a third 
peak.  The positions of the three peaks and the width of the third peak were optimized to 
obtain the best fit to the experimental spectrum.  For very thin oxide layers, the oxide 
coverage was calculated from the SiOx:Si 2p peak area ratio.  This was determined by 
dividing the area under the third peak by the total area of the Si 2p3/2 and 2p1/2 peaks.35  
The SiOx:Si 2p peak area ratio was then divided by a normalization constant of 0.21 for 
Si(111) to estimate the fraction of surface atoms that was oxidized.33–35 
We estimated that there were approximately 0.25 equivalent monolayers of SiOx 
on the acetylene-terminated Si(111) surface after 6 days’ exposure to air (Figure 5.1).  
This is consistent with other results that have shown stability toward oxidation for as 
long as 60 days in air.43  Following the formation of 1s and the reduction of 1s to 2s at  
–800 mV (Scheme 5.3) in aqueous electrolyte, the amount of SiOx was calculated to be 
0.29 and 0.34 equivalent monolayers, respectively.   
The H-C≡C-[Si(111)] surface was also characterized using high-resolution C 1s 
XPS (Figure 5.2B).  The resulting spectrum was deconvoluted and fitted to three peaks, 
the silicon-bonded carbon at 283.8 BeV, the carbon-bonded carbon at 284.9 BeV,  
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Figure 5.1.  XPS data of H-C≡C-[Si(111)], collected in the Si 2p region, and taken after 
exposure to air for up to 160 h.  The peaks for SiOx species should appear between 100 
and 104 BeV.  The amount of oxidation of the Si(111) can be estimated from this data to 
be about 0.25 equivalent monolayers.  The Si 2p features are normalized to the same 
height for all three scans. The 37, 79, 160 h scans are shown offset from the 0 h scan to 
reveal the spectral detail. 
 
143 
 
Figure 5.2.  High-resolution XPS spectra of H-C≡C-[Si(111)], and of that surface 
following the click reaction to form 1s and the reduction of 1s to 2s.  (A) Si 2p region 
revealing the near absence of oxide growth during the Cu(I)-catalyzed click reaction, and 
during the reductive transformation of 1s to 2s.  (B) Scan of the C 1s region of H-C≡C-
[Si(111)].  The Si-C peak is unique to H-C≡C-[Si(111)] surfaces.  The C-C peak 
contains contributions from the C≡C bond and adventitious carbon from the environment.  
The C-O peak present also arises from adventitious hydrocarbons.  (C) Scan of the N 1s 
region of 1s, validating the click formation of 1s.  The area ratio of the three peaks is 
1:2:1, respectively.  (D) Scan of the Fe 2p region showing the formation of 3s via the 
amide coupling of ferrocene carboxylic acid to 2s.  The control plots are of 1s (dark grey) 
and the H-C≡C-[Si(111)] surface (light grey) after exposure to ferrocene carboxylic acid 
under the same conditions. 
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and the oxygen-bonded carbon at 286.8 BeV.  As developed by Nemanick,41,42 peaks 
were fitted to Voigt functions having 70% Gaussian and 30% Lorentzian line shapes.  
The peak center-to-center distances were fixed at 1.1 BeV between the Si-C and C-C 
peaks, and at 2.9 BeV between the Si-C and O-C peaks.  To calculate the surface 
coverage of the acetylene, the integrated area under the silicon-bonded carbon peak was 
ratioed to the total integrated area of the Si 2p3/2 and 2p1/2 peaks and normalized with 
respect to scan time.  The ratio calculated was referenced to a methyl-terminated Si(111) 
surface that was scanned under the same conditions.  The effective coverage of acetylene 
on the Si surface was 97 ± 5 %, consistent with other measurements of such surfaces.43  
The statistical uncertainty in this number is largely determined by the signal-to-noise 
ratio of the XPS data (~30:1). 
The high-resolution N 1s spectrum of 1s illustrates the attachment of the 
benzoquinone (1) via click chemistry (Figure 5.2C).  There is no peak at 405 BeV, 
signifying the absence of free azide.  This result indicates that the azide-modified 
electroactive benzoquinone is not just freely adsorbed but covalently bonded to the 
surface.52  The N 1s spectrum was deconvoluted and fitted to three peaks, each 
composed of 80% Gaussian and 20% Lorentzian line shapes.60  The three peaks 
correspond to the amide nitrogen at 401.7 BeV, the doubly bonded nitrogen atoms (in 
the 1,2,3-triazole ring) at 400.3 BeV, and the singly bonded nitrogen (in the 1,2,3-
triazole ring) at 398.2 BeV, respectively.  The ratio of peak areas was found to be 1:2:1, 
consistent with the structure of 1s.  After electrochemical cleavage to 2s, the N 1s region 
remained unchanged. 
Figure 5.2D is a high-resolution scan of the Fe 2p region that demonstrates the 
attachment of ferrocene carboxylic acid onto 2s to form 3s.  The Fe 2p3/2 and 2p1/2 peaks 
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occur at 711.3 and 724.8 BeV, respectively.  It is difficult to quantify the amount of iron 
from such data because the peak shape is highly asymmetric and hard to deconvolute 
with a single Gaussian/Lorentzian function due to the strong multiplet splitting.60  
However, as discussed below, the surface coverage of 3s can be estimated from cyclic 
voltammetry measurements.  Figure 5.2D also shows two control experiments.  
Although a trace amount of ferrocene residue was detected on the controls, this 
measurement does confirm that the large majority of ferrocene is the result of the 
covalent bond formation between carboxylic acid of the ferrocene and the free amine of 
2s. 
 
5.4.3  Electrochemical Measurements 
Figure 5.3A depicts the cyclic voltammogram (CV) for 1s.  The prominent 
cathodic peak in the first scan confirms the presence of electroactive benzoquinone and, 
therefore, that the click reaction proceeded.  Molecular coverage was obtained by 
integrating the cathodic peak of the first scan, where all the modified benzoquinone was 
reduced to hydroquinone.  Complete conversion of 1s to 2s accompanied by the release 
of 2l (Scheme 5.3) was achieved at potentials below –0.9 V.  Consecutive CV scans 
demonstrated that no detectable benzoquinone remained.  For the determination of 
coverage, the area under the cathodic peak was obtained after subtracting the non-
Faradaic current.  This area was converted to the number of molecules by a 
stoichiometric ratio of 2 electrons to 1 electroactive molecule.  Then, the number of 
molecules was divided by the electrode surface area and then normalized to the Si atop 
atom surface density (7.8 × 1014 /cm2 for Si(111)).17  The coverage calculated for 1s on 
the H-C≡C-[Si(111)] was 6.7 ± 0.3 %.  
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Figure 5.3.  Cyclic voltammograms (CVs) for 1s and 3s.  (A) The electrochemical 
activation of 1s to 2s.  The black trace is of the first scan, and the grey traces are of two 
subsequent scans, indicating nearly complete conversion of benzoquinone to 
hydroquinone during the first scan.  (B) The reversible oxidation of 3s.  Two subsequent 
scans are shown.  CVs were performed at a rate of 100 mV/s with voltages relative to 
Ag/AgCl. 
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The amine terminus presented by 2s provides a handle for subsequent reaction, 
including amide coupling chemistry, which is commonly utilized to attach biomolecules 
to surfaces.  An exemplary surface is 3s, the product of the amide coupling of ferrocene 
carboxylic acid with 2s.  The CVs of 3s (Figure 5.3B) display reversible Fc0/+ redox 
behavior, as expected for ferrocene oxidation.  The peak spacing confirms that ferrocene 
is covalently attached (but not adsorbed) onto the surface. The coverage was calculated 
by integrating the anodic peak after subtracting the non-Faradaic current.  The number of 
molecules was divided by the electrode surface area and normalized to Si atom surface 
density which is 7.8 × 1014 /cm2 for Si(111).17  The coverage calculated for 3s was 0.5%.  
We do not fully understand the low coverage of ferrocene molecules.  A likely 
possibility is that the time and/or temperature conditions for the coupling reaction were 
not optimal.  It is also possible that degradation of the surface by oxidative potential 
treatments might also reduce the coverage of ferrocene.  
 
5.5  DISCUSSION 
The coverage values for H-C≡C-[Si(111)], surface 1s, and surface 3s are 
summarized in Table 5.2, calculated with respect to all atop sites on an unreconstructed 
Si(111) surface. 
The 97% coverage of the H-C≡C-[Si(111)] surface is consistent with the Si 2p 
XPS in Figure 5.1 (and other studies43) that indicated little surface-bound SiOx.  The 
acetylene carbons are sp-hybridized, implying a perpendicular attachment to the Si(111) 
surface.  The atomic radius for C is smaller than that for Si (0.70 Å versus 1.10 Å), and 
there is a 3.8-Å spacing between atop sites on Si(111).  These values support the notion  
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Table 5.2.  The molecular surface coverages for various Si(111) surfaces, as measured 
by XPS or electrochemistry (EC). 
 
Surfaces Coverage (%) 
H-C≡C-[Si(111)] 97 ± 5 (XPS) 
1s – benzoquinone 6.7 ± 0.3 (EC) 
3s – ferrocene 0.5 (EC) 
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that a 100% passivation of Si(111) surfaces can be achieved using the approach we 
described here. 
Additional support for 100% acetylenylation of Si(111) comes from the ATR-
FTIR measurements of H-[Si(111)] and H-C≡C-[Si(111)] (Figure 5.4; black and grey 
traces, respectively).  Whereas XPS allows analysis of the elemental composition of 
surfaces, infrared spectroscopy (IR) gives information about the types of chemical 
functionality on a surface.  The spectra shown in Figure 5.4 are expanded to highlight 
the region containing the signature Si-H (2083 cm–1) stretching frequency that is 
observed for the H-[Si(111)].  The Si-H stretch is strong and sharp, indicating that the 
surface sites are passivated with one hydrogen atom per atop site.  This is expected for a 
H-[Si(111)] freshly prepared by an NH4F(aq) etch.61  For H-C≡C-[Si(111)], the  
2083 cm–1 vibration has quantitatively disappeared, again consistent with 100% 
acetylenylation and with other work.43  A weak C≡C stretch might be expected in this 
region (2120 to 2175 cm–1),43,49 although we have not observed it.  When H-[Si(111)] is 
ethylated through a similar chlorination/alkylation procedure, the coverage of ethyl 
groups on the atop sites of the Si(111) surface is reduced by steric interactions to 
approximately 80%.40  Following the Grignard alkylation of Si(111), no Cl is detected 
on the surface,33 and FTIR data indicates that the remaining Si(111) atop sites are 
hydrogenated.62  For the ethylated surface, the 2083 cm-1 feature is broadened, shifted 
(to 2070 cm–1) and reduced in intensity to 14% of that observed for the H-[Si(111)] 
surface.62  
The coverage of the electroactive benzoquinone 1 on Si(111) to form 1s was 
calculated to be ~7% of all available Si(111) atop sites.  We previously reported on 
electrochemically activating Si(111) and Si(100) surfaces through the use of protected  
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Figure 5.4.  ATR-FTIR characterization of a H-[Si(111)] and H-C≡C-[Si(111)], in the 
region of the 2083 cm–1 Si-H mode. 
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hydroquinones that were attached to H-terminated Si surfaces via UV activation.17  For 
those molecules, coverages of up to 23% were achievable on Si(111), although bulkier 
protection groups on the hydroquinone led to slightly reduced surface coverages, 
implying steric interactions played at least some role in limiting coverage.  It is likely 
that steric interactions play a dominating role in determining the efficiency of the click 
reaction to form 1s.  While the acetylene footprint may be approximated by the van der 
Waals radius of the carbon atom, the 1,2,3-triazole ring formed upon the click reaction 
will obviously be much larger.  In fact, it is possible that the click chemistry is only 
effective at the step edges of the Si(111) surface.  We have extensively characterized 
various Si(111) surfaces that have been alkylated using the two-step 
chlorination/alkylation chemistry using high-resolution Scanning Tunneling Microscopy 
(STM).  For both methylated34,39 and ethylated40 Si(111), we find that about 10% of the 
Si surface atoms lie at step edges.  This arises from etch pits that are apparently formed 
during the chlorination step, implying that the H-C≡C-[Si(111)] surface likely shares a 
similar morphology.  In that case, acetylene groups located at step edges would not have 
the steric constraints that would limit the formation of the triazole ring.  It is interesting 
that the 7% coverage of 2s is similar to the number of Si atop sites that would reside at 
step edges.  We are currently investigating the H-C≡C-[Si(111)] and 1s surfaces using 
high-resolution STM to test this hypothesis. 
We observed minimal oxide growth on an acetylenylated surface even after  
6 days’ exposure to air, indicating nearly 100% passivation of the surface (Figure 5.1).  
Following the formation of 1s and electrochemical reduction of 1s to 2s to reveal the free 
amine, the amount of SiOx was slightly increased to 0.29 and 0.34 equivalent 
monolayers, respectively.  The oxidation growth observed was due to the click chemistry 
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on acetylenylated surfaces that were minimally exposed to air during cleaning and 
preparation for reaction, and the electrochemistry which was carried out in an ambient 
(and aqueous) environment.  It is notable that the limited oxide growth on the silicon 
even after all surface modifications afforded well-behaved electrodes. 
There have been several reported examples of click reactions on metal surfaces, 
although relatively few papers have attempted to report quantitative coverage values.  
Chidsey’s group51–53 has reported on coverages of up to 55% of ferrocene molecules 
clicked onto N3-(CH2)n-S-[Au] SAMs.  On gold, each organic group has approximately 
twice the area available to it, as compared with the area available to each acetylene 
group on Si(111) [21.4 Å2/molecule for gold and 12.8 Å2/molecule for Si(111)].17,63,64  
However, even for the much more loosely packed SAM, steric interactions were 
attributed as the reason for the incomplete (55%) yield of the click reaction. 
The stated goal of this work was to develop a general strategy for 
electrochemically directing the biofunctionalization of Si(111) surfaces without 
oxidizing the underlying Si(111).  To this end, we demonstrated the electrochemical 
activation and subsequent attachment of the model biomolecule, biotin, using a 
modification of the chemistry described in Scheme 5.3 (see Experimental Methods).  To 
detect surface-bound biotin, we utilized Au nanoparticle-labeled streptavidin (strept-Au) 
and followed through with electroless amplification of the Au to produce particles that 
were imaged using Scanning Electron Microscopy (SEM).  Representative data from this 
experiment, shown in Figure 5.5, indicate that the selectivity for attachment of strept-Au 
onto 2s is about 100-fold greater than on two control surfaces, H-C≡C-[Si(111)] and 1s, 
both of which were also treated with biotin and exposed to strept-Au. 
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Figure 5.5.  Demonstration of bioattachment to acetylenylated Si(111) through reductive 
formation of 2s followed by the amide coupling of biotin.  (A) XPS of the biotinylated 
Si(111) surface following exposure to strept-Au, but prior to the electroless Au 
amplification.  The Au 4f region is comprised of two spin-orbit coupled peaks: Au 4f7/2 
(~84 BeV) and Au 4f5/2 (~88 BeV).  The dotted trace is from H-C≡C-[Si(111)], and the 
grey trace is from 1s, each exposed to biotin and strept-Au as controls.  The three SEM 
images (B, C, D) are of the activated and biofunctionalized surface, plus two controls.  
All images were taken following the electroless amplification step.  The scale bar is  
1 µm.  (B) 2s, incubated with biotin, and exposed to strept-Au.  (C) H-C≡C-[Si(111)] 
incubated with biotin, and exposed to strept-Au.  (D) 1s incubated with biotin, and 
exposed to strept-Au.  There are at least 500 Au nucleation sites on B, 5 on C, and 7 on 
D. 
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5.6  CONCLUSIONS 
Acetylenylation of the Si(111) surface via the two-step chlorination/alkylation 
procedure was combined with click chemistry to provide a non-oxidative approach for 
adding chemical functionality to a silicon surface.  Si(111) surfaces can be nearly 100% 
passivated with acetylene groups.  A specifically designed, electroactive benzoquinone 
molecule has been immobilized to the H-C≡C-[Si(111)] surface.  A 7% coverage of the 
benzoquinone was found, suggesting that the click reaction may have occurred at step 
edges on the H-C≡C-[Si(111)] surface.  The attachment of an electroactive 
benzoquinone was highly selective and was accomplished with only a minimal amount 
of oxidation of the underlying Si(111).  The electroactive benzoquinone was reduced and 
cleaved from the surface to produce an amine terminus.  In separate experiments, 
ferrocene carboxylic acid and biotin were selectively and covalently immobilized to the 
electrochemically activated surface.  
We believe this approach can be employed as a general platform to prepare 
functional surfaces for various applications and can be extended toward the selective 
biopassivation of arrays of various types of nanomechanical and/or nanoelectronic 
sensor devices. 
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Appendix A 
Iterative In Situ Click Chemistry Creates Antibody-Like Protein Capture Agents 
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Appendix B 
Complete Hit Sequencing Results 
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x1 x2 x3 x4 x5 
hit1 r r y h r 
hit2 m/v r w k r 
hit3 k r w y y 
hit4 w k k k w 
hit5 h f f f r 
hit6 s r -- r r 
hit7 r r w h y 
hit8 r k w w w 
hit9 r w s f r 
hit10 r r g w r 
hit11 g f r r w 
hit12 r t r r w 
hit13 m r w k r 
hit14 y r k r w 
hit15 a -- -- -- -- 
hit16 r r i r w 
hit17 -- -- k/l w -- 
hit18 r w -- -- r 
hit19 k/l r -- w r 
hit20 w r f r y 
hit21 d/p y y r r 
hit22 r y w k k 
hit23 k/l r r r w 
hit24 y r r k w 
hit25 r k/l f y r 
hit26 r w w k r 
 x1 x2 x3 x4 x5 
hit27 w r -- y r 
hit28 h r w r r 
hit29 w y r k r 
hit30 l r f r r 
hit31 w k r k k 
hit32 r r r w s/m 
hit33 r r k f w 
hit34 r r w r y 
hit35 w r h y k 
hit36 r r y f r 
hit37 w r k w r 
hit38 w y -- r r 
hit39 y r r r h 
hit40 y r r r w 
hit41 p f y w r 
hit42 k y w r k 
hit43 r y w h k 
hit44 r w h w n 
hit45 r h f h h/f 
hit46 r r -- h r 
hit47 r y r r r 
hit48 y f h h/w w 
hit49 r r r w y 
hit50 w r r r r/-- 
hit51 r w k f h 
 
Table B.1.  First-generation anchor ligand screen An1 results. 
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 x1 x2 x3 x4 x5 x6 
hit1 y r w f k f 
hit2 h/r h/r f l l/r r 
hit3 f r f y y r 
hit4 h/r f f k l -- 
hit5 k l f l k l 
hit6 l f l w l k 
hit7 f f f r y -- 
hit8 h/r f f f r -- 
hit9 r w w l k f 
hit10 h/r f f r y y 
hit11 l k l f l k 
hit12 f r r w w k 
hit13 h/r y f f k l 
hit14 l k f f f k 
hit15 h/r f f r r -- 
  (A) 
 
 x1 x2 x3 x4 x5 x6 
hit1 h l y f l r 
hit2 l k l w f k 
  (B) 
 
Table B.2.  Second-generation anchor ligand screen (A) An2a and (B) An2b results.  
The two anchor ligand candidates (hlyflr and lklwfk) are highlighted in yellow. 
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 Azn x2 x3 x4 x5 x6 Azn 
hit1 Az4 k i w i G   
hit2 Az8 r l w v G Az4 
hit3 Az8 r r r k r Az8 
hit4 Az4 l l v i k Az4 
hit5 Az4 m i l i k   
hit6 Az8 i i i m r Az4 
hit7 Az8 i i i w r Az8 
hit8 Az4 n v i i f   
hit9 Az4 i f l v k Az8 
hit10 Az4 k i w i G Az8 
hit11 Az4 r r k f r Az8 
hit12 Az4 r v w l r Az8 
hit13 Az8 k y r r r Az4 
hit14 Az8 r r k v w Az4 
hit15 Az4 i f l v k Az8 
hit16   k r k r f Az4 
hit17 Az8 k i w i k   
hit18 Az8 y r k f k   
hit19 Az4 i f f r v Az8 
hit20   a r k k y Az4 
hit 21   r k r t i Az4 
hit 22 Az8 k m v f k Az4 
hit23 Az4 l i m k i Az4 
 
Table B.3.  In situ biligand screen Bi1 results.  Potential 2° ligand candidates are 
highlighted in orange. 
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                        (A) 
    
 x1 x2 x3 x4 x5 x6 
hit1 k w i w G w 
hit2 k w i w G v 
hit3 k w l w G l 
hit4 k w i w G l 
hit5 k w i w G w 
hit6 k w l w G l 
hit7 G w i w G i 
hit8 k i f k i f 
  (B)  
 
Table B.4.  On-bead biligand screen (A) Bi2a and (B) Bi2b results.  Potential 2° 
ligand candidates are highlighted in yellow/green.  Consensus motif w-x3-w-G (where 
x3 = hydrophobic amino acid) is highlighted in red font. 
hit1 f k l w i k 
hit2 v w l w G G 
hit3 f w f w G G 
hit4 k w f w G G 
hit5 f k l w l k 
hit6 k w f w G G 
hit7 w w i w G G 
hit8 k G w l w G 
hit9 k l w i w G 
hit10 l w i w G l 
hit11 f k G f l i 
hit12 f w i w G k 
hit13 l w l w G i 
hit14 i i v l w k 
hit15 l i i f v  
hit16 v k f i l l 
hit17 l G f f w i 
hit18 k k l k k l 
hit19 f k l w i k 
hit20 w i w G G f 
hit 21 f f l l v k 
hit 22 k f k f w k 
hit23 l i k l f v 
hit24 l w f w G v 
hit25 f w f w G i 
hit26 G w f w G v 
hit27 G w i w G k 
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 Azn x2 x3 x4 x5 x6 Azn 
hit1 Az4 n i i i v  
hit2 Az4 i i l l k Az4 
hit3 Az4 n i i v l  
hit4 Az4 n m i f l Az4 
hit5 Az4 n v l v l  
hit6 Az4 n l i l f Az4 
hit7 Az4 n l i l f Az4 
hit8 Az8 r l w i r Az4 
hit9 Az4 n l i v f Az4 
hit10 Az4 r m w v k Az8 
hit11 Az4 i i l l k Az8 
hit12 Az4 i l v v r Az4 
hit13 Az4 n l l f l Az4 
hit14 Az4 n i i v y  
hit15  m k r k k Az8 
hit16 Az4 i l i r w Az4 
hit17 Az8 i i v f r Az8 
hit18 Az8 y f t r r  
hit19 Az4 n m i i v Az4 
hit20 Az8 i l i a k Az4 
hit21 Az4 i l l r w  
hit22 Az8 i v v f r Az4 
hit23 Az4 l l l v k Az4 
hit24 Az4 k v w i k Az4 
hit25 Az4 i m v l r Az4 
 
Table B.5.  First-generation in situ triligand screen Tri1 results.  Potential 3° ligand 
candidates are highlighted in orange. 
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 x2 x3 x4 x5 x6 x7 
hit1 r l w l r f 
hit2 r l w l r l 
hit3 r f f f r f 
hit4 r l f l r f 
hit5 l f f w f r 
hit6 l w f f f r 
hit7 l f l w f r 
hit8 l w l f f r 
hit9 l f f w l r 
hit10 r r r l w r 
hit11 r l w l r f 
hit12 w r r r r w 
hit13 r f r f r w 
hit14 f w f f w r 
 
Table B.6.  First-generation on-bead triligand screen Tri2 results.  Recall that the 
focused Library E was used for this screen.  Potential 3° ligand candidates are 
highlighted in orange. 
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 x2 x3 x4 x5 x6 x7 
hit1 n l i v f r 
hit2 n l i v l r 
hit3 n i i l l r 
hit4 i l f l f r 
hit5 n l i v l r 
hit6 n i i l w r 
hit7 n l i v f r 
hit8 n l i v f r 
  (A) 
 
 x2 x3 x4 x5 x6 x7 
hit1 n l i v f r 
hit2 n l i v f r 
hit3 n i i v f r 
hit4 n i i v f r 
hit5 n i i l l r 
hit6 n l i v l r 
hit7 n l i v f r 
  (B) 
 
Table B.7.  Results of second-generation triligand screens:  (A) Tri3 (in situ) and (B) 
Tri4 (on-bead).  The final 3° ligand sequence is highlighted in orange. 
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x1 x2 x3 x4 x5 
hit1 w f r r r 
hit2 s w v w G 
hit3 p v y f w 
hit4 d d y w G 
hit5 i w a y w 
hit6 d n w G f 
hit7 a w w a t 
hit8 r f r r f 
hit9 d w w h t 
hit10 r f r w r 
hit11 d e w p h 
hit12 a w w l w 
hit13 a w w a y 
hit14 d k k i y 
hit15 d w s i e 
hit16 s w w f y 
hit17 d w l r y 
hit18 s w a f y 
hit19 d l f l w 
hit20 d w a t w 
hit21 f k y r s 
hit22 d q r w r 
hit23 i w s t h 
hit24 l i v m w 
 
Table B.8.  Azide-free in situ triligand screen TriX results (control).  Note the poor 
hit homology, and the lack of resemblance with nlivfr. 
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Appendix C 
Custom Edman Degradation 
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 To allow for resolution of artificial azide-containing amino acids by Edman 
degradation, the Pulsed-Liquid cLC extended method was utilized (Figure C.1A) on 
the model 494 Procise cLC sequencing system (Applied BioSystems, Foster City, CA).  
It includes a modified gradient, Normal 1 cLC extended (Figure C.1B), and a flask 
cycle extended by 5 min (Flask Normal extended, Figure C.2). 
The chromatograms corresponding to elution of Az2, Az4, Az6 and Az8 
following Edman degradation are shown in Figure C.3 and demonstrate a 6-min 
retention time increase for every two methylene units added to the azidoalkyl side chain.  
Fmoc-Az2-OH was synthesized according to literature protocol,1 while Fmoc-Az6-OH 
was synthesized from 1,6-dibromohexane according to Scheme 2.1. 
 
(A)    
(B)    
Figure C.1.  (A) Pulsed-Liquid cLC extended method and (B) Normal 1 cLC 
extended gradient. 
178 
 
Figure C.2.  Final steps of Flask Normal extended flask cycle. 
 
 
Figure C.3.  Edman traces for artificial azide-containing amino acids. 
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Appendix D 
A Non-Oxidative Approach toward Chemically and Electrochemically Functionalizing 
Si(111) 
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